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Abstract 
 
Background Some respiratory diseases are believed to start early in life, yet manifest 
later as lung damage progresses. Early pathological changes are usually missed on 
traditional methods of lung function assessment. Therefore, multiple breath washout 
(MBW) may be of value in clinical practice as it is known to be more sensitive for early 
airway changes. This study aims to identify normative MBW outcome measures, 
particularly the lung clearance index (LCI), for the SF6-based Innocor MBW device as 
well as explore the effect of demographic and environmental factors on MBW measures 
in the paediatric population. 
 
Methods A cross-sectional study was carried out on a sample of healthy children (aged 9-
15 years; n=64) recruited from two schools in Stoke-on-Trent. Three runs of MBW 
testing were performed on each child in one sitting using the SF6-based Innocor device. A 
questionnaire was filled prior to testing by each child’s parent/guardian to assess the 
demographic and environmental factors of the study population. 
 
Results Sixty-two out of the 64 recruited subjects had valid measures, which were further 
analysed. The mean LCI was found to be 6.18 (SD=0.3). Gender, BMI, activity level, 
social deprivation, pollution level, and age were not found to have a significant effect on 
the outcome measures. The 95% limits of agreement was 0.96 and this equate to 15.5% of 
the normative value. The mean time for the three measurements was 17 minutes and 36 
seconds (min = 13 minutes and 20 seconds and max = 26 minutes). 
 
xviii 
 
Conclusion This study has suggested a normative LCI value for healthy individuals, 
particularly those aged 5 to 40 years. It also demonstrated the possibility of taking MBW 
testing from the research to the community setting using the portable Innocor MBW 
device. LCI may prove to be a valuable lung function assessment measure in the future as 
it is reliable, repeatable, sensitive, stable across age groups, and shows low variability 
among healthy individuals.  
 1 
 
1 Introduction 
 
The burden of respiratory diseases can be seen as a significant global problem (Murray 
and Lopez, 1997). Acute and chronic respiratory diseases are prevalent worldwide and 
can affect all age groups. Respiratory disease is considered a leading cause of mortality 
and may be a cause of premature death (Dodge et al., 2007). Chronic Obstructive 
Pulmonary Disease [COPD] and asthma are two of the five most threatening respiratory 
diseases worldwide (Bateman et al., 2008; Pauwels et al., 2001). They are considered 
leading causes of disability and death (World Health Organization, 2008). According to 
the World Health Organization, 64 million people worldwide have COPD (World Health 
Organization, 2017b). About three million (3.7 million) deaths every year are attributed to 
COPD, which means COPD contributes to 5% of all deaths around the world (World 
Health Organization, 2017b). Statistics have also shown that there are more than 235 
million people that suffer from asthma which, unlike COPD, is commonly seen in 
children (World Health Organization, 2017a).  
 
In the UK, respiratory diseases are the fifth most common cause of death and, due to an 
increase in incidence, is expected to be the fourth major cause of death by 2030 (World 
Health Organization, 2008). COPD in the UK is found to affect more than three million 
people (Raluy-Callado et al., 2015).  
 
In Kuwait, the burden of respiratory disease is increasing (Khadadah, 2013; Masjedi et 
al., 2018). Currently, it is estimated that chronic respiratory diseases are responsible for 
2% of total deaths in Kuwait (Miniño et al., 2011). Kuwait was found to have the highest 
prevalence of asthma  amongst the eastern Mediterranean countries (25.9%) (Khadadah, 
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2013; Masjedi et al., 2018). Chronic obstructive pulmonary disease (COPD) prevalence is 
also high in Kuwait (7.1%) (Masjedi et al., 2018).  
 
The increased incidence of asthma and COPD all over the world may be related to the 
increased exposure to risk factors such as smoking, pollutants and early life respiratory 
problems; the interaction of such risk factors may play a critical role in the development 
of lung disease later in life (Devereux, 2006). Further research in this area is thus urgently 
required. 
 
In Kuwait there is a rise in the prevalence of smoking and this could partly explained by 
the low levels of public awareness about lung disease risk factors, from both smoking and 
air pollution (Masjedi et al., 2018) . In Kuwait, it was found that tobacco smoking is the 
sixth most significant risk factor associated with disease burden in the population (World 
Health Organization, 2011) yet smoking continues to increase within the population in 
Kuwait. In 2010, nineteen percent of the Kuwaiti population were found to be smokers 
(World Health Organization, 2010). The increasing prevalence of smoking is leading to a 
rise in mortality and morbidity secondary to lung disease, a decrease in the quality of life 
of affected individuals and consequently an increase in health costs (Shahab et al., 2006). 
 
Several other factors have been associated with the onset of early pathological changes  in 
the lung, the most important of which are genetic predisposition, prematurity, method of 
childbirth, and prenatal and early-life environmental exposures such as smoking, viruses 
and allergens (Kouzouna et al., 2016). These factors act on the lung during a critical 
phase of its development, changing lung structure and metabolism and possibly inducing 
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abnormal responses to harmful agents, all of which eventually lead to chronic respiratory 
disease later on in life (Kouzouna et al., 2016).  
 
Maternal smoking during pregnancy, for example, has been thought to cause early 
harmful effects on the lung by causing in utero dysregulation of cytokine production and 
by interacting with asthma susceptibility genes (Hanrahan et al., 1992). Prematurity 
causes reduced lung airway calibre and exposes the neonate to hyperoxia, which causes 
exacerbated inflammatory responses in the developing lung (Rona et al., 1993). These 
early changes are thought to mark the onset of chronic respiratory disease in the growing 
individual (Carraro et al., 2014). It is thus important to understand key factors that 
contribute to the increasing incidence of lung diseases so as to ascertain how to identify 
susceptibility to these diseases and utilize the most effective methods of early detection.   
 
Chronic respiratory illness is believed to begin early in human life (Martinez, 2009). Even 
before clinical symptoms develop, pathological changes in the lung are already taking 
place at an early age (Martinez, 2009).  If we are able to detect these early changes, then 
it may be possible to intervene appropriately and reduce the risk of the problem becoming 
chronic and irreversible. Further, it may also be possible to identify factors that may 
exacerbate the pathological changes and take steps to educate patients on how to avoid 
these exacerbating factors. Unfortunately, however, the medical field is still lacking in 
approved diagnostic methods that are effective, efficient and practical in detecting early 
and subclinical chronic respiratory disease.  
 
For example, spirometry, the most commonly used method of diagnosing chronic 
respiratory disease (Pauwels et al., 2001), has been known for its insensitivity to small 
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airway obstruction and is therefore unable to detect the early changes that occur in the 
small airways of the lung. This causes a delay in diagnosis of chronic respiratory diseases 
and increases the number of early undetected cases in the population, who may benefit 
from early intervention. Instead of waiting until, for example, spirometry results of a 
patient are abnormal indicating that considerable deterioration of lung function has 
occurred and pathology has already reached a level significant enough to affect the large 
airways, research needs to find better tests of lung function that can pick up changes 
much earlier, when pathology is confined to the small airways and patients are still 
asymptomatic. This creates a need for research that aims to find methods of measurement 
of lung function that can be used in communities as screening tests, which, ideally, should 
be able to detect respiratory problems in early life such as in infancy or preschool. 
 
Respiratory screening tests will help discover the disease at its early stages and detect 
those who are susceptible to developing lung disease in order to control the disease before 
complications appear, delay its progression, and as a result, improve quality of life. 
Ideally, the testing method should be feasible for use for young children and newborn 
infants as understanding respiratory function in the very early stages of human life may 
give us insight on factors that affect normal lung development in the foetus as well as 
detect early abnormalities that may suggest future respiratory disease in individuals. 
Therefore, the focus of clinical research is directed towards finding a valid, simple, 
reliable, and feasible way of evaluating lung function that is more sensitive than 
diagnostic modalities currently used in medical practice. 
 
Efforts worldwide are being exerted to control the impact of chronic respiratory diseases 
on societies by improving health services and treatment. For example, the world’s 
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international respiratory societies (which include the American Thoracic Society, 
American College of Chest Physicians, Asian Pacific Society of Respiratory, Asociacion 
Latinoamericana del Torax, European Respiratory Society, International Union against 
Tuberculosis and Lung Disease, and Pan African Thoracic Society) have kept regular 
meetings to set common goals to deal with the impact of respiratory diseases in their 
societies. Their main focus was to find methods that help control disease incidence and 
improve management (Ferkol and Schraufnagel, 2014). Countries that recognise the 
impact of respiratory disease on their populations have also started supporting educational 
and research programmes to in an effort to minimise the burden of respiratory disease.  
 
In this research study, we investigate the clinical applicability and reliability of an 
established method of testing lung function known as multiple breath washout (MBW), 
which has not yet been approved for routine clinical practice. This method offers an 
advantage over the traditional pulmonary function tests and imaging modalities in that it 
is a very safe test and is sensitive to changes in the small airways, which may help detect 
subclinical chronic respiratory disease in children; these characteristics may make it 
feasible to use this method as a screening modality in the pediatric population. We further 
investigate the effect of several demographic and environmental factors on MBW 
outcome measures in children, assessing susceptibility to chronic respiratory disease 
based on such factors. This may help us identify which children are at an increased risk 
for chronic respiratory disease, and thus direct screening to a certain group of susceptible 
individuals rather than the entire population. We also established normative values for 
MBW outcome measures for the pediatric age group. 
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In order to conduct this study, it is crucial for one to have a good understanding of normal 
lung development, the normal physiology of breathing and ventilation, the 
pathophysiology of chronic respiratory diseases, and the mechanisms by which currently-
used lung function testing modalities assess lung function as well as the limitations and 
disadvantages of these lung function tests. The aim of the next chapter is to present a 
general background in these aspects of lung physiology and current methods of lung 
function assessment.  
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2 Background 
 
In this chapter, the aim is to briefly describe the normal anatomy, development, and 
physiology of the respiratory system, as well as the pathophysiology of the respiratory 
diseases relevant to the understanding of our study and testing method, which are 
bronchial asthma, cystic fibrosis, and chronic obstructive pulmonary disease. The 
relevance of these diseases to our study is the fact that they express changes in the small 
airways before involving the larger airways, and can thus be detected and monitored by 
the MBW method, the lung function assessment method of interest in our study. The 
chapter then goes on to explain the standard lung function tests available today in medical 
practice (spirometry and computed tomography (CT) imaging), the mechanisms by which 
these tests assess lung function, and their limitations. We also explain the mechanisms by 
which single and multiple breath washout tests assess lung function and the advantages 
that have made these methods of great interest to researchers in the past decade. 
Understanding the basics will facilitate and is crucial for the understanding of our 
research study and its significance.  
 
2.1 The development of the respiratory system 
2.1.1 Antenatal lung development  
 
Lung development in the fetus is divided into four chronological stages and is illustrated 
in Figure 1.  
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1. The embryonic period (0–6 weeks of gestation): In the embryonic period and 
specifically by the end of the fourth week of gestation, the lung appears as the 
ventral bud of the esophagus. Lobar and segmental portions of the airway tree 
develop, forming high columnar epithelium tubes. By the end of the embryonic 
period (by week six), an adult pattern of central vascular and airway structures 
develop (Ward et al., 2010).  
 
2. The pseudoglandular period (6–16 weeks of gestation): In this stage and just after 
the seventh week, the lung appears as a small primitive gland, giving this period 
its name. During this stage, the conducting airways develop. The airway branches 
into twenty generations until they reach the level of the acinus (the term for a 
respiratory zone of the lung). By the end of this stage (by week 16), vascular 
development is complete, and the level of terminal bronchioles is reached 
(Rackley and Stripp, 2012; Ward et al., 2010).  
 
3. The canalicular period (16–24 weeks of gestation): The pulmonary parenchyma 
starts to develop in this stage. At this point, a proliferation of blood vessels and 
a capillary network form around air sacs. Surfactant secretion also begins during 
this time (at 24 weeks) (Smith et al., 2010b; Ward et al., 2010). 
 
4. The saccular period (24–40 weeks of gestation): The last stage is when the blood 
vessels grow, respiratory tissue expands, and new arteries form. By the 26th week, 
the maturation of airway wall structure is achieved (Hislop et al., 1986; Smith et 
al., 2010a). The first actual appearance of the alveoli happens at around the 30th 
week of gestation. Approximately half of the total number of adult alveoli may be 
reached at the end of full-term pregnancy (Hislop et al., 1986; Langston, 1984). 
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Some, however, believe that the majority of alveoli (90%) develop after birth (J. 
Gordon Betts et al., 2014; Ward et al., 2010). Microvascular maturation, which is 
considered the final stage of lung development, happens after the alveolar 
development.   
 
2.1.2 Postnatal lung development 
 
Lung volume increases throughout childhood (Figure 1); during the first seven years of 
life, the growth rate of the lung reaches tenfold and continues until the age of 18 years 
(Burri, 2006). The increase in the number of airways stops at birth, while airway size 
continues to grow. Alveoli, however, continue to increase after birth in both number and 
size (Hislop et al., 1986; Smith et al., 2010a). The number of alveoli significantly 
increases in the late phase of the last trimester of pregnancy, followed by a rapid 
multiplication of alveoli until the age of 2 (Ward et al., 2010). The speed of alveolar 
multiplication decreases after the age of four and it stops at the age of 8. The number of 
existing alveoli normally varies in the adult lung, which makes alveolar number difficult 
to interpret and unreliable in determining pathology. Alveolar dimension/size is another 
point of interest. It seems to show small changes during the first years of life but it 
continues to increase until the age of 22 (Zeman and Bennett, 2006). In one study, 
increase in alveolar size was suggested to take place between 2 and 20 years (Merkus et 
al., 1996). Overall, postnatal lung growth is rapid, especially within the first year of life 
(Ward et al., 2010). 
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Figure 1 The development of the respiratory system  
This is an illustration of the development of the respiratory system divided in stages starting from fetal life 
(antenatal development) and progressing to postnatal development (Kajekar, 2007). 
 
2.2 Lung function 
 
2.2.1 The large and small airways  
 
The main function of the airways is to deliver air to the gas exchanging units of the lung, 
the alveoli. Lung airways are comprised of approximately 23 generations of branching 
tubes that extend from the trachea to the visceral pleura and are classified as large and 
small airways (McNulty and Usmani, 2014). The large airways, which start just terminal 
to the trachea, are termed bronchi and are cartilaginous conducting airways with a wall 
containing smooth muscle and connective tissue. These large airways contribute the 
majority of airway resistance in the lung. The small airways, on the other hand, are 
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termed bronchioles and are non-cartilaginous conducting airways with a fibromuscular 
wall and a diameter of less than 2 millimeter. At the end of the last bronchiolar divisions, 
the airway lining is interrupted by alveoli, the site of blood-gas exchange in the lung; 
these distal respiratory bronchioles that directly connect with alveolar ducts and sacs form 
the respiratory lung unit termed the acinus (Figure 2) (Jeffery, 1998). 
 
Figure 2 The anatomy of acinus 
This is the functional respiratory unit of the lung, which includes many alveoli; each terminal bronchiole 
gives rise to an acinus (Beachey, 2017). 
 
The small airways contribute to 10% of total lung airway resistance, while the larger 
airways constitute 90% of total airway resistance (Macklem, 1998). As a result, small 
airway obstruction may have a minor influence on total lung function, but may more 
profoundly affect gas exchange, particularly beyond the point of obstruction (at the 
alveolar level). In such cases, mechanical properties of the lung may not be affected, but 
ventilation distribution may be.  
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An important physiological difference between small and large airways involves the 
velocity and behavior of gas flow in these airways. In the small airways, due to the 
division of flow over larger cross-sections, gas flow is laminar, independent of gas 
density, and flows at a lower velocity compared to gas in the large airways, where flow is 
turbulent and density dependent. The laminar flow in small airways diminishes the impact 
of gas density on small airway resistance; however, in large airways, resistance is 
influenced by changes in gas density. Airway resistance was found to increase in large 
airways when a very dense gas was inhaled compared to airway resistance measured 
during inhalation of air, but no change was found in small airway resistance (Macklem, 
1998). As a result, the effect of gas density on airway resistance can be used to determine 
at what level (small or large airways) airway obstruction is present in lungs with 
obstructive respiratory disease.  
 
Another physiological difference between small and large airways is concerned with the 
low surface tension of the small airway lining. Unlike large airways, small airways have 
no cartilaginous support nor mucous glands and are lined with a surfactant, which 
protects these airways from collapsing, particularly at low air volumes in the lung (i.e. 
during expiration) (Macklem, 1998). Diseases that increase surface tension in the small 
airway lining (due to abnormal existence of mucus or inflammatory infiltrates, 
hypertrophy of smooth muscle lining the airways, or increase in airway wall thickness) 
lead to a collapse of these airways, trapping gas distally in the lung and precluding 
ventilation in the respiratory units distal to the obstruction (Macklem, 1998). 
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2.2.2 Ventilation 
 
Ventilation is the process of breathing, in which air moves into and out of the lungs 
(inspiration and expiration, respectively). It is driven by an interaction between 
atmospheric pressure (Patm), alveolar pressure (Palv), and intra-pleural pressure (Pip).  
 
The process of ventilation is dependent on the difference between air pressure in the 
atmosphere and air pressure in the lung. Contraction and relaxation of the diaphragm and 
intercostal muscles are responsible for most of the pressure changes that drive the process 
of inspiration and expiration, causing air to either flow in or out of the lung. Thoracic wall 
compliance, the ability of the thoracic wall to stretch, is an additional factor that affects 
the breathing process. The expansion of the thoracic cavity directly influences the 
capacity of the lungs to expand. Therefore, decreasing the thoracic wall compliance, such 
as in some diseases of the pleura, will limit the expansion of the thorax and consequently 
restrict the lungs to expand and fill with air. 
 
During inspiration, the diaphragm contracts, moving inferiorly towards the abdominal 
cavity, along with the intercostal muscles. This increases the size of the thoracic cavity 
and leads to lung expansion, which consequently decreases air pressure in the lung 
compared to atmospheric pressure; as a result, air flows from the atmosphere (the area of 
higher pressure) into the lung (the area of lower pressure) until equilibrium is reached; 
this is in consistency with the basic laws of physics. During expiration, the opposite 
occurs; as the diaphragm and intercostal muscles relax, elasticity of lung tissue causes the 
lung to recoil and decrease in size and volume, which causes air pressure in the lung to 
increase higher than atmospheric pressure, expelling the air out of the lung. Normal 
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expiration is a passive process, which means no energy is exerted in pushing air out of the 
lungs. Alveolar and intra-pleural pressure values are described in relation to atmospheric 
pressure; therefore, negative alveolar or intra-pleural pressure is lower than the 
atmospheric pressure and positive alveolar or intra-pleural pressure is greater than 
atmospheric pressure.  
 
Alveolar pressure changes during the different phases of breathing, as was described 
above. Because the alveoli are connected to the atmosphere through the airways, the 
interpulmonary pressure of the alveoli always equalizes with the atmospheric pressure. 
Intrapleural pressure is the pressure of the air within the pleural cavity, which is the space 
between the visceral and parietal pleurae. Like alveolar pressure, intrapleural pressure 
also changes during the different phases of breathing. However, due to certain 
characteristics of the lungs, intrapleural pressure is always lower than the alveolar and 
atmospheric pressures, measuring approximately -4 mmHg throughout the breathing 
cycle. Transpulmonary pressure is the difference between the intrapleural and alveolar 
pressures, and it determines the size of the lungs.  
 
2.2.3 Gas exchange 
 
It is in the lungs where the process of gas exchange takes place, in which red blood cells 
exchange the carbon dioxide brought from the body with oxygen from the air (Maynard, 
2006). The process of gas exchange occurs at the tissue level in the alveoli across the thin 
(0.5 µm) alveolar-capillary membrane. Exchange of gases is directed by the difference of 
the partial pressure across this membrane, in other words, diffusion (Ward et al., 2010), 
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where gas molecules diffuse passively from the medium with higher concentration to that 
of lower concentration.  
 
Gases are brought to respiratory tissues from the atmosphere by means of two 
mechanisms: convection and diffusion. Convection is the process by which air molecules 
are transferred from the atmosphere into the lungs. Diffusion is the process of moving the 
respiratory gases across tissue membranes. Diffusion is driven by differences in partial 
pressure of gases across the alveolar-capillary membrane from the area of higher 
concentration to that of lower concentration. Therefore, when the partial pressure of O2 in 
the alveoli is higher than in the bloodstream (deoxygenated blood), O2 will diffuse from 
the alveolar space through arterial capillaries and bind with haemoglobin in the blood; 
blood will consequently be oxygenated.  On the other hand, CO2 will diffuse from the 
blood in alveolar capillaries, where there is higher concentration of CO2 (partial pressure 
CO2), through the thin capillary membrane into the alveolar space, from where it will be 
eliminated from the body through expiration.  
 
The quality of ventilation depends on the quality of gas exchange. The function of body 
tissues is maintained as long as the gas concentration in the alveolar gas exchange unit is 
in balance. A dysfunction in the gas exchange process reflects a failure in the respiratory 
system. One of the available methods used currently in the medical field to assess 
ventilation quality is arterial and venous blood gas analyses, which measure the amount 
of gases (O2 and CO2) into the blood as well as blood pH levels. 
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2.2.4 Respiratory volumes and capacities 
 
Respiratory volumes represent the different volumes of air moved by or associated with 
the lungs at a given point in the respiratory cycle and described as: tidal volume (TV), 
residual volume (RV), inspiratory reserve (IRV), and expiratory reserve (ERV) (Figure 
3). Tidal volume is the amount of air that normally enters the lungs during normal 
breathing (about 500 mL) (Wanger et al., 2005a). Expiratory reserve volume is the 
amount of air one can forcefully exhale past a normal tidal expiration (up to 1200 mL for 
men) (Wanger et al., 2005a). Inspiratory reserve volume is produced by a deep inhalation, 
past a tidal inspiration. This is the extra volume that can be brought into the lungs during 
a forced inspiration (Wanger et al., 2005a). Residual volume is the air left in the lungs 
when one exhales as much air as possible. The RV makes breathing easier by preventing 
alveolar collapse (Wanger et al., 2005a).  
 
Respiratory capacities are combinations of two or more respiratory volumes (Figure 3). 
Total lung capacity (TLC) is the sum of all the lung volumes (TV, ERV, IRV, and RV); it 
represents the total amount of air an individual can hold in the lungs after a forceful 
inhalation (6000 mL air for men; about 4200 mL for women) (Leith and Brown, 1999). 
Vital capacity (VC) is the amount of air a person can move into or out of his/her lungs, 
and is the sum of all of the volumes except RV (TV, ERV and IRV), which is normally 
between 4000 and 5000 mL (Wanger et al., 2005a). Inspiratory capacity (IC) is the 
maximum amount of air that can be inhaled past a normal tidal expiration, corresponding 
to the sum of the TV and IRV (Leith and Brown, 1999). Functional residual capacity 
(FRC) is the amount of air that remains in the lung after a normal tidal expiration (Leith 
and Brown, 1999); it is the sum of expiratory reserve volume and RV. 
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Figure 3 Respiratory volumes and capacities 
This illustrated (a) respiratory volumes: inspiratory reserve volume (IRV), tidal volume (TV), expiratory 
reserve volume (ERV) and residual volume (RV), and (b) illustrates the different combinations of volumes 
that result in respiratory capacities: VC = IRV + TV+ERV , IC = TLC – FRC, ERV = FRC – RV, IRV = 
TLC - (FRC + VT) (J. Gordon Betts et al., 2014). 
 
Besides respiratory volumes, the respiratory system also contains anatomical dead space, 
which is the air that is present in the airway but never reaches the alveoli and, therefore, 
never participates in gas exchange. Alveolar dead space, on the other hand, represents the 
air that reaches the alveoli but does not participate in gas exchange due to alveolar 
malfunction as a consequence of disease or abnormal blood flow. The total dead space 
refers to the anatomical and alveolar dead space together, which represents the total 
amount of air in the respiratory system that is not being used in the gas exchange process 
(Macklem,1998).
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2.3 Ventilation distribution and homogeneity 
 
In a normal individual, inhaled gas is distributed evenly (homogeneously) throughout the 
lung, and the mixing and turnover of alveolar gas is relatively rapid. However, when 
airway obstruction is present, gas distribution tends to become uneven (inhomogeneous) 
and the mixing and turnover of the gases takes longer. 
 
Ventilation inhomogeneity occurs primarily when one of three mechanisms exists: (1) 
convection-dependent inhomogeneity (CDI) in the zone of proximal airways to terminal 
bronchioles, (2) diffusion-limitation-related inhomogeneity which is infrequent, or (3) 
diffusion-convection-interaction-dependent inhomogeneity (DCDI), which involves 
alteration in the interaction between convection and diffusion at the intermediate zone 
(acinar entrance)  (Robinson et al., 2013b). Assessment of ventilation inhomogeneity can 
therefore be used as a valid measure of lung disease. SBW as well as MBW testing, the 
method of lung function assessment studied in this research, rely on measuring ventilation 
inhomogeneity in the lung and will be further explained later in this chapter. 
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2.4 Risk factors for lung disease 
 
In the literature, the association between exposure to risk factors in early life and the lung 
function of an individual in early childhood and later on in adulthood has been 
comprehensively reviewed (Kouzouna et al., 2016). Exposure to risk factors in early life 
may cause immediate or long term negative effects on the developing lung, leading to 
abnormal growth of lung structures, such as the airways and lung tissues; this results in 
abnormal lung functioning due to low compliance, low lung volume and increased airway 
resistance (Kouzouna et al., 2016). This dysfunction progresses to manifest as respiratory 
disease. A malfunctioning lung may be susceptible to recurrent infections and numerous 
pathologic risk factors that may cause permanent damage of the lung tissues and chronic 
illness. 
 
A systematic review conducted in 2016 (Kouzouna et al., 2016) was aimed at evaluating 
the early life factors that are associated with subsequently reduced lung function. It 
revealed the results of 25 studies that investigated the associations between exposure to a 
total of 74 early life risk factors and lung function. The authors of this systematic review 
supported the notion that in the early stages of life, a person is susceptible to exposure to 
some factors such as: early infection, bronchial hyper-reactivity (BHR) / airway lability, a 
diagnosis of asthma, wheeze, family history of atopy or asthma, respiratory symptoms 
and prematurity / low birth weight all of which may negatively influence the lung 
function later in life. The negative effect on lung function was represented by prospected 
forced expiratory volume in 1 second (FEV1) deterioration, where FEV1 represents the 
amount of forced expired air a person can exhale in one second. 
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Lungs may be susceptible to several pathologic risk factors that increase the risk of 
chronic respiratory disease and can be classified into two categories: those that present in 
the antenatal period and those that present in the postnatal period.  
 
Antenatal risk factors include maternal smoking, which is found to affect airway growth 
and therefore leads to lung function abnormalities; a reduction in the maximum expiratory 
flow of functional residual capacity and static compliance and conductance were found in 
infants of mothers who smoked during their pregnancy (Goksor et al., 2007). Infants who 
are exposed to antenatal smoking were also found to be more susceptible to lower 
respiratory infections, asthma, and wheezing (DiFranza et al., 2004). The rate of chronic 
respiratory disease was seen to be higher in infants whose mothers had smoked during 
pregnancy than those who had smoked after giving birth (Greenough, 2000). Maternal 
exposure to secondhand smoking during pregnancy or after birth may also be a leading 
cause of acute chest illness in young children (Strachan and Cook, 1997). Second-hand 
smoking during pregnancy was also found to increase the risk of developing childhood 
asthma (Hollams et al., 2014). Lung function has been found to be negatively affected at 
school age for children of mothers who smoked during pregnancy (Strachan and Cook, 
1997). This effect is limited to the early childhood period, as the variation decreases with 
age. This proposed effect of maternal and second-hand smoking may have a more 
profound impact on future respiratory health and thus requires further investigation.  
 
Additional antenatal risk factors for diminished lung function and chronic lung disease 
found in the literature are low birth weight and prematurity (Beyer et al., 2009; 
Greenough, 2000). Prematurity is associated with lung function abnormalities, such as 
low lung compliance, low lung volume, elevated airway resistance, and decreased 
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functional residual capacity (Hjalmarson and Sandberg, 2002). Prematurity affects lung 
function mainly as a consequence of incomplete lung growth and maturation. The adverse 
effects of prematurity on the lungs has both an immediate and long-term effect on 
respiratory function. Neonatal respiratory distress syndrome (NRDS), which is a hyaline 
membrane disease, and bronchopulmonary dysplasia (a long-term consequence of NRDS) 
are prematurity-related respiratory conditions that predispose to chronic respiratory 
disease, such as asthma and COPD (Stocks and Sonnappa, 2013).  
 
Chest infection and viral illness in early childhood are considered postnatal risk factors 
associated with a subsequent decrease in lung function. The literature shows lower 
predicted FEV1 values in children exposed to early childhood infection. Viral infections 
before the age of 3, such as respiratory syncytial virus infection, rhinovirus infection, and 
bronchiolitis, are related to reduced lung function (Guilbert et al., 2011). Other postnatal 
risk factors that may affect lung function in children are obesity and socioeconomic 
status. According to the WHO, 80% of chronic respiratory disease deaths occur in low 
and middle income countries (Abegunde et al., 2007). This may be a consequence of poor 
healthcare (Abegunde et al., 2007). Environmental pollution may also predispose to 
chronic respiratory disease. 
 
Asthma has been associated with early risk factor exposure (Kouzouna et al., 2016). 
Some studies link lung function reduction to abnormalities of the lung secondary to 
congenital or immunological causes since birth (Postma et al., 2015). On the other hand, 
COPD appears later in life (40-50 year olds); however, exposure to early risk factors was 
still found to be associated with the development of COPD in adults (Phelan et al., 2002). 
Persistently low lung function as well as early exposure to heavy smoking was found to 
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increase the risk of COPD development (Svanes et al., 2010a). Moreover, severe asthma 
in childhood was found to be associated with COPD in older age (Phelan et al., 2002).  
 
The effect of early-life risk factors is complex, as each risk factor needs to be 
independently investigated. Accordingly, the effect of risk factors may be considered as a 
single group entity in our study. Some are health factors, such as viral infections or 
prematurity, some are social factors, such as social deprivation, and some are 
environmental factors like exposure to tobacco smoke, all of which are considerably 
important.  
 
2.5 Lung diseases 
 
Lung diseases vary in their nature and in their time of onset. Some disease conditions start 
early in life and manifest early, such as cystic fibrosis (CF). Some diseases start early in 
life but reveal later, such as COPD. Other diseases affect people anytime in life, such as 
bronchial asthma. These three diseases were found common amongst the living 
population and they have the characteristics of starting in the small airways of the lung 
and progressing to involve the larger airways.  
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2.5.1 Cystic fibrosis 
Definition 
 
Cystic fibrosis (CF) is a disease that affects the respiratory system. It is an autosomal 
recessive genetic disease affecting the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene on chromosome 7 that manifests clinically in early childhood. 
Caucasian people have 1:2500 of the autosomal recessive trait, making it the most 
common genetic cause of morbidity and mortality in this population (Spitz and Coran, 
2013).  
 
Prevalence  
 
In the European Union, 1 in 2000-3000 newborns were reported to be affect by CF. In the 
USA, an incidence of 1 in 3500 newborns was reported. In Asia, CF is severely 
underdiagnosed, but existing evidence indicates that prevalence is rare (World Health 
Organization, 2019). 
 
Pathogenesis 
 
The main characteristics of this disease are obstruction of the lung airways due to 
increased viscosity and subsequent stasis of epithelial mucus as well as exocrine 
pancreatic insufficiency. The CFTR mutation stops regulating epithelial chloride 
channels, and thus ionic transport is impaired; mucus as a consequence becomes 
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dehydrated, causing the abnormally increased viscosity of mucus secretions. This 
negatively affects the action of cilia and impairs its function, causing persistent mucus 
existence in areas of the body where it should be cleared, such as the lung. Consequently, 
bronchial and lung infection become frequent. The persistent bronchopulmonary 
infections cause bronchiectasis, resulting in permanent damage and dysfunction of the 
lung (Cotes et al., 2009). 
 
Symptoms 
 
Initially, the patient develops recurrent symptoms of cough and respiratory infections, 
despite the normal results of initial lung examinations and investigations. The disease is 
usually discovered as it progresses and further lung damage occurs. This delay in 
diagnosis may lead to the patient losing the opportunity to reserve his/her lung function. 
Other symptoms involve the digestive system and include foul-smelling greasy stool 
(steatorrhea), intestinal blockage, and poor weight gain and growth. 
 
Diagnosis 
 
Lung damage that is caused by CF can be demonstrated as changes in lung structure. 
Such changes can be observed on computed tomography (CT) imaging as abnormal 
dilatation of the bronchi, bronchial wall thickening and gas trapping (Sly et al., 2009). 
Spirometry, the most commonly used method for testing lung function, unfortunately, is 
unable to detect the early changes that occur in CF and requires patient cooperation, 
which cannot be achieved in the very young (Gustafsson et al., 2008). Sweat chloride and 
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sputum testing are other diagnostic tests that are undertaken when there is clinical 
suspicion for CF. 
 
Monitoring 
 
In recent years, the mean age of death of CF patients has increased to 39 years in the UK 
(Bell et al., 2011). This has been achieved due to advances in monitoring of disease 
progression, guiding appropriate treatment and care. The main method of monitoring CF 
today is by serial CT of the lung, as it can detect early signs of progression before 
development of symptoms. The risk of radiation exposure, however, is a concern 
especially in children. This has created an interest in discovering new safer methods of 
lung function assessment, such as MBW testing (Lum et al., 2007). 
 
2.5.2 Asthma  
Definition 
 
Asthma is a chronic inflammatory disorder of the airways where there is an abnormal 
response towards particular allergens. Asthma is considered a burden on a personal and 
economical level globally. There are three types of asthma classified according to cause. 
The first is extrinsic asthma, which is caused by an external trigger and leads to an 
allergic response. This is a symptomatic type that appears in childhood and is affected by 
different factors. They may develop IgE antibody to a particular antigen. The second type 
is intrinsic asthma, in which no external cause is recognized. It is believed to be occur 
 26 
 
secondary to chronic or recurrent infections. This type appears in adults, and it is IgE-
independent. The third type is a combination of the first and the second (Beachey, 2013). 
 
Prevalence 
 
The prevalence of asthma is approximated to 300 million worldwide, and the mortality 
rate increases in spite of the improvement of health services and care (Braman, 2006). 
According to WHO, annual death rate of asthma is estimated to be 250,000 worldwide 
(World Health Organization, 2019). The prevalence of clinical asthma is found to be ≥ 
10.1% of the UK population, while it is estimated to be 7.6-10.0% in Kuwait (Khadadah, 
2013).  
 
Pathogenesis 
 
Asthma is characterised by airway narrowing, impeded airflow, nonspecific airway 
hyper-responsiveness, and increased mucosal inflammation and recruitment of 
inflammatory cells. Asthmatic patients have a hyper-reactive response to certain 
allergens. Factors such as dust, tobacco smoke, exhaust fumes, emotional stress, viral 
infections and exercise can provoke the abnormal reaction of the airways. In asthmatic 
patients, the immune system reacts to specific materials (allergens) causing the airway 
epithelia to be injured. The mucus membrane becomes swollen producing a thick sticky 
mucus. This abnormal reaction is accompanied by contraction of the smooth muscles of 
the bronchi, which minimizes the airway diameter and therefore increases the resistance 
to air flow. The recurrent attacks may initiate long term damage to the airway that leads to 
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formation of fibrous tissue at a lower epithelial layer, which causes mucus glands to 
increase (Beachey, 2013). 
 
Symptoms 
 
Symptoms of asthma are mainly shortness of breath, wheezing, which is more obvious in 
children, chest tightness of pain, and frequent cough. 
 
Diagnosis 
 
An asthma attack is accompanied with wheezing, indicating tightness or constriction of 
the bronchi. The asthmatic patient suffers breathlessness (dyspnea) attacks which vary in 
their intensity and often happen after exercise or physical activity. Severe attacks may 
start with a dry cough and chest tightness and progress due to bronchospasm, possibly 
leading to respiratory failure and death. Assessment of asthma is mainly achieved using 
the spirometer (Beachey, 2013). 
 
Monitoring and treatment 
 
The intervention programs that have been established for asthma are found to improve 
healthcare and show a remarkable reduction in hospitalization and death rate. These 
programs are being implemented in communities all over the world with the common 
goal of controlling asthma in the community. For example, education programs targeted 
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to patients and families of patients with asthma as well as school staff have been 
constructed to increase awareness about asthma, increase recognition of the signs and 
symptoms of an asthma attack, and how to address such an attack. Personalized 
instructions and recommendations are given also given as a part of some intervention 
programs to patients through home or clinic visits for discussing ways of reduction of 
asthma triggers based on a child’s skin allergy test. Undiagnosed and undertreated cases 
of asthma are primary factors of morbidity and mortality in this disease (To et al., 2012). 
 
Treatment of asthma depends on the relief of symptoms. Rest, relaxation, bronchodilators 
and avoidance of causative factors comprise the management of asthma attacks. The 
method of treatment that is used for long term maintenance of asthma as well as control 
of asthma attacks are anti-inflammatory drugs (corticosteroids) and bronchodilators. The 
latter work on relaxing the smooth muscles of constricted airways as an emergency relief. 
Genetic factors, atmospheric pollution and maternal smoking during pregnancy are risk 
factors for raised IgE levels. Consequently, asthma and airway hyper-responsiveness may 
develop.  
 
Clinically, the process of dealing with and controlling asthma depends on observing and 
monitoring of lung function and symptoms. Although lung function may appear normal 
and well controlled clinically, inflammation of the airways may exist (Sont et al., 1996). 
The most popularly used method in assessing the severity of asthma is spirometry, in 
addition to assessment of symptoms. Nitric oxide (NO) is another method used as a non-
invasive marker in the assessment of airway inflammation in asthma. The level of exhaled 
NO is found to reflect airway inflammation in an asthmatic patient (Jatakanon et al., 
1998). However, NO level decreases when using inhaled corticosteroids in the treatment 
 29 
 
of asthmatic patients and is therefore not helpful in these particular group (Kharitonov et 
al., 1996).  
 
2.5.3 Chronic obstructive pulmonary disease (COPD) 
Definition 
 
COPD is defined as an incompletely reversible airway obstruction that is demonstrated by 
a ratio of post-bronchodilator forced expiratory volume in one second to forced vital 
capacity (FEV1/FVC) of less than 70%. This definition is based on the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) guidelines (Mannino et al., 2006). Other 
definitions exist for COPD according to how the disease is classified. Symptomatically, it 
is defined as chronic bronchitis and, anatomically, as emphysema. The latest definition 
however is airway obstruction, which follows a physiological disease classification 
(Snider, 2003). 
 
Prevalence  
 
COPD represents a significant healthcare burden and the forth leading cause of premature 
death worldwide (Calverley et al., 2003).  The prevalence was estimated to be 328 million 
COPD  incidence worldwide (Quaderi and Hurst, 2018). In addition to the tremendous 
costs of investigating and managing the disease, there is a further cost burden due to 
disability and impaired quality of life (Ferrer et al., 1997) . 
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Pathogenesis 
 
The pulmonary defect that occurs in COPD is noted to appear clinically in the fourth 
decade of life. The onset of the disease, however, may happen in early life in some cases. 
COPD is characterized by incompletely reversible lung damage, progressive airway 
obstruction, and persistent inflammation of the airways (Halbert et al., 2006). COPD 
patients have been found to have increased inflammatory cells in the small airways 
correlating to the severity of airflow obstruction (Turato et al., 2002). 
 
The prevalence of COPD is related to some factors. Smoking is the most significant 
associated risk factor. Prevalence of COPD was previously considered significantly 
higher in males, but a rise in smoking rates in females is causing prevalence to rise in the 
female population. COPD incidence is also noticed to increase with age. Exposure to 
inhaled substances such as occupational smoke or dust and ambient air pollution are 
probable risk factors that may need further investigation. 
 
Symptoms 
 
The main symptoms of COPD are shortness of breath, wheezing, chest tightness, and 
chronic cough. 
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Diagnosis 
 
COPD starts in the small airways and therefore early detection of the disease may help 
control its progression and delay the irreversible damage that occurs with time (Svanes et 
al., 2010b). This fact may highlight the importance of the investigation of this disease at 
its early stages. 
 
Currently, diagnosis of COPD is achieved by spirometry results that show a post-
bronchodilator FEV1/FVC ratio of less than 70%, which signifies irreversible or partially 
reversible airway obstruction, which characterizes COPD and distinguishes it from 
asthma; in asthma, airway obstruction is reversed by bronchodilator therapy, normalizing 
the FEV1/FVC ratio. 
 
Small airway obstruction is one of the three major phenotypes of COPD, but is not 
represented by the FEV1/FVC ratio, as this ratio assesses for larger airway obstruction. 
CT imaging can detect small airway changes in COPD; however, it is not routinely 
performed on COPD patients as patients present for assessment after the disease 
progresses to affect the larger airways, manifests as symptoms, and is detectable by 
spirometry. 
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Monitoring and treatment 
 
FEV1/FVC ratio is a measure of airway resistance and is thus found to elucidate only 
large airway obstruction. It is incapable of demonstrating the diversity of the symptoms 
and quality of life in COPD due to the notion that the primary location of the disease 
pathology is the small airways and lung parenchyma (Ward et al., 2010). In addition to 
the pathological and physiological changes in lung airways, radiographic assessment 
indicates loss of the airways or size differences. Galban and Colleagues (2012) found that 
no apparent defects appeared on radiographic images of patients with less severe disease 
although disease was present in sites of the lung (Galbán et al., 2012). All of the 
preceding information emphasises that the irreversible damage to the airways significant 
enough to cause symptoms, which is termed emphysema, is a late stage of the disease, 
while the illness potentially commences in the changes of small airways, where 
investigation should be directed but currently limited (Postma et al., 2015). 
 
Detecting changes in the small airways in early stages of COPD is considered a challenge, 
especially if a non-invasive technique is required. It has been found that small airway 
disease marks the beginning stage of COPD. Therefore, the demand for a feasible method 
that is sensitive to the early changes in the small airways of the lungs at an early stage is 
greatly needed. 
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2.6 Measurement of respiratory function 
 
Lung function measurement is used to determine the abnormality of the respiratory 
system and detect the site of defect. Measuring lung function also assists in monitoring 
the progression of disease, specifies its severity, and determines the effectiveness of 
treatment. Lung diseases are mainly found to cause damage to either the airways or the 
alveoli. Consequently, either lung volumes or lung capacities will be affected (Ward et 
al., 2010).  
 
Available testing methods enable measuring the different variables that are required to 
evaluate lung function. Measured parameters could be divided into four categories: lung 
volume, ventilation parameters, diffusion capacity and expiratory flow rate (Beachey, 
2013). 
 
A variety of modalities are available to measure lung function. Some of these modalities 
measure lung volume, such as spirometry, plethysmography, and multiple-breath washout 
(MBW). Computed tomography (CT) is another method that is used to demonstrate lung 
defects by imaging of lung structure. Comparison of the most important methods of lung 
function assessment (plethysmography, spirometry, CT, and MBW) is summarized in 
Table 2 in section 2.6.3.17 of this chapter. 
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2.6.1 Spirometry 
 
Spirometry is a non-invasive lung function testing tool that measures lung capacities, 
dynamic volumes and flows (Miller et al., 2005). It is considered the most common tool 
for lung function testing, as it is a simple and feasible technique that measures how 
efficiently and rapidly the lungs fill and empty with air during inhalation and exhalation, 
respectively (Beachey, 2013). Spirometry a Latin word which means Spiro- to breathe 
and meter- to measure. It was invented in the 1840’s by an English surgeon named John 
Hutchinson. The device was a calibrated bucket placed upside down in water. The volume 
of exhaled air from fully inflated lungs could accurately be measured by exhaling into a 
tube leading into the bucket. Around 1950 obstructive (limited flow rate) and restrictive 
diagnosis were determined vital capacity measured restriction. In 1950 measurement of 
air volume during a given time frame was introduced i.e. FEV1 (Spriggs, 1978). 
Spirometry is not only used for diagnostic purposes; it is also used to follow up the 
progression of respiratory disease and accordingly evaluate treatment plans (Pierce, 
2005).  
 
Spirometers are categorized into two types depending on the method of technology that is 
used: volumetric and flow-measuring spirometers. The volumetric type is designed to 
measure the immediate amount of air the person can breathe in and out of the lung. It 
shows this amount through a volume-time graph called a spirogram (Figure 3.a). The 
second type of spirometer is designed to measure the speed of air movement during 
inhalation and exhalation. Flow-measuring spirometers are usually smaller in size than 
the volumetric ones and they provide a flow-volume graph (Figure 3.b) (de Jongh, 2008). 
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Figure 3 Graphical representation of spirometric measurements. 
This illustrated (a) Volume-time plot records cumulative volume expired over time. The red dot represents 
the forced volume expired in one second (FEV1), (b) The flow-volume loop is an alternative graphical 
representation of spirometry that plots expired flow rate over volume of air expired. The green dot 
represents the peak expiratory flow (PEF) (Tseng et al., 2017). 
 
The measurement process 
 
During spirometry an individual starts by making a tight seal around the spirometer 
mouth piece. The individual then takes a voluntary deep breath that fills the lungs to total 
capacity and breathes out as quickly and forcefully as possible until all the maximum 
amount of air is expelled out of the lungs. The result of this measure is demonstrated 
through a graphic display of expired and inspired volume of air against time, as a 
spirogram or a flow-volume curve. Severity of lung disease is measured and quantified by 
measurements of inspired and expired lung volumes in spirometry. 
 
 
 
 
PEF 
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The outcome measures 
 
The main outcome measures of the spirometer are: FEV1, which is the amount of forced 
air a person can breathe out in 1 second, when volume is plotted against time; and the 
FVC (Miller et al., 2005), the total amount of air a person can breathe out of his lungs. 
Forced expiratory ratio (FER) is the ratio of FEV1 to FVC, which shows how much air the 
individual can expire in the first second out of the total expired air (Miller et al., 2005).  
FER = FEV1/FVC 
A healthy person is expected to force out between 0.75 and 0.90 (75%-90%) of his total 
FVC (Ward et al., 2010). This ratio may be higher in healthy children.  
 
Spirometry can be used to measure other outcome measures such as peak expiratory flow 
(PEF), which represents the a person’s maximum speed of expiration. It may be 
equivalent to the forced vital capacity (FVC). Maximum voluntary ventilation (MVV) is 
another value that can be measured by the spirometer and it is the maximum amount of 
air that a person can breathe in and out within one minute (de Jongh, 2008) (Figure 4). 
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Figure 4 Output of a spirometer 
This illustrating the outcome measures of the spirometry; note that  FRC and RV are not measured by 
spirometry (J. Gordon Betts et al., 2014). 
 
The interpretation of the outcome results (FEV1, FVC, PEFR) of spirometry depends on 
comparing the measured value with normative reference values in conditions using the 
same testing protocol. Obtaining a value that is out of the range of the reference limits 
indicates an abnormality of ventilation (Pierce, 2005). 
 
The clinical usefulness of spirometric measures 
 
Spirometry has a role in diagnosis, monitoring and evaluating the role of the pulmonary 
system. It helps identify lung abnormalities by measuring airflow during expiration and 
inspiration. It measures the amount and the time that is taken to exhale and produces from 
this several outcome measures. The outcome measures help to distinguish between 
obstructive and restrictive respiratory diseases (Miller et al., 2005). It helps evaluate 
respiratory signs, symptoms and abnormal laboratory tests imaging modalities, such as 
chest radiographs. It also plays a critical role in the assessment of lung conditions for 
smokers and the people exposed to environmental hazards.  
Not measured  
by spirometer 
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In obstructive diseases, such as COPD or acute asthma, FER value is < 0.70. In 
asthmatics, FEV1 and FVC are found to increase after bronchodilators (Johannessen et al., 
2006). Spirometry assists in evaluating reversibility of obstructed airways. The 
reversibility of airways can be demonstrated by an increase in FEV1 or FVC ≥ 12% and ≥ 
200 mL in response to bronchodilators, which reflects bronchodilator effect on airflow 
obstruction (Pellegrino et al., 2005). A significant response to bronchodilators reversible 
airway obstruction rather than COPD. 
 
FEV1 is used clinically to determine the progression of COPD by indicating the stage and 
severity of the disease. Depending on the value of FEV1, COPD is divided into four 
stages: 
 
 Stage 1: mild  FEV1 ≥ predicted value, FEV1/FVC <70% 
 Stage 2: moderate  FEV1 between 50-79 % of predicted value, FEV1/FVC 
<70% 
 Stage 3: severe  FEV1 between 30-49% of predicted value, FEV1/FVC <70% 
 Stage 4: Very severe  FEV1 <30% of predicted value, FEV1/FVC <50% with 
chronic respiratory failure (Hajiro et al., 2000).  
 
Restrictive diseases such as lung fibrosis, on the other hand, cause a reduction of both 
FEV1 and FVC while the FER is normal or high. Therefore, FER is not considered helpful 
in making a diagnosis of restricted lung disease (Wang et al., 2009).  
Table 1 compares spirometry finding in obstructive vs restrictive lung diseases. 
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Table 1 Obstructive vs restrictive lung diseases 
Obstructive lung disease Element of comparison Restrictive lung disease 
Limitation of airflow due to 
partial or complete obstruction 
Definition 
Reduced expansion of the lung 
companied by decreased TLC 
↓ 70% FER (FEV1/FVC) Normal or ↑ 
Marked ↓ FEV1 Normal or slight ↓ 
Normal or ↓ FVC ↓ 
This illustrating the comparison between obstructive and restrictive lung diseases showing the difference of 
the spirometry outcome measures 
 
The limitations of spirometry 
 
Spirometry is a valid and easily applicable method; it is the gold standard lung function 
testing method in many respiratory conditions, yet it has its disadvantages. It requires 
active participation and cooperation of the individual. Consequently, applying this 
method may present as a challenge for the young population, mainly preschool-aged 
children and infants, or for unconscious subjects. The Rapid Thoracoabdominal 
Compression (RTC) technique has been adapted to be used in infants where eliciting a 
maximal expiratory effort is challenging (Merkus et al., 2005). Using this technique 
requires the infant to be sedated and dressed in a plastic jacket that wraps around the chest 
and abdomen with a mask over the mouth and the nose. Then, external pressure is applied 
on the chest and abdomen by inflating the jacket at the end of inspiration, and expiratory 
flow and volume are subsequently measured. The measured FRC through this technique 
is unstable and highly variable, affecting reproducibility of measurements; this impacts 
the sensitivity of the test to airway changes and poses a major limitation for this 
technique. Additionally, this technique demands providing specialised equipment in 
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pulmonary function clinics which is considered a further disadvantage (Zaoutis and 
Chiang, 2007). 
 
One more limitation of the spirometer is that FEV1 is appropriate to be performed on 
adults, but when taking children's measurements, FEV0.75 or FEV0.5 values are found to 
be more suitable or a better measurement of lung function (Pesant et al., 2007). Moreover, 
FEV1 is a changing parameter in time, with individual variation of up to 5% within a day 
and possibly up to 12% from week to week (Ellemunter et al., 2010); this is the situation 
among the adult population, but a chance of error is expected to be even higher among the 
paediatric population, affecting the reliability of FEV1 measurements in this age group. 
 
Although spirometry is the most commonly used tool for lung function testing, spirometry 
is found to be insensitive to early changes in the pulmonary system, particularly the 
peripheral airways. Therefore, it is unable to detect abnormalities in the airway at early 
stages (Lum et al., 2007). An estimation of 75% of airway obstruction found to occur 
before spirometry can detect the abnormal changes (Burgel et al., 2013).  
 
2.6.2 Plethysmography 
 
Plethysmography is a well-established method of pulmonary function testing. The idea of 
the plethysmography was first described in 1956 by DuBois et al who presented the 
method as a rapid and practical measurement of lung volumes that depended on 
measuring the change in the volume of the gas when it was compressed (DuBois et al., 
1956). It simply measures the amount of air the lungs can hold. The plethysmography 
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technique is based on Boyle's law, which states that "under isothermal conditions, when a 
constant mass of gas is compressed or decompressed, the gas volume decreases or 
increases and gas pressure changes such that the product of volume and pressure at any 
given moment is constant" (Coates and Burton, 1997; DuBois et al., 1956). The amount 
of air held in the lungs, which is represented as the TLC may be most accurately 
measured by plethysmography. It assists the physician particularly in identifying whether 
the problem is caused by lung structure damage or due to loss of expansion ability. 
 
 
Figure 5 The body plethysmography in a clinic setting 
(Bersten, 1999) 
 
Plethysmography helps in evaluation of airway obstruction and aids in diagnosis of 
respiratory conditions. Additionally, it contributes in monitoring disease progression and 
treatment response (Marin, 2004).  
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Plethysmography uses tidal breathing to measure airway resistance and functional 
residual capacity (FRC). It depends on the idea of measuring the change in pressure while 
breathing. This technique follows the same principle in infants as is followed in adults. 
For infants, however, it requires small and sensitive equipment to accommodate for the 
difference between the body and lung size of the baby. This technique is computerized, 
which facilitates calibration and monitoring of a baby’s sudden unwanted events such as 
apneas (Marin, 2004). Figure 5 depicts the plethysmography machine used in clinical 
practice today. 
 
The measurement process 
 
During plethysmography, the individual is expected to sit in an airtight chamber with a 
mouth piece and nose clip. The procedure requires breathing normally and quietly (tidal 
breathing) followed by a series of soft panting at a frequency of 0.5-1.0 Hz. Pants with 
higher or lower than this range lead to error. The pants are taken against a closed shutter 
while the pressure is measured in the sealed chamber and lung volume is measured. 
Afterwards, the shutter is unlocked allowing the individual to breathe out the air and 
empty the lung. A full inhale follows to fill the lung with air once more (Beachey, 2013).  
 
The outcome measures 
 
FRC and RV are two outcomes that can be measured by using the plethysmography 
technique. Both outcomes are found to be increased in some diseases, such as asthma, 
bronchitis and emphysema. This is explained by the increased resistance in the airways 
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causing an increase in trapped air, which is manifests as an increase in residual air volume 
and capacity. This technique allows measurement of TLC and allows detection of severe 
airflow obstruction (Coates and Burton, 1997) (Figure 6). 
 
 
Figure 6 Volume tracing for body plethysmographic measurement of static lung volumes. 
This illustrating the outcome of body plethysmography (a) when the shutter is closed FRC is measured, 
followed by a full exhalation all the way to (b) where RV is measured; then a full inhalation is taken to 
reach (c) TLC, which is  measured (bronchiectasis toolbox, 2019). 
 
The clinical usefulness of the measures 
 
In restricted lung disease, there is a decrease in TLC, FRC, RV and VC. Usually RV is 
the earliest affected value in restricted lung disease; therefore, it is used to measure 
airway resistance. In obstructive disease, FRC and TLC will increase as the lung reacts to 
keep the airways open by reducing lung recoil, in an effort to maximise lung volume 
(Barisione and Pellegrino, 2015). Plethysmography is used to confirm a restrictive 
component of lung disease that can only be suggested by spirometry. Body 
a 
b 
c 
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plethysmography is often considered to be an accurate and repeatable measurement of 
TLC, and can thus be of diagnostic value in restrictive lung disease when combined with 
spirometry (Barisione and Pellegrino, 2015).  
 
The limitations of plethysmography 
 
The plethysmography technique may present a few disadvantages. Chambers may cause 
anxiety, discomfort, and claustrophobia for some people. It might be inappropriate for 
very obese patients or those with skeletal deformities. Dizziness, light-headedness, and 
shortness of breath may result from this test due to the build-up of heat, pressure, and 
carbon dioxide. Despite the simplicity of its principle, the usage of this equipment exists 
in highly specialized centers and requires trained staff. Plethysmography is expensive and 
requires precise performance which makes it a difficult routine procedure to perform for 
assessment of lung function (Marin, 2004). 
 
2.6.3 Computed tomography (CT) 
 
Computed tomography (CT) is another method used to assess lung abnormalities that 
provides visualisation of structural lung defects through imaging. CT imaging was 
invented by British engineer Godfery Hounsfield and South-African-born physicist Allan 
Cormack of Tufts University back in 1972, and they were later awarded the Nobel Prize 
for their great contribution to medicine and science. CT was first performed on humans in 
1974 and was limited to imaging of the head only. Later in 1976, whole body CT imaging 
was made available, and by the 1980s, it became a widely-used method of imaging in the 
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medical field (Beckmann, 2006). Over the years, this imaging modality underwent great 
improvements in speed, patient comfort, and resolution. Computed tomography is a 
technique that is highly sensitive to small lung abnormalities. It can estimate lung tissue 
and air volumes as well as estimate lung volumes occupied by changes in density 
(Wanger et al., 2005b). It is considered an important tool for detecting lung diseases in 
early stages. This technique is considered to be noninvasive and accurate. It is a non-
painful and relatively quick imaging procedure (Tiddens et al., 2010), though it exposes 
the patient to the risk of ionizing radiation. 
 
The clinical usefulness of the measures 
 
CT is an accurate measuring technique in the field of respiratory diseases. It has been 
evaluated in different studies and for various conditions. It is found most useful in 
detecting lung cancer at early stages when there is a high cure rate. When combined with 
angiography, CT has also been found to play a vital role in the diagnosis of acute 
pulmonary embolism (PE). The results of the study showed that CT is sensitive and 
specific in diagnosing PE compared to ventilation-perfusion lung scans (V-P scans) and 
other diagnostic modalities (Sodhi et al., 2010). 
 
The measurement process 
 
CT is a technique that depends on taking computerized cross sectional images of an organ 
in several directions (three dimensions) and the outcome image can be displayed on a 
computer screen, printed as a high-resolution image, or copied to a CD or DVD. As this 
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method depends on exposure to radiation, the dose is associated to the individual’s size 
and the level of software technology being used by the machine. 
 
The CT imaging process resembles the usual x-ray examination, in that it depends on 
differences in absorbance of body tissues to x-ray radiation. The difference in CT 
scanning, however, lies in that the patient in CT scanners are exposed to numerous 
rotating x-ray beams that are received on the opposite side of the beam by electronic x-ray 
detectors. The software combines these multidirectional images to form an image of 
excellent resolution for assessment of disease. In other occasions, the examination table 
may rotate itself in the scanning process to create a spiral path, known as a spiral CT scan 
which have added resolution. During the scan, the individual is requested to lie down on 
the examination table, usually in a supine position. The usage of straps and pillows may 
help stabilize the patient during the examination. Movement during the scanning should 
be kept to a minimum. The procedure usually takes 30-60 minutes in total, including the 
time of preparation of the patient. 
 
The outcome measures 
 
CT scans provide a detailed image of the lung and thoracic cage volume. The high 
resolution computerized tomography (HRCT) scan is preferred in lung conditions as it 
provides great detail of the anatomical structure of the lung in order to clearly identify and 
locate small airway and emphysematous changes (Cotes et al., 2009) (Figure 7). 
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Figure 7 HRCT axial cuts in a COPD patient. 
This showing HRCT axial cuts in a COPD patient in which direct visualization of the small airways in (A-
C) demonstrate air filled ring like structures and in (D)demonstrate  air filled branching tubular structures. 
Identify the reference please (Gupta, 2011).  
 
The limitations of CT 
 
CT has its disadvantages. Although it is an accurate lung structure testing method, it 
exposes the patient to an ionizing radiation dose, which may pose a health risk to the 
patient when frequently repeated (Cooper and MacLean, 2006). Consequently, it cannot 
be considered a routine method for measuring lung function. 
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It is a time-consuming procedure, especially for younger children. CT was found to be an 
inappropriate method for subjects with limited ability to cooperate. Therefore, it is a 
challenging method in the case of young children or infants. In such cases when the scan 
is essential to make a diagnosis, sedation or general anesthesia may be administered, 
which exposes the subject to further risks besides radiation. These disadvantages make 
CT an inappropriate method for routine assessment of pulmonary disease, and is reserved 
for selected cases and conditions. 
 
2.6.4 Inert gas washout 
 
Two methods have utilized the principles of inert gas washout: the single breath washout 
(SBW) method and multiple breath washout (MBW) method. 
 
2.6.4.1 Single breath washout (SBW)  
 
Single breath washout testing, also known as single-breath oxygen testing, is a method of 
measuring lung function using the technique of gas washout. The principle of SBW is to 
assess the efficiency of ventilation distribution through gas mixing within the time frame 
of a single breath (Fowler, 1949). It aims to evaluate uniformity of gas distribution in the 
lung.  
 
The measurement process 
 
This method is characterized by an inspiratory vital capacity (VC) maneuver, starting 
from residual volume (RV) and inspiration of pure 100% O2, in the case of using 
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endogenous gas (e.g. N2), until reaching total lung capacity (TLC). This is followed by 
expiration in which the washout phase of the gas starts to reach RV once again. In case of 
using exogenous inert gas, such as SF6, then a wash-in phase is required during inhalation 
from RV to TLC. 
 
The outcome measures 
 
Breath washout testing aims to assess the uniformity of gas distribution in the lungs. The 
washout is represented by an expirogram which represents expired gas against expired 
volume (Figure 8). The expirogram shows the washout process in four phases. In phase I, 
the inert gas concentration recorded is 0% throughout, reflects gas washout from the 
conductive airways (i.e. the anatomic dead space). This is followed by phase II, which 
shows a rise in the curve directed upward, reflecting the gas washout from the dead space 
and bronchi, where there is mixing of gas but no gas exchange. Phase III represents 
washout of gas from the alveoli depicted as a slightly sloping plateau; this plateau occurs 
due to the almost constant inert gas concentration in alveoli. If inspired oxygen or air 
inhaled during washout is distributed evenly to all alveoli so that all alveoli have equal 
inert gas concentrations, then phase III of the tracing is almost horizontal (alveolar 
plateau). However, if inspired oxygen is distributed unevenly (usually due to lung 
disease), then the end-inspiratory inert gas concentrations are not equal throughout the 
lung. Clinically, the phase III presents the most informative outcome measure by 
calculating the slope of phase III. Finally, phase IV represents the closing volume and 
shows a sharp increase in concentration, reflecting discriminatory small airway 
obstruction, causing air to be expelled beyond that point (Gold and Koth, 2016). 
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The slope of phase III is measured over the mid portion of the expirogram [25%-75% of 
TV of expiration] and it is determined as the line of best fit (Bush and Sly, 2019). The 
derived indices are SIII which reflects the combined CDI (convection-dependent 
inhomogeneity) and DCDI (diffusion-convection-interaction-dependent inhomogeneity) 
contributions and airway closure and trapped gas volume assessment. 
 
The clinical usefulness of the measures 
 
The SBW technique helps assess the efficiency of evenness of gas distribution in the 
lungs within a single breath. Clinically, getting the measurement of slope lll is the most 
useful feature of the SBW testing as it indicates the inhomogeneity of gas distribution in 
the lungs. SBW cannot provide CDI and DCDI in separate form as an outcome of SIII, 
though it may help locate the defective part of the lung; this ability to localize 
abnormality is affected by the molar mass of the inert gas used, in which gases of smaller 
molar masses (i.e. He) localize at the entrance of the acinar area, while heavier gases (i.e. 
SF6) show abnormal results at distal aspects of the acinar entrance (Olfert and Prisk, 
2004). 
 
The limitation of the SBW 
 
SBW is impractical in infants and younger children as it requires performing conventional 
Valsalva manoeuvre, which requires a person to cooperate and follow instructions. 
Moreover, performing SBW requires maintaining the respiratory flow through inspiration 
and expiration between 400-500 ml and reproduction of vital capacity, limiting this 
technique to adults and children above 12 years of age. Moreover, in the respiratory 
phase, the gas distribution and airway closure varies within the regions of the lungs due to 
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the influence of gravity (Wilson et al., 1987). The SIII in SBW is affected to a great 
degree by this difference. In addition, SIII does not have the ability of separating CDI and 
DCDI contribution. The SIII obtained from VC SBW may not be a representation of the 
actual peripheral airway contribution (Kjellmer et al., 1959). 
 
 
Figure 8 Single breath washout spirogram. 
This demonstrated the single breath washout spirogram: Phase I represents the anatomic dead space gas 
concentration; phase II represents the gas concentration in the dead space and bronchi; phase III (also 
known as the “alveolar plateau”), represents emptying of pure alveolar gas; phase IV, exhaled gas after the 
onset of airways closure (PFT BLOG, 2014). 
 
 
Multiple Breath Washout (MBW) 
 
Multiple Breath Washout (MBW), like SBW, is a lung function test that measures 
ventilation inhomogeneity (Aurora, 2010). It uses tidal volume for measuring lung 
function. MBW is an old technique introduced in 1952 by Fowler who described his work 
on the cardiorespiratory diseases and utilized this method to measure the behavior of gas 
distribution in the lung (Fowler et al., 1952); following researchers, however, lost interest 
in the method due to its limitations. The development of the computerized multiple breath 
washout system and the sensitivity in gas detection were the key features that brought 
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about the resurgence of the MBW technique in the research community decades after it 
was first introduced. The MBW technique was developed recently by Gustaffson and 
Ljungquist (Robinson et al., 2009). The principle of the technique is to use a tracer gas 
that could be endogenous, such as nitrogen or argon, or exogenous, such as sulfur 
hexafluoride (SF6), helium (He), or methane, to assess the efficiency of lungs by 
assessment of the inert tracer gas clearance (Fowler, 1949).  
 
The peripheral airways are those branches of bronchioles beyond the 8th generation. At 
this level, airway resistance is not visible. Therefore, the traditional methods that assess 
airway resistance, such as the spirometer, are unable to detect changes at this level. When 
peripheral airways are affected by respiratory disease, the air will be distributed unevenly, 
and inhomogeneity of ventilation occurs (Stewart and Criner, 2013). This is the reason 
gas dilution methods are preferred in diseases that affect the peripheral airways, as 
ventilation inhomogeneity becomes a more helpful measurement of pulmonary function 
than airway resistance.  
 
The measurement process 
 
The MBW process requires the individual to be in a comfortable position using a mouth 
piece and nose clip attached to the MBW machine. Usually, the individual is seated 
unless the patient’s health status restricts him/her from sitting. MBW technique can be 
performed either with inhalation of an inert tracer gas such as sulphur hexafluoride (SF6) 
or helium, or by using 100% oxygen to wash out endogenous resident nitrogen. The latter 
technique has been available for several decades and takes slightly less time to perform as 
it skips the wash-in phase. If an exogenous tracer gas is used, the process is divided into 
two phases. First, the patient washes in the gas by breathing in the inert tracer gas through 
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the machine. The subject continues with tidal breathing until he/she reaches a specific gas 
concentration in the lungs, after which the second phase, the wash out phase, will start. 
The purpose of this phase is to breathe continuously to clear the lung of the inhaled gas. 
The main outcome measured by this technique is the LCI (lung clearance index) which 
indicates the turnovers required to eliminate the exogenous gas out of the lung. Unlike 
SBW, MBW requires passive cooperation and minimal coordination as it is performed 
during tidal breathing. Therefore, it is suitable for almost all ages, including infants, and 
can be done on sedated patients (Aurora, 2006).  
  
The gases used in MBW 
 
MBW assesses ventilation inhomogeneity by washing out an inert tracer gas, which can 
either be endogenous (naturally resident in the body tissue) or exogenous (not found 
naturally in body tissue), from the lung. The inert gas must fulfil certain characteristics to 
be used in breath washout: it should be safe to inhale in the recommended concentration, 
should not interact with the gas exchange process in the lung tissue, and should not 
dissolve in the body tissues (Robinson et al., 2013b). Endogenous gases that have been 
used in MBW testing were nitrogen (N2) and argon (Ar), while exogenous gases include 
sulphur hexafluoride (SF6), Helium (He), and methane (CH4). The inert gas choice was 
found to influence the outcome measures of the MBW; this was explained by the 
difference in behavior of the gas inside the peripheral airways, influenced by molar mass 
of the gas, gas density, and gas diffusion rate. This affects the location of the diffusion-
convection front which occurs at an intermediated zone where convection and diffusion 
interact in the lung airways. The behaviour of the gas inside the peripheral airways was 
found to be influenced by gas density (Olfert and Prisk, 2004). The gas diffusion rate is 
known to be inversely proportional to the molar mass of the gas, therefore affecting the 
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diffusion-convection front location, which is located less peripherally when using lighter 
gases compared to heavier ones.  
 
Each gas has its advantages and disadvantages when used in MBW. N2 is considered 
endogenous or naturally available as it naturally resides physiologically within the lung. 
Therefore, no wash-in of inert gas is required. However, to achieve and measure N2 
washout from the lung, 100% O2 is required. The disadvantage of using 100% O2 lies in 
that it may impact the breathing pattern, especially in infants (Singer et al., 2013), which 
alters MBW values, making the test unreliable. Another disadvantage of N2 is that it 
overestimates FRC when used as a tracer gas (Lundin, 1953).  
 
Helium (He) is one of the lowest density gases, especially when compared to SF6, which 
is considered a heavy gas due to its high density and molar mass (He versus SF6 is 4 
versus 146 grams/mole). This feature of He increases the rate of leaking during washout 
testing and is therefore not routinely used. SF6 is considered a low risk gas and is safe 
when used within the recommended concentration. SF6 is non-toxic, non-inflammable, 
and insoluble in water (Koch, 2003), and is qualified to be used as a tracer gas in MBW. 
It is free of side effects when used in a concentration of 4% made affordable with an 
abundant amount of O2. However, SF6 has its disadvantages as it is considered a potential 
greenhouse gas, is considered high cost, and has not been approved for medical use in 
some countries. Nevertheless, it is commonly used worldwide in medical fields such as 
ophthalmology and ophthalmic surgery (Koch, 2003). 
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The outcome measures 
 
 Lung clearance index (LCI) is the main parameter that is calculated from MBW curves 
(depicted in Figure 9) and is used for early detection of peripheral airway changes. It is a 
measure of ventilation inhomogeneity and is basically a description of how much 
ventilation is required to completely clear the functional residual capacity (FRC). LCI 
represents the turnovers of the air volume required to wash out an inhaled inert gas from 
the lungs until it reaches 1/40th (2.5%) of the starting inert gas concentration. The LCI can 
also indicate the general anatomic location where ventilation inhomogeneity (or 
alternatively, ventilation heterogeneity) is occurring, specifically the peripheral 
conducting or acinar airways, which are found at the terminal ends of each bronchiole.  
 
LCI is a quantifiable measure of ventilation inhomogeneity (Robinson et al., 2010). It 
allows early detection of uneven air distribution and reveals lung defects at early stages, 
which may direct management before disease progression, and as a result, may delay 
irreversible lung damage and preserve lung function. Moreover, this technique helps 
monitor disease progression and is effective in evaluation of treatment strategies. The use 
of LCI as a method to assess ventilation inhomogeneity is the recent direction in 
pulmonary care. Nonetheless, this approach may be unable to localize the region of 
inhomogeneity (Robinson et al., 2013a). 
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Figure 9 Washout curve.  
This illustrated the washout curve where the black trace represents flow (left axis). The grey trace 
represents inert gas concentration (right axis). A is the end of the wash-in, where gas concentration during 
inspiration and expiration is identical and equal; B is the start of the washout phase, showing the start of the 
gradual decrease in SF6 concentration throughout the washout phase (Aurora et al., 2005b). 
 
 
LCI is the most commonly used outcome measure in the MBW device. It is an indication 
of the overall ventilation inhomogeneity of the lung. LCI represents how many turnovers 
the lung completed to eliminate the inert gas till it reached 1/40th of the starting 
concentration. Mathematically, LCI can be calculated by dividing the cumulative expired 
tidal volume (CEV) that is required to diminish the inert gas by FRC during washout. 
 
LCI = CEV / FRC 
 
LCI value will increase when airways are obstructed causing delay in clearing of the inert 
gas and consequently further turnovers are required to clear the inert gas out of the lung. 
Therefore, increased LCI value indicates ventilation inhomogeneity and lung function 
abnormality. 
 
A B 
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The LCI reported for an individual is the mean of 3 (minimum 2) technically accepted 
measurements, considering standard deviation (SD) and coefficient of variation (CoV).   
FRC is also a calculated measure by MBW. FRC is simply defined as the air volume 
remaining in the lungs at the end of tidal expiration. FRC is considered an absolute lung 
volume which cannot be measured by conventional lung function testing methods such as 
spirometry. It can be measured by plethysmography, helium dilution or MBW. Refer to 
Figure 4 in section 2.7.1.2. earlier in this chapter for an illustration of lung volumes and 
capacities, including FRC. 
 
The MBW device measures the tidal breathing of the subject continuously during the test, 
providing a measurement of the cumulative exhaled volume as well as the expired SF6. 
By measuring the initial and end SF6 concentration, the functional residual capacity 
(FRC) can be calculated during washout. 
 
FRCgas = Vgas / Cinitial– Cfinal 
 
Where: Vgas is net volume of inert gas expired, Cinitial is the inert gas concentration at the 
start of washout and Cfinal is the concentration of inert gas at the end of washout.  
 
The secondary but helpful outcome measures Scond and Sacin are more informative than 
LCI, as they not only indicate presence of inhomogeneity, but they also localise the defect 
site of ventilation. Scond indicates the inhomogeneity at the conductive airways, which 
terminates at the small airways at the end of the bronchioles before the alveoli. Sacin 
reflects ventilation heterogeneity at the entrance of the acinar region. These indices reflect 
the ventilation process in the peripheral and distal parts of the lung. 
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Scond and Sacin are derived from the normalized phase III slope (Figure 10). Each tidal 
breath when plotted the inert gas concentration against exhaled volume then divided into 
three phases. Phase III refers to alveolar gas exchange, which represents 65-95% of 
expiration. These indices reflect the ventilation process in the peripheral and distal parts 
of the lungs. The gas transport in the acinar area is driven by diffusion, which means that 
the movement of gas molecules is controlled by the difference in concentration; 
movement of molecules in diffusion occurs from areas of higher concentration to lower 
concentration. Gas movements in conductive airways, however, is driven by convection, 
which is a mechanism controlled by the difference in pressure between two mediums. 
Essentially when the mechanism of DCDI and CDI is disturbed in conductive and acinar 
region, heterogeneity results and is expressed in Scond and Sacin. Therefore, analysis of 
phase III slope assists in determining Scond and Sacin indices.  
 
In case of lung disease and ventilation inhomogeneity, the slope of phase III gets steeper 
than that seen in a normal lung. In normal lungs, the slope of phase III is expected to be 
zero, indicating that ventilation was distributed evenly all over the ventilated lung areas. 
When there is obstruction in a certain lung area, gas exchange takes longer time, causing 
an increase in the phase III slope, which indicates inequality of gas exchange and air 
distribution due to the defected areas. Normalizing the phase III slope is achieved by 
dividing it by the average of inert gas (SF6) concentration. The normalized phase III 
values are plotted against the turnovers required to clear the inert gas out of the lungs, 
which occurs when the starting concentration (1/40th) of the inert gas is reached. Scond and 
Sacin can then be calculated from this graph. 
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Figure 10 Calculation of Scond and Sacin on normalized phase III slope. 
This illustrated the calculation of Scond and Sacin on normalized phase III slope vs turn overs; x-axis 
represents the number of turnovers (TO), and y-axis represents the normalized phase III slope  (Robinson et 
al., 2013b). 
 
Ventilation inhomogeneity of gas exchange can be explained by the mechanism that is 
responsible for the change and increase in the normalized alveolar slope (Sn), which is a 
diffusion-dependent mechanism. At the first 5 breaths, the increase of Sn is diffusion 
independent. The reason for the progressive increase in Sn in the MBW process is 
inhomogeneity occurring between the acinar areas, resulting from uneven emptying of air 
units. The inhomogeneity occurring in the acinar areas is a result of inequality of airways 
constructions beside exhalation of air from large gas exchange sites. The notion is that the 
first 5 breaths reflect the inhomogeneity of ventilation in smaller units which happened by 
a diffusion dependent technique. Beyond the 5th breath inhomogeneity is attributed to 
larger units, which caused the increase in Sn. The washout breaths demonstrating the 
quality of ventilation process representing the better ventilated areas progress to less 
ventilated areas.  
Scond is calculated by the slope of the regression line of normalized phase III slopes versus 
lung turnover values at 1.5 and 6 values. 
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Scond= deltaTO6-TO1.5 
 
Sacin is calculated by subtracting the result of Scond value multiplied by TO of the first 
breath from SIII of the first expiration. 
 
Sacin= SnIII (1st expiration) – (Scond 1st breath . TO (1st breath)) 
 
Normal values of Scond and Sacin were found to be roughly around 0.033 and 0.075 
respectively (Verbanck et al., 1998). These values were derived from outcome measures 
done for N2 washout, which may slightly differ from the actual normal values of Scond and 
Sacin when using SF6 rather than N2 as the inert gas in MBW. Still, all these findings were 
based on N2 MBW, and there were no standard rules for testing Scond and Sacin for 
diagnostic purposes yet.  
 
Determining normal values of Scond and Sacin values has helped identify conditions in 
which an abnormality in the peripheral airways was present and therefore helped in 
assessing the abnormal changes occurring in lungs with respiratory disease. The changes 
of Scond and Sacin were obviously identified in asthma and COPD cases; the values were 
influenced by the degree of severity of the disease. Scond and Sacin values were both 
negatively affected (higher) in cases of asthma, but were impacted differently by the use 
of bronchodilators. To explain more, Scond in asthma cases was found to show significant 
ventilation inhomogeneity that may be partially reversed with bronchodilators. However, 
the abnormal Sacin values in asthmatics improved to normal values in response to 
bronchodilators. A notion that increased Sacin was found in COPD patients, though Scond 
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was subjected to the level of COPD severity referring to the vitality of Scond and Sacin as a 
diagnostic tool for such diseases. 
 
The clinical usefulness of the measures 
 
MBW is a sensitive technique for detecting early changes in small airways and early 
stages of lung disease. Multiple-breath inert gas washout (MBW) has been found to be an 
applicable testing method that can be used throughout the different age groups (Aurora, 
2006). It is an appropriate tool that assesses gas mixing efficiency and inhomogeneity 
throughout childhood (Wall, 1985). Unlike other tools, MBW can be performed on 
unsedated infants (Hjalmarson and Sandberg, 2002) as long as it is done during 
spontaneous breathing. 
 
MBW is considered a non-invasive testing method. It can be done on patients who are 
poorly cooperative and does not require a high level of consciousness. It may be the best 
choice for paediatric lung function testing because it utilizes tidal breathing, and is 
feasible, reproducible, harmless and sensitive as a diagnostic tool (Fuchs et al., 2012). 
 
The limitation of the MBW 
 
The MBW as a method of measuring lung function still has its disadvantages as is the 
case with any other method. It is considered a time-consuming technique as each subject 
is required to perform three trials of the test to take the mean reading of all three results as 
the final outcome measure. Each measurement trial consumes approximately 5-10 
minutes in the case of a child, more time in older subjects, and further time in lungs with 
abnormalities as they have impaired clearance ability. However, some studies have been 
 62 
 
conducted to address and overcome this issue (Hannon et al., 2014; Yammine et al., 
2012). Another disadvantage is the use of 100 % oxygen to clear out the nitrogen (when 
nitrogen is used as the tracer gas), which may be a source of harm especially for neonates; 
research studies are being conducted to investigate alternative ways to the use of 100% O2 
in nitrogen gas MBW testing (Fuchs et al., 2008). A further limitation involves the high 
cost of the machine and the fact that it requires special training. Although LCI is sensitive 
in detecting early airway changes, it has been found to be less informative with more 
advanced airway disease; in other words, LCI is considered a less valuable indicator of 
lung function with significant airway obstruction compared with early disease stages 
(Horsley, 2009). 
 
 
2.6.5 Comparison between the aforementioned tests of lung function and 
advantages of MBW 
 
The demand for a more sensitive method that is able to detect the pathological changes at 
early stages of chronic respiratory disease is increasing. Most of the available common 
methods have their disadvantages and limitations and are summarized in Table 2. The 
MBW seems to overcome many of these shortcomings. Finding a single method that has 
all the desired features is not easy. Early diagnosis and feasibility is regarded as a priority 
when it comes to choosing a diagnostic modality in respiratory disease. 
 
Spirometry lacks the sensitivity to small airway changes and it is difficult to be used for 
children aged less than five years old. It also requires patient cooperation which means it 
is not suitable for unconscious patients as well as children of young age. Normal values in 
spirometry are different for different ages, genders, stature and fitness level and values 
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change at different times of day and with time. In contrast to spirometry, MBW is found 
to be sensitive to early changes in the small airways. MBW can be used for young 
children and infants either conscious or unconscious as it depends on tidal breathing. LCI 
obtained from MBW has the advantage of remaining unchanged over time in healthy 
individuals. Changes occur when the disease has developed in a part of the lung. 
Therefore, MBW is a better method than spirometry for measuring early lung changes.  
 
CT is an accurate method for detecting structural changes and lung volumes. 
Nevertheless, it has its disadvantages. It exposes the individual to the danger of radiation 
which limits its use as a routine procedure. It is a hospital based technique that demands 
well-trained staff. Additionally, the patient should be in a stable status or sedated to avoid 
moving during the procedure. In contrast, MBW using SF6 is a simple procedure that can 
be performed in or out of the clinic, besides SF6 is provided as small gas cylinders that 
can be fixed in the portable Innocor, which makes it more appropriate for routine 
investigation. MBW is a safe method when compared to CT while it has a similar 
accuracy in detecting changes in lung function. 
 
Plethysmography is a simple method albeit it may be avoided by a number of people 
especially those who are intolerant to tight places or are claustrophobic. Some may claim 
it to be an unpleasant experience and disapprove going through the procedure. 
Plethysmography must be held in the clinic. On the other hand, MBW with its simplicity, 
can be performed in and out of the clinic. 
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Table 2 A comparison between lung function testing methods spirometry, plethysmography, CT and MBW 
Method Spirometry Plethysmography CT  MBW 
Measurement  Lung volume Lung volume Lung structure (image) Lung volume 
Advantages Valid 
Easy 
Gold standard for lung function 
testing 
Not expensive 
Portable  
Fast 
Allows for repetitive 
measurements in quickly 
assessing the reproducibility 
of results 
Results do not vary with the 
severity of underlying 
airway obstruction 
Non-invasive 
Sensitive to small airway 
changes 
Accurate  
Non-invasive 
Provides portability 
Sensitive to small airway 
changes 
 
Limitations Associates with many potential 
sources of errors and variability 
Affected by several factors such 
as height, equipment, 
environment and operator 
Requires patient  
coaching 
Requires active participation of 
the patient 
Not suitable for all ages (such as 
preschoolers and infants) 
FEV1 changes with time 
(variability during the day and 
throughout the month) 
Insensitive to small airway 
changes 
Problems such as bullae or 
hiatal hernias may be 
included in lung volume 
estimates 
Expensive 
Some patients cannot 
tolerate it due to body size 
(obese) or skeletal 
abnormalities or 
claustrophobia 
May develop shortness of 
breath 
Risk of exposure to radiation 
Usually requires sedation or 
anesthesia for infants and 
young children 
Requires highly specialized 
staff  
Requires patient cooperation 
and awareness 
Expensive 
 
Time-consuming 
Uses 100% O2 when using N2 
MBW 
Cost 
Requires training  
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2.6.5.1 Devices that measure MBW 
 
The devices used for MBW have been modified and developed over the years. Today, 
there are four main devices utilized in MBW testing. The gold standard is the mass 
spectrometer which is custom made for the purpose of MBW testing and can be utilized 
using any gas; however, it is not commercially available. Three commercial MBW 
devices are currently available in the market: the Innovision Innocor, the Eco Medics AG 
Exhalyzer D, and the EasyOne Pro. Table 3 provides a brief comparison of the four MBW 
devices and a more detailed overview of the Innocor device is presented in the following 
section, as it is the device we used in our study. 
 
 
Table 3 MBW devices 
 Innovision 
Innocor 
Eco medics AG 
Exhalyzer D 
Easy One Pro Mass 
spectrometer 
Design Closed, 
rebreathing 
circuit 
Open circuit 
washout design 
Open circuit 
wash-in and 
washout design 
using bias flow 
 
Open circuit 
washout design 
using bias flow 
 
Open circuit 
washout 
Inert gas used SF6 N2 and SF6 N2 N2 and SF6 
portability Self contained 
Portable 
Semiportable 
computer 
required 
Self contained 
portable 
Non-portable 
This illustrated the comparison between the three commercially available MBW devices (Innovision 
Innocor, Eco medics AG Exhalyzer D, and Easy One Pro) and the gold standard respiratory mass 
spectrometer. 
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2.6.6 The Innocor SF6-based MBW device  
Equipment (Innovision, Odense, Denmark) 
 
The Innocor device (Figure 11) was originally designed to measure cardiac output for 
cardiac patients. The Innocor principle is based on measuring gas concentration during 
the expiration phase utilising photoacoustic spectroscopy multi-gas analyzer technology 
(Agostoni et al., 2005). Adaptation has been made to measure LCI and FRC and a 
customised interface was used for this purpose. The customised interface consists of a 
mouth-piece connected to a filter, which is connected to a flowmeter with a gas sampling 
line. 
 
 
Figure 11 the Innocor device 
This illustrated a.) Innocor device with patient interface. b.) MBW interface: flowmeter with gas sampling 
line, filter and mouth piece c.) SF6 cylinder fixed in the Innocor. D.) The Innocor device with the laptop. 
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MBW using the Innocor device derives several outcome measures. The main outcome 
measure derived was LCI. Several secondary outcome measures are the FRC, Scond, and 
Sacin. The next chapter will review the literature investigating the use and applicability of 
MBW testing, leading into our research questions. 
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3 The Literature Review 
 
3.1 The literature search 
 
The search of the articles for this study was done through EBSCO and was conducted 
through two main databases: Medline and Cinhal. The keywords were classified under 
four categories: action, structure, measurement, and measurement evaluation. 
The CINAHL database (Table 4) yielded 65 articles. The titles and abstracts of 
the articles were screened to check their relevance to the subject of this study. As a result 
of the primary screening, 52 articles were found relevant, and 15 were excluded.  
 
 
Table 4 Search terms and results through CINHAL databasee 
 Key words of 
structure 
Key words of 
action 
Key words of 
method of 
measurement 
Key words of 
evaluation 
Key words Lung Breath  MBW Validity  
Pulmonary  Respire* FEV1 Reliability  
Airway  Ventilat* LCI Sensitivity  
Alveol*  Spirometry Reproducibility  
   Repeatability  
   Error  
   SE 
Code  S1 S2 S3 S4 
Use of OR 113,465 108,118 7,309 252,418 
Age filter (0-18 
years-old) 
15,014 25,523 1,670 53,322 
Use of AND S1+S2+S3+S4 = 65 
 
 
Through Medline database (Table 5), the search yielded a result of 39 papers, and after 
going through the titles and abstracts, the number of relevant articles were found to be 19.  
Subsequently, after reading through all the relevant articles and considering any 
duplication, a total of 24 articles was related to the research subject out of the two 
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databases.   
 
Selection of the studies for inclusion was based on the following criteria: 
1. Studies that measured lung function, as the concern in our study is lung function 
measurement. 
2. A paediatric population, as our study is concerned with paediatric lung function 
assessment. 
 
Interventional studies were excluded from our search because the focus of this thesis was 
to analyse psychometric properties of the available methods of lung function 
measurement.  
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Table 5 Search results through Medline database 
 Key word Code  Articles number 
Key word of structure Lung S1 5,877 
Pulmonary  S2 4,794 
Airway  S3 24,094 
Alveol* S4 7,733 
Use of OR S1 or 
S2 or 
S3 or 
S4 
S5 40,127 
Key word of action Breath  S6 18,205 
Respire* S7 86,288 
Ventilat* S8 30,182 
Use of OR S6 or 
S7 or 
S8 
S9 110,385 
Key word of method of 
measurement 
MBW S10 14 
FEV1 S11 3,299 
LCI S12 92 
Spirometry S13 5,322 
Use of OR S10 or 
S11 or 
S12 or 
S13 
S14 7,624 
Key word of evaluation Validity  S15 62,358 
Reliability  S16 67,143 
Sensitivity  S17 102,445 
Reproducibility  S18 42,725 
Repeatability  S19 1,160 
Error  S20 53,581 
SE S21 6,889 
Use of OR S15 or 
S16 or 
S17 or 
S18 or 
S19 or 
S20 or 
S21 
S22 266,741 
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Use of AND S5   and 
S9   and 
S14 and 
S22 
S23 155 
Use of AND with age filter 
(0-18) 
S23 with age filter S24 39 
 
 
3.2 Review of literature 
3.2.1 Introduction 
 
There has been a growing interest in the research community and literature for the 
assessment of ventilation inhomogeneity by the MBW technique as it showed a 
distinctive ability to detect early lung disease in a relatively easy and safe manner. These 
distinctive features of MBW testing have guided efforts in assessing applicability of this 
method in the diagnosis and monitoring of lung disease particularly in children, as MBW 
testing relies on measurements obtained during tidal breathing. Over the years, the MBW 
method has been improved and modified to make it more usable and easier to apply 
clinically, with special focus on the paediatric population. Many studies have investigated 
the clinical applicability and sensitivity of MBW testing in diagnosing and monitoring of 
different respiratory diseases, such as cystic fibrosis. Comparisons have been made with 
other methods used in assessing pulmonary function. Different MBW devices and tracer 
gases have also been compared in the literature. In this literature review, we aim to 
discuss the aforementioned aspects of MBW testing that lead up to our research 
questions. 
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3.2.2 The clinical value of MBW as an assessment of pulmonary function  
 
In medical practice, a need for new methods of assessment of lung function was observed 
over the years, as the standard methods of pulmonary function testing demonstrate 
limitations that affect the diagnosis and monitoring of chronic respiratory illness. One 
disease in particular in which this need was observed is cystic fibrosis, as the current gold 
standard method for diagnosing and monitoring this chronic illness remains to be the 
computed tomography (CT) image. Because cystic fibrosis presents in childhood, 
performing serial or annual CT imaging to monitor disease progression and guide 
treatment presents as a significant source of radiation exposure to a child; this poses an 
increased risk of future secondary cancers in this population of children. In the paediatric 
age group, the risk of radiation-induced malignancy is more significant compared with 
adults due to the highly-proliferating cells seen in the growing body of a child; highly-
proliferating cells are at greater risk of undergoing radiation-induced DNA damage and 
consequently dysplasia of the cells, which may develop into cancer. The risk increases 
with an increase in the cumulative dose of radiation, meaning that the more CT scans a 
child undergoes, the greater the risk. Therefore, the presence of a method that spares a 
child the radiation of a CT scan whilst still providing equally highly sensitive measures of 
lung function in cystic fibrosis patients has become a goal to medical researchers. 
Perhaps, that is why much of the literature investigating the usability of the MBW method 
is conducted on patients of cystic fibrosis.  
 
MBW testing has been suggested to be an appropriate substitute and safer alternative 
to computed tomography. In a study conducted by Ellemunter. et al (2010), the accuracy 
of LCI was compared to CT imaging in detecting patients in early stages of cystic fibrosis 
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that showed normal FEV1 readings. Results showed that LCI was able to obtain similar 
diagnostic accuracy compared to lung CT scans. Furthermore, a serial measurement of 
LCI demonstrated the ability of early identification of progression in cystic fibrosis while 
avoiding exposure to CT radiation (Ellemunter et al., 2010). This study proved that LCI 
had equal diagnostic ability and power in identifying lung abnormality comparable to that 
of CT imaging. Another study conducted by Aurora et al. supported the sensitivity of LCI 
to early deterioration of lung function (Aurora, 2010). In this study where results of LCI 
and CT were compared, both were able to detect early CF lung disease, while both had 
missed some of the cases. A study performed by Gustafsson et al further supports the 
aforementioned studies by demonstrating that a normal LCI indicates absence of 
structural lung damage on high-resolution computed tomography (HRCT) (Gustafsson et 
al., 2008).  
 
MBW testing has also been suggested to be an appropriate substitute to spirometry for 
the assessment of ventilation inhomogeneity (VI) in the lung. MBW testing demonstrated 
higher accuracy and sensitivity to abnormalities in lung function by identifying higher 
than normal measures of ventilation inhomogeneity. One of the most commonly utilized 
spirometry measures for detecting abnormality of airway function in children is the FEV1. 
Studies have found that MBW testing was able to detect abnormal lung function that was 
missed with a normal FEV1 reading obtained by spirometry, which means that MBW was 
able to detect early stages of lung damage that were undetectable by FEV1 (Green et al., 
2011). Furthermore, another study demonstrated that LCI was the earliest measurement to 
deteriorate in children with progressive CF during serial follow-up evaluation, followed 
by decreases in spirometry results (FEF0.5, FVC, and FEV1) (Kraemer et al., 2005).  
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Beside its significantly lower sensitivity to deterioration of lung function in children, 
spirometry carries a considerable disadvantage in that it cannot be performed on infants 
and young children as it requires patient cooperation and is effort-dependent. MBW 
testing, however, depends on tidal breathing and thus requires minimal patient 
cooperation when performed on young children and can be carried out during sleep for 
infants. This means that for very young patients in which lung assessment is required, 
physicians are limited to blood gas analyses and imaging modalities, such as the CT, 
creating a greater need for lung function testing methods such as MBW in this age group 
(Sarma et al., 2012). 
 
One study conducted by Bakker et al. aimed to compare nocturnal oxygen level and 
cough as tools to measure and detect pulmonary changes in CF children with MBW 
testing. The study showed that LCI can detect significant lung changes in CF, while 
nocturnal oxygen and cough could not (Bakker et al., 2012). 
 
Studies were also found in the literature investigating the ability of MBW to detect other 
chronic lung diseases that could not be detected with spirometry. For instance, a study by 
(Green et al., 2011) found that MBW was able to detect changes in primary ciliary 
dyskinesia (PCD), which has similar features to CF in that lung damage primarily occurs 
in the peripheral airways. Although MBW is shown to be more sensitive than spirometry 
in detecting PCD, further research is required to confirm this conclusion (Green et al., 
2011). LCI was also used to detect the abnormal changes that occur in bronchiectasis 
patients corresponding to detectable abnormalities on CT scan in a study conducted by 
(Rowan et al., 2014). LCI was found to be more sensitive to such structural changes 
compared to FEV1 obtained by spirometry (Rowan et al., 2014). 
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As the MBW technique is characterized by sensitivity to ventilation inhomogeneity, LCI 
was demonstrated to be one of the most reliable parameters to quantify ventilation 
inhomogeneity (VI) (Yammine et al., 2014). A study conducted by Singer et al. (2013) 
demonstrates the sensitivity and reliability of LCI as a lung function testing method and 
supports its use as a routine paediatric care procedure as it is considered practical and 
feasible particularly for this age group (Singer et al., 2013). MBW outcome measures also 
have the advantage of being reproducible; a study conducted by Aurora et al (2006) 
concluded that the MBW method yields accurate readings despite repetition between 
different laboratories (Aurora, 2006).  
 
Furthermore, LCI was found to have the distinctive characteristic of being age-
independent especially in childhood, which makes it suitable for research purposes 
(Yammine et al., 2014). Spirometry, in contrast, varies with age, body size, and gender 
and therefore makes comparisons between values of different individuals or values 
gathered on follow-up of disease for the same individual more complex and difficult to 
interpret (Wang et al., 2009; Wang et al., 2017). Most of the studies that investigated the 
effect of age and body size on LCI found that LCI was not affected by these factors 
(Aurora et al., 2005a; Horsley et al., 2008a). One study, however, by Lum et al made a 
contradicting conclusion; he found that LCI was dependent on age and height, decreasing 
in a nonlinear pattern as height increases (Lum et al., 2013). However, he stated that these 
changes were particularly marked in the first five years of life. The literature has 
explained the reason for this observed pattern in young childhood in that LCI is 
dependent on structural and functional lung growth in this age group (Habib and Lutchen, 
1991; Haidopoulou et al., 2012; Schmalisch et al., 2006). Moreover, LCI was found to be 
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greatly affected by differences in lung volumes, especially airway dead spaces, in the 
early years of life. The increased dead space in MBW testing in infants may also be due 
to the use of a face mask instead of the mouth piece used in older children (Schmalisch et 
al., 2015). 
 
Another study, which was conducted by Verbanck et al  found that LCI, Sacin and Scond 
consistently increased with age; however, the study population age range was 25-65 years 
(Verbanck et al., 2012). Therefore, this increase in MBW outcome measures with age 
may occur only in adults beyond a certain age. Further studies are needed to investigate 
the possible effect of age on LCI in the adult population. In general, however, LCI was 
found to be an age-independent measure of lung function, particularly among children 
beyond the first few years of life.  
 
3.2.3 MBW devices 
 
Use of the MBW technique for assessment of lung function was introduced in the 
literature over 60 years ago. In the past decade or so, however, this method has regained 
attention and popularity in the medical research community, and a growing interest in 
developing this technique for use in medical practice has been seen. The respiratory mass 
spectrometer is the current gold standard technique for performing MBW; however, the 
lack of having this device commercially limits its use in the clinical setting. This has 
increased the demand for commercial MBW devices to help increase the clinical 
applicability of this method. Three commercial devices, as described in the previous 
chapter, were developed to meet the requirements of clinical use of MBW testing, namely 
the Innovision Innocor device, the Eco Medics AG Exhalyzer D (a side-stream ultrasonic 
 77 
 
flow system prototype), and the EasyOne Pro. These devices vary in several aspects, such 
as their degree of measurement validation, suitability for different age groups, 
affordability, regional regulatory agency approvals, portability, the type of tracer gas 
utilized, and transparency of outcome calculation. For more information about the 
differences in the devices, refer to Table 3 in the chapter 2.  
 
None of the commercial MBW devices have been designed to suit all ages. However, 
work is ongoing to create a commercial device that fits all age groups. Currently, the 
Innocor and EasyOne Pro are the commercially available MBW devices that can be used 
in school-aged children and beyond. One study has even shown successful applicability of 
the EasyOne Pro on children in the preschool age group on individuals as young as three 
years of age (Fuchs et al., 2011). The commercial Eco Medics AG Exhalyzer D was 
initially designed for infants and very young children, up to five years of age (Fuchs et al., 
2009); however, studies have demonstrated successful use in older children as well. The 
mass spectrometer has been used for all age groups, but as mentioned before, is not 
commercially available (Fuchs et al., 2006).   
 
3.2.4 Variations in MBW outcome measures between different devices and gases 
 
Studies have shown that the outcome measures that are produced by different devices 
vary and are thus not comparable to one another and cannot be used interchangeably in 
assessment of lung function. Mean values of various MBW outcome measures in normal 
individuals varied across the four MBW devices. For example, the mean LCI for healthy 
individuals assessed in a study using the mass spectrometer and SF6 as a tracer gas was 
found to be 6.19 (Jensen et al., 2013), and in another study using Innocor and the same 
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tracer gas (SF6), it was found to be 6.3 (±0.5) (Horsley et al., 2008a). The EasyOne Pro 
which uses N2 as a tracer gas was used in a study by (Fuchs et al., 2009) and found a 
mean LCI in normal individuals of 6.2(±0.4); however, in another study by (Jensen et al., 
2013), it was found to be 6.81 in a healthy population using an N2-based mass 
spectrometer. These differences between devices is demonstrated in Tables 6 and 7 and 
illustrated in Figures 12 and 13. As a result of these variations among devices, it was 
agreed upon collectively by the research community that normative and disease values 
and ranges must be individualized to each device and that measurements obtained for 
individuals could not be compared with each other if different devices were used. 
 
The literature has also shown variation in MBW outcome measures with the use of 
different gases (Table 6Table 7). In a study by (Kent et al., 2014), outcome measures 
using N2 gas were found to be higher than measures obtained using SF6. In another study 
by (Jensen et al., 2013), a significant difference was found in LCI values measured with a 
MBW device using two different gases: N2 and SF6; mean LCI using N2 in healthy 
children was found to be 6.81(±0.05), while mean LCI measured using SF6 gas in the 
same individuals was 6.19(±0.05). This variation increased even further in the diseased 
state; the mean LCI in children with CF was found to be 11.29(±0.05) using N2 and 
10.05(±0.05) using SF6. In conclusion, and as demonstrated by in the comparison we 
constructed in Tables 6 and 7 and graph in Figure 12, a variation was observed between 
LCI measures obtained using N2 and measures using SF6 that was greater in the diseased 
population compared to that observed between the healthy populations.  
 
These differences in the outcome measures obtained using N2 vs SF6 was thought to be 
explained by the differences in the behaviour of these gases in the peripheral airways, 
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which is influenced by the molar mass or density of the gas and gas diffusion rate (Olfert 
and Prisk, 2004). SF6 is a heavy gas and may, therefore, behave differently in the 
peripheral airways compared with the lighter N2 gas. However, in studies that compared 
LCI obtained with SF6 to LCI obtained using He (which, like N2, is considered a light 
gas), an increased variation in LCI measures in the diseased group was not seen with He 
compared to SF6 (Jensen et al., 2013). This means that the molar mass alone could not 
explain the increasing variation in LCI seen with N2 in diseased subjects.  
 
Further differences in physical properties between N2 and SF6 were therefore 
investigated. The diffusion rate of a gas is known to be inversely proportional to the 
molar mass of the gas, thus affecting the diffusion-convection location of the gases in the 
lung, in which lighter gases are located less peripherally in the lung than heavier ones. 
This places lighter gases in slowly-ventilated lung units compared to the rapidly-
ventilated more peripheral lung units where heavier gases, such as SF6, are found. The 
endogenous nature of N2 causes N2 to diffuse from lung tissues into these slowly-
ventilated units contributing to the volume of trapped gas in the lung. This is represented 
by the higher FRC values obtained with N2, which has been demonstrated by (Jensen et 
al., 2013) who compared FRC in healthy subjects and subjects with CF using N2 and SF6. 
Mean FRC in the control group was calculated to be 1.60(±0.06) when using SF6 and 
1.92(±0.07) when using N2; mean FRC in the CF group was found to be 1.41(±0.06) 
using SF6 and 1.89(±0.05) using N2. N2, which continuously diffuses from the lung tissue 
into the slowly-ventilated lung units, acts as a trapped gas and therefore takes longer to be 
washed out of the lung compared to the heavier SF6; this phenomenon is amplified in a 
diseased lung as the volume of trapped gas in the lung further increases pathologically. 
This was demonstrated by a study that observed that healthy subjects required an 
additional five breaths to complete washout using an N2 compared to SF6, whereas 
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patients with CF required 18 additional breaths to complete washout of N2 compared to 
SF6. The number of breaths required to complete washout using N2 was found to increase 
in direct proportion to the volume of trapped gas measured in the lung (Jensen et al., 
2013). 
 
The choice of tracer gas used in research studies as well as in the clinical setting in MBW 
testing should be made in view of the properties, advantages, and disadvantages of each 
gas. An overview of the different gases used in MBW can be found in chapter 2 section 
2.5.6.12.). Most studies in the literature utilized N2 and SF6 as tracer gases in MBW. The 
fact that N2 is an endogenous gas presents itself as an advantage as no exogenous gas 
source needs to be washed into the lung. However as explained above, variation in values 
is greater with N2 compared to SF6, and is more profound in the diseased population. This 
variation may make it more difficult to set clear normative values for N2-based MBW 
testing and thus decrease the method’s sensitivity to diagnose lung disease. It may also 
make monitoring of established lung disease for signs of progression unreliable as 
variation increases profoundly in the diseased lung. Another disadvantage of using N2 as 
a tracer gas occurs due to the need for 100% O2 to washout the endogenous nitrogen for 
calculation of the MBW outcome measures. Singer et al (2013) found that 100% O2 has 
an impact on the breathing pattern, especially in infants (Singer et al., 2013), which 
affects the MBW outcome measures. This change in breathing pattern results in a 
decrease in the tidal volume of full-term infants (Yammine et al., 2014) and a significant 
decrease in tidal volume in those who are preterm (8%) (Jost et al., 2016). In an attempt 
to decrease exposure to 100% O2 so that breathing is not affected, (Singer et al., 2013) 
conducted a study using N2 and a 40% O2 washout protocol in infants and compared it to 
the traditional 100% O2 washout protocol. The study demonstrated that, unlike the old 
protocol utilizing 100% O2, the new protocol did not change the breathing pattern of the 
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infants and did not cause hyperoxia (Singer et al., 2013). Further studies are needed to 
investigate the validity of this new suggested protocol. 
 
A further disadvantage of the N2-based MBW system is that the required 100% O2 gas is 
highly flammable, while SF6 is not, making SF6 overall safer for use; however, SF6 is 
considered a greenhouse gas, making it more dangerous for the environment (Koch, 
2003).  
 
Table 6 A comparison between the mean LCI (SD) values in healthy individuals  
Name of the study 
Healthy 
population 
Age 
range 
Mean age 
(SD) 
MBW device 
Inert 
gas 
LCI mean (SD) 
Aurora et al., 2004b 33 6-16 11.3 (3.1) MS SF6 6.45 (0.49) 
Poncin et al., 2017 50 8.5-13.9 11.2 Exhalyzer N2 7.05 (0.55) 
Poncin et al., 2017 50 8.5-13.9 11.2 Easy Pro N2 6.78 (0.63) 
Poncin et al., 2017 51 23.1-28.3 25 Exhalyzer N2 6.92 (0.35) 
(Poncin et al., 2017) 51 23.1-28.3 25 Easy Pro N2 6.42 (0.54) 
(Aurora et al., 2005a) 30 - 4.3 (0.8) MS SF6 6.89 (0.44) 
(Horsley et al., 2008b) 17 21-47 31.3 (6.0) Innocor SF6 6.7 (0.6) 
(Horsley et al., 2008b) 29 5.3-16.2 11.1 Innocor SF6 6.2 (0.5) 
Horsley et al., 2008) 12 6-16 11.0 Innocor SF6 6.3 (0.5) 
Horsley et al., 2008) 48 19-58 33.0 Innocor SF6 6.7 (0.4) 
Table 6This illustrated the mean (SD) of LCI value in healthy individuals of different age groups using 
different MBW devices and inert gases from previous studies in the literature. 
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Table 7 A comparison between the mean LCI (SD) values in CF individuals  
Name of the study 
CF 
population 
Age range 
Mean age 
(SD) 
MBW 
device 
Inert 
gas 
LCI mean (SD) 
Aurora et al., 2004b 22 6-16 11.5 (3.2) MS SF6 11.53 (2.86) 
Poncin et al., 2017 47 (9.5-16.1 ) 13.4 Exhalyzer N2 9.76 (2.26) 
Poncin et al., 2017 47 (9.5-16.1 ) 13.4 Easy Pro N2 8.32 (1.64) 
Poncin et al., 2017 34 21.0-32.9 24.9 Exhalyzer N2 13.73 (3.63) 
Poncin et al., 2017 34 21.0-32.9 24.9 Easy Pro N2 10.01 (2.46) 
(Aurora et al., 2005a) 30  4.3 (0.77) MS SF6 9.61 (2.19) 
(Horsley et al., 2008b) 22 17-47 28.9 (10.1) Innocor SF6 12.8 (3.3) 
(Horsley et al., 2008b) 18 7.8-16.7 12.5 (3.5) Innocor SF6 7.3 (2.3) 
Horsley et al., 2008) 33 17-49 30.0 Innocor SF6 13.1 (3.8) 
This illustrated the mean (SD) of LCI value in CF patients of different age groups using different MBW 
devices and inert gases from previous studies in the literature. 
 
3.2.5 Variability within LCI measures in healthy and diseased populations 
 
LCI values may vary among healthy children and the literature has presented the values 
of LCI in both healthy and unhealthy populations using different MBW devices and 
gases. However, within normal individuals, a variability within the LCI values was seen 
when using the same device and gas. The possible reasons for this variability has not been 
studied previously. This may raise the question of whether there are any factors that may 
explain this LCI variance within the normal population.  
 
The values of LCI and other MBW outcome measures for healthy individuals were 
altered when the MBW device or the inert gas used changed (Robinson et al., 2013a). 
Therefore, comparing the LCI and any other MBW outcome measures should be done 
within the same system and same tracer gas utilized.  
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The values (mean and standard deviation) of LCI for both healthy and diseased 
individuals were collected from previous studies (Aurora et al., 2005a; Aurora et al., 
2004; Fuchs et al., 2011; Fuchs et al., 2009; Gustafsson et al., 2003; Horsley et al., 2008a; 
Hülskamp et al., 2009). Both healthy and unhealthy (CF, asthma, extremely preterm 
children) results are plotted in graph in Figure 12 below. The distribution of LCI values 
throughout the ages in healthy subjects showed that age had no effect on LCI values in 
healthy individuals. However, the distribution of LCI values for subjects with a known 
pathology showed a significant increase with age remarkably beyond the age of 15 (Table 
7). 
 
 
Figure 12 LCI values through age in healthy and diseased subjects 
This illustrated the relation between LCI mean values and age in diseased and healthy subjects. The x-axis 
represents the age in years and the y-axis represents the LCI value. The black and red dots represent the 
values of LCI for diseased and healthy subjects, while the black and red lines illustrate the linear mean of 
LCI in diseased and healthy subjects, respectively. The graph shows the difference in LCI values 
throughout age in both diseased and healthy subjects. LCI appeared to obviously increase in diseased 
individuals, while healthy individuals appeared maintain LCI values within the same range (Aurora et al., 
2004b), (Aurora et al., 2005a), (Poncin et al., 2017), (Poncin et al., 2017), (Horsley et al., 2008b), (Horsley 
et al., 2008). 
 
We compared the means of LCI from previous studies in the literature to check whether 
there was a difference between the diseased and healthy groups. A t-test was carried out 
for the mean values of LCI in the healthy control data that was gathered from previous 
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studies. The paired sample test showed a p-value <0.001, which indicated a significant 
difference between the value of LCI means of healthy subjects and the diseased group. 
The graph in Figure 12 demonstrates that some LCI values of the groups with the disease 
were in the normal range of healthy values, which again raises the question regarding the 
presence of associated factors that may influence LCI values within the normal range. 
 
The variation of LCI values for the diseased subjects was found to be greater than the 
variation of LCI values for the healthy individuals, as can be seen in the graph in Figure 
12. This wide variation for LCI values in the diseased subjects may be explained by the 
differences in disease stage and severity within the group. Although the variation of LCI 
values in the healthy group was less compared to the diseased group, there was still some 
variation within it. The reasons for this variance among the LCI values of healthy subjects 
is not yet clear. It may be due to variable exposure to risk factors that may affect lung 
function. This is a question to be investigated. 
 
Figure 13 and Figure 14 demonstrated below allowed more detailed comparison between 
variability of mean LCI values between healthy and diseased (CF) children and adults, 
respectively. Comparison between variability across different devices and gases can also 
be observed. For numerical values, reference can be made to the previous tables in this 
chapter (Table 6 and Table 7).  
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Figure 13 The mean LCI (SD) values for healthy and diseased children population in previous studies 
 
This illustrated the mean LCI (SD) values for healthy and diseased children population in previous studies. 
MS1 SF6 (Aurora et al., 2004b), MS2 SF6 (Aurora et al., 2005a), Exhalyzer N2 (Poncin et al., 2017) , Easy 
Pro N2 (Poncin et al., 2017) , Innocor1 SF6 (Horsley et al., 2008b), Innocor2 SF6 (Horsley et al., 2008). 
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Figure 14 The mean LCI (SD) values for healthy and diseased adults population in previous studies.  
This illustrated the mean LCI (SD) values for healthy and diseased adults population in previous studies. 
Exhalyzer N2 (Poncin et al., 2017), Easy Pro N2 (Poncin et al., 2017), Innocor1 SF6 (Horsley et al., 2008b), 
Innocor2 SF6 (Horsley et al., 2008). 
 
3.2.6 Clinical usability and practicality of MBW 
 
The literature has demonstrated the clinical usability and practicality of the MBW 
method, especially with the continuing evolution of the commercial devices available in 
the market today. Portability has facilitated research greatly and is obvious by the 
increasing research being conducted in further investigating this method and its clinical 
applicability.  
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MBW testing using SF6 is found to be a sensitive measure of lung disease, but it has the 
disadvantage of being a time-consuming procedure (5-10 minutes per MBW run, for a 
total of 3 runs), when compared to other lung function tests such as spirometry, which 
takes 2-5 minutes to complete; this may be seen as a limitation to its use clinically; 
however, the MBW has the advantage of being significantly more sensitive in detecting 
lung abnormalities than spirometry, as was previously described in the chapter, which 
may make the longer MBW test duration acceptable in view of its greater sensitivity. In 
comparison to CT imaging on the other hand, MBW testing was found to take equal or 
perhaps less time to complete, as CT imaging takes on average a total of 30-60 minutes 
(Lex Jr, 2008). 
 
MBW is repeated 3 times per session and the average reading is taken into consideration. 
This repetition contributes to the increased time of testing. To overcome this issue, a 
research paper was presented by Yammine et al. (2012), who studied the shortened MBW 
technique for 68 school-aged children; he conducted the MBW test in two ways: by 
performing two complete runs instead of three, and by applying the three runs but with 
less concentration of the gas (1/20th instead of 1/40th). The study found that MBW can be 
shortened and still obtain sensitive results by following the two mentioned methods 
(Yammine et al., 2012). A study done by Hannon et al. (2014) found that LCI 1/20th is 
repeatable and sensitive with the same diagnostic performance of the LCI 1/40th with the 
advantage of consuming less time (Hannon, Bradley et al. 2014). Yammine et al (2012) 
found that decreasing the cut-off concentration to 1/20th did not compromise the 
diagnostic ability of the MBW test in patients with mild CF; further studies may be 
needed, however, to assess the reliability of the use of this as a cut-off point in calculating 
LCI for more severe lung disease (Yammine et al., 2012).  Therefore, modifying the 
washout technique by decreasing the cut-off point of the washout phase, achieved by 
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reducing inert gas concentration to 1/20th, for healthy lungs and lungs with mild lung 
disease, as well as by performing two complete runs instead of three could be considered 
a convenient method to shorten the time of MBW testing sessions. 
 
Providing a commercial type of MBW was necessary to increase the practicality of using 
this method as well as widening the scope of its use in clinical practice. The gold standard 
MBW method, which is the mass spectrometry, may limit the ability of MBW to be used 
as a screening tool for testing lung function due to its large equipment size, the fact that it 
is a hospital-based device, and the high cost of the machine. One such study 
demonstrated that the sidestream ultrasonic flow sensor (USFS) prototype system, also 
known as the Eco medics AG Exhalyzer D, MBW outcome measures and tidal tracer gas 
concentrations are comparable to those obtained using a mass spectrometer (Fuchs et al., 
2008). This demonstrates the ability of commercial MBW devices, such as USFS and 
Innocor, to produce similar results to the hospital-based mass spectrometry machine. 
Commercial devices may be the key to further usage of MBW to detect early lung disease 
among children.  
 
3.2.7 ARS/ETS recommendations 
 
MBW has been available for many years, and as researchers investigate this method for 
potential use in clinical practice. Therefore, a need for a unified protocol to be followed 
emerged to allow for comparisons of results from one study to the other. As MBW 
depends on measuring the volumes and concentrations of gases during breathing, an 
advanced sensor system which can detect and measure the different gases that enter the 
respiratory system during the test was required. Further analytical processing of the 
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measurements obtained was also required to calculate measurements such as LCI. These 
procedures in analysing the data required organization and integration into one set of rules 
to unite the method of measurement and analysis of the data. As a result, in early 2013 the 
European Respiratory Society and the American Thoracic Society provided a document 
(ERS/ATS consensus statement (Robinson et al., 2013a), which included evidence-based 
recommendations related to the testing, measuring and analysing of the MBW process 
and the criteria that needed to be followed when conducting the testing procedure. Taking 
into consideration this statement and following its outlines would result in measurements 
that follow consistent and uniform principles and protocols that are more valid and easy 
to compare. The goal of this document was to give a clear description of the SBW and 
MBW methods both in a physiological and practical aspect, determine the tools required 
to perform the test as software and hardware, provide the quality control system and 
validation, outline the outcome measures that are intended, and demonstrate the 
calculation method that is followed to extract the outcome measures that indicate 
ventilation inhomogeneity. It also outlines the criteria for accepting the measured data for 
different systems (SBW and MBW) and different ages (children and adults) (Robinson et 
al., 2013a).    
 
3.2.8 The current situation with MBW in the clinical setting 
 
MBW testing in children has been shown to be feasible, reproducible, and accurate in 
making diagnoses. It was shown to be more accurate compared to the other available lung 
function tests in detecting small airway diseases like CF (Aurora et al., 2011). Aurora et 
al (2011) conducted a study to assess whether LCI using MBW can predict progression of 
lung disease in preschool children with CF. This study concluded that abnormal LCI was 
 90 
 
found highly predictable for subsequent lung function deterioration in children with CF 
(positive predictive value of 94%), whereas most children with initially normal LCI 
results remained normal as time passed (negative predictive value of 64%). LCI was 
compared to FEV1as a predictor of progression in the study; FEV1 positive predictive 
value in the study group was calculated to be 100%, but negative predictive value was 
only 25% (Aurora et al., 2011). 
 
MBW testing compared to the other available lung function tests may be the best method 
in detecting abnormality of the small airways in children, which is considered to represent 
the early stages of chronic lung disease. MBW has another advantage that makes it 
suitable for the children population, which is based on the fact that only tidal breathing 
and no forceful breathing manoeuvres or major cooperation from the child are required. 
This presents MBW testing as a potential screening tool for chronic lung disease in 
children. 
 
The MBW method has not yet been used as a routine test in the clinical setting 
worldwide. Some health centres in European countries, however, have utilized the MBW 
technique as a follow up procedure performed annually in CF patients, in which an 
increase in 1 unit of LCI could not be considered negligible, as such an increase indicated 
disease progression (Singer et al., 2013). As a consequence, the treatment plan for such 
individuals was re-considered. However, MBW testing has not been applied in clinical 
practice in other parts of the world such as the United States and Canada (Subbarao et al., 
2015).  
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The MBW method shows promising research results and based on what is published in 
the literature and the ongoing research being done on this method of lung function 
assessment, we may very likely see the approval for use of the MBW devices in clinical 
practice in the near future. 
 
In conclusion, small airway obstruction may not be revealed by means of routine lung 
function tests that depend on measuring airway resistance, such as spirometry. Therefore, 
the use of a testing tool that is capable of detecting the obstruction in small airways is 
required, especially when the obstruction may be the onset of further serious illness, as is 
the case in CF, asthma and COPD. MBW testing has been confirmed to be a competent 
method for detecting small airway changes. The use of this method may be the future of 
early detection of lung diseases that start in the small airways. Consequently, obtaining 
normative data is essential for providing a reference for detecting lung function 
abnormalities. 
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4 Methodology  
4.1 Research objectives 
 
The main objectives of this research were:  
 Identify normative values of LCI when using SF6 based portable MBW machine 
 Identify normative values of Scond and Sacin when using SF6 based portable MBW 
machine 
 Model the relationship between relevant demographic and environmental factors 
and LCI, Scond, Sacin, and FRC measurements 
 Quantify reliability and clinical usability of LCI obtained from SF6 based portable 
MBW machine. 
 
4.2 Method  
4.2.1 Ethical approval 
 
In preparation for this study, ethical approval was obtained from the ethics committee of 
Keele University (Appendix 1). The information sheet for the parents (Appendix 2) and 
for the child (Appendix 3), the consent form for the parents (Appendix 4) and for the 
child (Appendix 5), the invitation letter (Appendix 6), and the questionnaire (Appendix 7) 
are presented in the respective appendices. 
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4.2.2 Study design 
 
There are two approaches one can take to get normative values: longitudinal or cross 
sectional studies. A longitudinal study acquires repeated measures as a child grows. Such 
a design will give a clear indication of age-related normative values and data that explores 
change over time. However, such a design is time consuming. Furthermore, such studies 
have increased risk of data loss due to attrition. A cross section study design is conducted 
across a range of ages with a single measure taken on each child. This will give us valid 
data for the different age ranges for a selected sample without loss of data. However, the 
time course of change cannot be mapped as accurately as longitudinal studies. As this was 
a PhD programme study with limited time for recruitment, a cross sectional observational 
study with a single assessment was undertaken.  
 
4.2.3 The demographic and environmental variables measured by this study  
 
As discussed in section 2.4, it is known that various factors including environmental 
factors such as exposure to tobacco smoke, early life respiratory infection, premature 
delivery, and socioeconomic status can reduce lung function. In addition, we wanted to 
investigate the association between demographic variables such as age, gender and BMI 
and MBW outcome measures. Accordingly, we needed to have data on these factors for 
the included children. These factors were considered as the independent variables in this 
study.  
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Demographic and environmental data of the children was collected through a 
questionnaire (Appendix 7) sent out to the parents. In order to maximize the accuracy of 
the data, the questions were prepared in a simple and clear language. 
 
The questionnaire provided the following: 
• Weight = measured in kilogram in the school by an electronic scale 
• Height = measured in meter in the school by a height measuring tool 
• Date of birth = collected by the researcher on the testing day 
• Gestational age / Full-term or premature (derived from gestational age) = collected 
in the questionnaire from the parents/guardian 
• Health status or presence of any medical conditions = answered by the 
parents/guardian in the questionnaire 
• Free school meals representing social deprivation = answered by the 
parents/guardian in the questionnaire 
• Distance from the main road (derived from post code) representing pollution = 
post code collected in the questionnaire and distance calculated in kilometer using Google 
Maps 
• Smoking or exposure to second hand smoking = answered by the parents/guardian 
in the questionnaire 
• Duration of exposure to smoking = answered by the parents/guardian in the 
questionnaire 
• Early childhood respiratory infection or hospitalization (until the age of 2) = 
answered by the parents/guardian in the questionnaire 
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• Level of activity = answered by the parents/guardian in the questionnaire 
 
The invitation letter and accompanied documents were printed and sent to the 
parents/guardians, via the School, in a sealed envelope given to the child. Parents were 
asked to read the documents and return the documents signed if they were happy to 
consent for the child to take part in the experiment. The researcher picked up the signed 
documents from the School.  
 
4.2.4 Sample size 
 
In the absence of any data related to standard error of measurement a power calculation 
was not carried out. the sample size for this study was based on estimate that were 
informed by the following considerations 
 
(a) In order to get descriptive statistics or parametric statistics there is a need for 10 to 20 
subjects (Harris and Taylor, 2003). 
 
(b) For modelling purposes and when looking for statistical relationships between age as a 
variable of demographic factors, a minimum of 10 subjects per independent variable is 
required (Field, 2009). 
 
To identify a representative sample size in this study, we have 11 independent variables 
(age, gender, height, BMI, living distance from main road, poverty (represented by free 
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meal), smoking, exposure to passive smoking, activity level, hospitalization before age of 
two, and premature birth). For each variable, 10 subjects need to be recruited; this will 
lead to a required sample size of at least 110 subjects. In other words, in order to obtain 
meaningful data that could provide valid descriptive statistics such as mean and 
confidence interval, we determined the need to have a minimum of ten subjects to 
represent each age group (5-18 years). The minimal clinically important difference is 
unknown for this measure. Therefore, we decided to take a pragmatic sample size of 140 
subjects. During estimation of sample size, some practical issues required consideration 
such as missing data, participant refusal to continue the study or losses to follow up. To 
consider these situations, we decided to add 10% to the total calculated sample size, 
which resulted in 140 + 14 (10 %) = 154 subjects in total.    
 
4.2.5 Inclusion criteria 
 
Children between the ages of 5 and 18 years old (≥5 and ≤18), capable of understanding 
and following the instructions. The university insurance permits studies on children 5 
years of age or older only; access to preschool children within the organization is not 
allowed. 
 
Consent to participate, given by both child and parents/guardian. Legally, even though 
children of 16 years of age or more are able to give consent for themselves without 
parents/gaurdian, parental/guardian consent was still required for such participants. It is 
important to note that although we got parental/guardian consent, the decision to take 
measurement was based on verbal consent from the participant on the day of 
measurement. 
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4.2.6 Exclusion criteria 
 
 Children who were receiving antibiotics for a lower respiratory tract infection at 
the time of testing, as it was  found to have a decrease in the value of LCI up to 
1.27 unit (Sonneveld et al., 2015). 
 Children who were diagnosed with asthma, viral-induced wheeze, protracted 
bacterial bronchitis, CF, or any other chronic respiratory condition. 
 Children who had used anti-asthma medication within 3 months prior to the study. 
 All of the above criteria may have affected their small airways and since the study 
aims to create a base for normative LCI data, therefore these were excluded to 
avoid abnormal results. 
 
4.2.7 Invitation letter 
 
A written invitation letter was prepared and sent by the researcher to 12 schools in the list 
(Appendix 8) in Stoke-on-Trent as required by the ethics committee (Appendix 1). The 
Schools listed in Appendix 8 were chosen pragmatically and was based on contacts that 
existed within ongoing research studies at the School of Health and Rehabilitation. The 
list included eight primaries, two secondary and two mixed schools. The invitation letter 
was directed to the head teacher of the school. The letter covered the aim and the purpose 
of the study and briefly described the intended technique to be used in the study. The 
letter was accompanied with the following documents: the information sheet for both the 
parents/guardians and the child (Appendix 2) and (Appendix 3), a consent form to be 
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signed in the case of agreement to participate in the study for both the parents/guardians 
and the child (Appendix 4) and (Appendix 5), and a questionnaire investigating the risk 
factors (Appendix 7). Once a School responded to the letter the researcher visited the 
Head Teacher (or the authorize representative) to get appropriate consent to contact the 
relevant pupils. 
 
4.2.8 Contacting the schools 
 
After obtaining permission from the schools, the researcher contacted the head-teacher 
and a meeting was arranged to provide further information and clarify any doubts 
regarding the study. During the meeting, several aspects concerning the study were 
agreed upon: the commencing date of data collection, the room where the testing was 
going to take place, identifying a named chaperone from within the school who would 
also help the researcher with data collection, and the arrangement for the participation of 
the students. By the end of the meeting, I made sure that all inquiries and doubts about the 
testing procedure and process were cleared for the head-teacher satisfaction.  
 
4.2.9 Consent form 
 
A written consent was prepared, one to be signed by the participant (Appendix 5) and 
another by the participants/guardian (Appendix 4) before measurements were taken.  
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4.2.10 Parents/guardians Information sheet  
 
The parents/guardians information sheets (Appendix 2) contained brief information about 
the aim of the study, the target population, the testing procedure, and the rights of the 
participants during the study. Contact details of the researcher and research supervisors 
were included at the end of the information sheet for further information and details. 
 
4.2.11 Child Information sheet 
 
A two-sided leaflet (Appendix 3) was prepared in a simple way to explain the research the 
young children were participating in and the reason behind their participation. Both 
information sheets were adopted from ongoing research conducted in Manchester hospital 
for LCI research, with permission.  
 
4.2.12 Extracting the study measures 
 
For the Innocor outcome measures, there are two methods for calculating the indices of 
the MBW, the first being a built-in system within the device which is designed to 
calculate FRC and LCI by the end of each washout test. The second method of calculating 
the outcome measures of the MBW is an offline washout software that is a specialized 
custom software designed with algorithms that calculate the required indices. This offline 
washout analysis package was used, prepared in Igor Pro v6 (Wavemetrics Inc., Lake 
Oswego, OR, USA). This is based on the same washout analysis package already 
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deployed in several other clinical studies and clinical trials (Alton et al., 2015; Bell et al., 
2018; Davies et al., 2013).  
 
The built-in system of the device provides FRC and LCI, which are considered the most 
commonly used indices of ventilation inhomogeneity. The customized offline washout 
software provides further and more precise measurements of washout such as tidal 
volume, flow gas delay, wash-in and washout start; it also extracts more informative 
indices for washout, such as Scond and Sacin, and amends the faulty parts of the process, 
such as SnIII slope and leaks.  
 
The outcome measures were extracted and analysed by two persons, myself and an expert 
in Innocor MBW, independently. Both researchers followed the recommendation of the 
ERS/ATS consensus statement criteria for measurement acceptability. The measurements 
which did not comply with the published quality criteria were excluded from the study 
(Robinson et al., 2013b).  
 
Extracting the raw data from the Innocor device using the special custom built software 
Igor pro1 (version 6.37) that is designed to extract outcome measures was represented as 
an expirogram that showed the flow, O2, CO2 and SF6 concentrations during testing time 
(Figure 15). The customised offline software program enabled extracting further outcome 
measures other than LCI and FRC.  This software runs on Windows2. The LCI file that 
                                                 
1 Manchester MBW analysis_091114_V4- 
2 Windows 10 education©2018Microsoft corporation 
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contained the washout raw data was stored in a format that required a special program to 
convert it into a readable file using Innofileconverter3.  
 
The main windows included:  
 Control panel: the main way of entering the data into MMBWA. 
 Main washout window: displayed the washouts tracing the flow, O2, CO2 and the 
SF6 graphs. 
 Flow gas delay: displayed the flow gas delay for the first ten breaths of the 
washout. 
 Shortcut bar: enabled importing the raw data, delete it, set washing and washout 
start, and save the wash out file. 
 Folder table: showed test results contained within the selected folder. 
 Expirogram: displayed the main washout graph and enabled the adjustment of 
phase lll slope Figure 15 
 Phase lll slope analysis. 
These windows permit the researcher to analyse and adjust the washout of each testing 
trial individually to determine the LCI and FRC values. The entire extracted outcomes of 
each test displayed in an Excel file included the values of the outcome measures for each 
test and for each subject. 
                                                 
3 Innofileconverterv2 1.2.1.1 
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Figure 15 Expirogram of MBW (my data) 
This illustrated MBW wash-in and washout measures in volumes vs time in seconds: illustrate flow of gas, 
O2%, CO2 % and SF6 concentration throughout complete wash-in and washout process 
 
 
Each expirogram was checked manually by inspecting wash-in and wash-out phases to 
assure the quality of the test and comply with the recommendation of consensus statement 
(Robinson et al., 2013a). The testing process had to meet the following criteria to be 
accepted: 
 
- The participant had to be seated in an upright position with the head in the midline. 
- The nose clip had to be tightened and the mouth piece sealed in order to prevent escape 
of the air in or out of the interface.  
Wash-in phase 
Washout phase 
SF6 1/40th  
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- The participant had to complete three acceptable MBW runs, where acceptability is 
determined by checking the following: 
 
 Wash-in phase should have stable tidal volume and equal inert gas concentration 
within the breath cycle. 
 The washout phase must have a regular breathing pattern and avoid large breaths 
and coughs. 
 Termination of the test is accepted when at least three consecutive breaths were 
taken beyond reaching 1/40th of inert gas concentration at the end of washout, and 
six turnovers must be completed if intended to calculate SnIII. 
 Leaking should not occur; leakage is indicated by a sudden drop in the inert gas 
concentration during wash-in. 
 The participant was allowed an adequate time break between the runs of the test to 
assure that inert gas concentration has returned to the original value. 
 The test underwent further investigation when FRC difference within the three 
runs exceeded 10%, and was rejected if >25%. 
 
The researcher examined the expirogram for each phase of the testing to assure the 
quality of testing and remove the outliers which did not follow the criteria. The graph of 
the phase III slope was checked for each breath to get more accurate Scond and Sacin values. 
Flow gas delay was checked for each test to be identified and corrected when required 
based on ERS/ATS consensus statement (Robinson et al., 2013a).  
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4.2.13 Training to undertake the measurements 
 
Using MBW to measure lung function for the children required a training period. The 
training aimed to qualify the researcher with the testing procedure in order to achieve a 
total understanding of the measurement process, get the researcher familiar with the 
testing equipment, and allow the researcher to manage the entire testing procedure 
independently.  
 
The training plan included two parts, observational and practical. I started attending the 
cystic fibrosis pediatric clinic in Royal Stoke University Hospital on a weekly basis where 
MBW was conducted for CF patients in order to get familiar with the technique. I have 
attended approximately 100 sessions through the observation period for recurrent CF 
patients. The MBW testing was conducted by a research nurse and eventually a physician 
who were trained by an expert in MBW. During the observation period, I was not allowed 
to conduct the test due to governance restrictions. The practical part of the training was 
conducted by measuring the LCI for colleagues under supervision of the research nurse in 
the hospital in four separate sessions.  
 
The training for measuring LCI was completed before commencing the data collection 
and the equipment was available for the study by providing a loan letter from the hospital 
confirming that this equipment is available for proceeding with the research (Appendix 
9). 
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During collection of the data, I was independently performing the testing process; when 
there was a problem with the technique or the device, I obtained the advice of the expert 
to overcome the problem. After completing the data collection, I underwent three training 
sessions to acquire the process of extracting and analyzing the data. The training sessions 
were conducted by an expert in Innocor MBW in Manchester Hospital.  
 
4.2.14 Preparation of the Innocor kit 
 
On the day of the testing, the kit should switch on and left to warm up for at least 20 
minutes before the arrival of the first participant. All of the required testing parts were 
prepared in a separate package for each participant for easiness and time efficiency. Each 
package included a clean washed mouth-piece, a new nose clip, a clean washed air bag, 
and a new filter. 
 
The connections of the machine parts were checked to be in the right places to ensure no 
chance of leaks. Lines of the machine were checked throughout their length to ensure they 
were not tangled or twisted. The gas cylinder was checked to be fixed tightly before 
commencing the test.  
 
Next, calibration was carried out before testing started to reinforce the test quality and 
was repeated every four hours during the testing process. In case of replacing or cleaning 
the flowmeter, calibration had to be repeated to avoid change of pressure interpretation. 
The calibration procedure started with recording ambient temperature, air pressure and 
humidity.  
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Afterwards, oxygen was adjusted and the flowmeter was calibrated using a 3-litre syringe 
at room temperature and a bacterial filter. The calibration process of the flowmeter was 
achieved by smoothly filling and emptying the syringe in three different speeds to mimic 
different respiratory rates. The results were displayed in a table showing the recent gain of 
the air to be compared to the previous gain. A correct linearization occurs when the 
difference between the old and new is ±2%. 
 
The last step was the flow-gas delay calibration which required connecting a filter to the 
RVU. Intense forced inhalation was performed after total air breathed was expired slowly. 
This manoeuvre aims to create a sharp transition in flow and therefore drop in C O2 
concentration. CO2 analysis is used to align gas flow and signal, which assists in analysis 
of raw data. This manoeuver is repeated eleven times. At the end of this process the 
average is displayed and compared with the previous one. If the difference exceeded 10 
ms, then the process must be repeated.  
 
 
 
4.2.15 Preparation of the environment 
 
The researcher set-up the weighing scales and the height measure ready for use. A 
comfortable chair was used to assure the comfort of the participant during the testing 
procedure. The breathing kit was held by an adjustable stand to modify the different 
heights of the participants. The use of a tablet device (or a screen) to show an animation 
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film was aimed to help distract the participant and maintain the tidal breathing mode 
during the testing process. A small fan was placed in front of the participant to increase 
the air flow during the wash-out phase and prevent rebreathing of SF6. A glass of water 
and tissues were available to be provided to the participants when needed. 
 
4.2.16 Preparation of the participant 
 
The tests were held in the school with the company of a school teacher/assistant who 
helped in calling and organizing the attendance of the participants. On the arrival of the 
participant, I introduced myself and made sure that the participant was familiar with the 
study and testing procedure. The participant was informed about the testing procedure and 
what was expected from him/her. Height and weight were measured and recorded in a 
new file in the Innocor. The participant was instructed about how to perform the 
measurement including using the mouth piece and the placement of a nose clip. After the 
participant was seated and it was assured that he/she had no further inquiries, the 
participant was ready to start the test and the mouth piece and nose clip were adjusted 
onto the patient. The participant was asked to get familiar with the position and be sure 
that he was comfortable before starting the test.  
 
4.2.17 Performing the MBW test 
 
The testing procedure was divided into two phases, wash-in and washout. Wash-in was 
performed from a sealed bag filled with a mixture of room air and test gas (94% O2, 1% 
SF6 and 5% N2O) up to a volume of 3L. As the wash-in commenced, the participant was 
asked to take 5 deep breaths at the beginning to speed up the wash-in and then continued 
 108 
 
with normal tidal breathing until the inspired and expired concentration of the SF6 became 
equal and the concentration reached 4%. Throughout the wash-in phase, I monitored the 
O2 and FiCO2 to keep them >18% and <3%, respectively. Simultaneously, I kept a close 
observation on the participant and the monitor to check for any leaks during the test; leaks 
can be indicated by sudden step changes in volume. After the wash-in phase was 
completed, I switched to the washout phase of the gas where supply of the gas is 
disconnected. The participant was reminded to keep a tight seal around the mouth piece 
and to breathe normally. A fan was used during the washout phase to prevent rebreathing 
the expired SF6 as the room air was used to washout the inert gas. The washout continued 
until the SF6 concentration returned to 1/40
th of the starting concentration, and the 
procedure was completed. The washout was stopped automatically by the machine when 
the SF6 returned to its starting concentration. The measuring of the breathing gases 
continued for 5 breaths after the washout stopped. This was done to guarantee that the 
lung was cleared of the inspired SF6 gas (Figure 16).  
 
Figure 16 Inert gas (SF6 ) concentration throughout a washin-washout measurement. 
This illustrated the inert gas (SF6 ) concentration throughout a washin-washout measurement, the SF6 
increases concentration through the wash-in phase until reach the equilibrium level when inspired equals 
the expired gas concentration (4%) then the manual switch to the wash-out phase and the inert gas 
concentration decreases until it reaches the initial concentration (1/40th) of starting wash-out concentration 
when the test is stops automatically. 
 
 
While the air bag for the following test was being prepared, I made sure that the 
participant was comfortable and satisfied with the testing procedure and willing to 
proceed to the next trial. As soon as the bag was prepared, the testing started. The same 
steps were repeated for the second and third trials. Once the three trials were completed 
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and no further test was required, the participant was informed that this was the end of the 
test. After each participant, and before starting the following test, the testing kit was 
cleaned with antiseptic wipes to control infection, and all the used equipment (mouth 
piece, filter, nose clip and air bag) were removed and replaced with clean and washed 
ones.   
 
The test was repeated three times unless one of the trials were unsuccessfully completed 
because of leak or device fault. In such cases, a fourth trial was performed with the 
approval of the participant. Each trial consumed between 5-10 minutes.  
 
4.2.18 Method of statistical analysis 
 
Raw data for each participant was presented as three readings of each variable. The 
intended outcome measures were divided into primary outcomes, which were LCI and 
FRC, and secondary outcomes, which were Scond and Sacin. In order to extract data there 
was a need for three (minimum of two) valid readings of each outcome measures. The 
three (or two) valid outcome measures were entered in SPSS4 in addition to the data 
extracted from the questionnaire. A simple descriptive data analysis was required to 
calculate the mean and standard deviation for the three readings to be used in modelling 
analysis. We also calculated the coefficient of variation (CoV), which is an indication 
of dispersion around the mean. It is also used to measure variability of measurements 
(Harrell Jr. et al., 1984).  
 
                                                 
4 IBM SPSS statistics 24 
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Prior to statistical analysis, the data went through pre-processing procedure. 
1- Removal of the outlier values by checking the entire readings in order to eliminate 
the readings that did not correspond to the recommended criteria of the ERS/ATS 
consensus statement (Robinson et al., 2013a). Outliers were identified by using 
box plot for each outcome measure and subsequently removed from the data. 
 
2- Checking of serial dependency for the remaining of the data by plotting a graph of 
each outcome measure values to illustrate the values of first, second and third 
measurement. If the readings were independent and there was no serial 
dependency, then we used the mean of the three readings (or the mean of two) to 
represent dataset as for guidance given by the European guidance (Field, 2009; 
Harrell Jr. et al., 1984). 
 
3- Testing for the normality was done using Shapiro-Wilk test, which is a simple 
descriptive data analysis test used to check normality and is used on data obtained 
from a small sample size. The normality test allowed identifying whether the 
variables are normally distributed in our sample and therefore helped in deciding 
to use parametric (when the data is normally distributed) or non-parametric tests 
(the data is not normally distributed) for statistical/correlation analysis (Harris, 
2003). 
 
4- Reliability of the outcome measures: as extracting the data based on applying 
certain rules and following the recommendation of the ERS/ATS consensus 
statement, then a simple mistake in extracting the data may negatively influence 
the results and consequently the entire project. Therefore, making sure that the 
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process of data extraction is correct and the results were precise, we decided to 
reassure the process by checking the reliability of the outcome measure data by 
comparing the analysis of the data that was extracted by the researcher to the 
analysis of the same data to be extracted and analysed by an expert in the MBW 
testing. To do this comparison the Bland and Altman test was used to check the 
difference and agreement between the two data results introduced by a plot graph. 
In this graph a display of the mean and SD in the scatter plot graph of the 
difference between the two values (Giavarina, 2015). Bland and Altman test 
helped to check the reliability of the data and freely interchange between them. 
The Bland and Altman graph illustrated the X-axis to represent the average of the 
two result measurements and the Y-axis represented the difference between the 
two results. The Bland and Altman plot analysis is a simple way to evaluate a bias 
between the mean differences, within which 95% of the differences of the second 
method, compared to the first one fall (Bland and Altman, 1999).  
5- SPSS was used to enter the data; each participant was represented in a single file 
that included the entire outcome measures of the MBW values and the outcome 
measures of the questionnaire.  
6- Assess the influence of demographic variables and environmental factors on the 
outcome measures 
 
The environmental factors were identified as the following: exposure to tobacco 
smoke, early life respiratory infection, premature delivery, socioeconomic status and 
living distance from main road, while demographic variables identified as age, gender 
and BMI.  
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To carry out the statistical analysis to investigate the relationship between MBW 
outcome measures and demographic and environmental factors, I used two data sets:  
1- Dataset 1: the Keele dataset which I have collected in the schools in Stoke-on-
Trent for children aged 5-18-years old and included the measurement of MBW 
and the questionnaire (Appendix 7). This dataset was used to look at the effect of 
demographic and environmental factors on MBW outcome measures. 
 
Dataset 1 was used to answer the following questions: 
- Whether there was any significant difference between the means of the variables 
based on demographic and environmental factors. Testing the difference between 
outcome measures based on demographical and environmental factors was 
investigated using ANOVA and t-test for means.  
- Whether demographic and environmental factors had a significant effect on the 
variables in the study population. Modelling this relationship was achieved using 
linear regression. 
 
 
2- Dataset 2: a combination of Keele dataset + the secondary anonymous dataset that 
have been collected in Manchester at the same period (as a part of LCI research 
conducted in Manchester) which goes beyond the age range that we were looking 
at. Since reporting age related norms and modelling age relationship with MBW 
outcome measures requires a larger age range, I am using the merged dataset to set 
a reference for normal LCI values for the intended age group and explore the 
effect of age on the MBW outcome measures.  
 
Dataset 2 was used to answer the following questions: 
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- What are the normative data of MBW outcome measures (LCI, Scond and Sacin) 
throughout the age range. 
- Whether there was any significant difference between the means of MBW 
outcome measures based on age-groups by using ANOVA. 
- Whether there was correlation between the age factor and the MBW outcome 
measures (LCI, Scond and Sacin) using Pearson’s correlation. 
- Modelling the relationship between age and MBW outcome measures and 
whether LCI is varied with age using linear regression.  
 
4.3 Time scale of the PhD 
 
 The PhD commenced 26th January 2015. 
 The progression report submitted in January 2017. 
 The observational visits to the Royal Stoke University Hospital started in 
September 2015 and ended in December 2017; the visits occurred on a weekly 
basis and depending on the attendance of the cystic fibrosis patients in the 
outpatient clinic. 
 The training sessions on how to use the Innocor device commenced with the 
expert during the observation period; these sessions were arranged according to 
the expert’s schedule.  
 The ethics form was submitted to the University ethics committee in August 2017 
and the approval was obtained in January 2018. 
 Contacting the schools started in August 2017 and arrangements with the schools 
were made after the ethical approval was obtained.  
 All the children were recruited and assessed between March and August 2018. 
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 The training sessions on how to extract and analyze the raw data from the Innocor 
device were arranged with the expert according to his schedule following the end 
of recruitment. 
 The data extraction and analysis commenced in August 2018. 
 The submission of the thesis was on 25th January 2019. 
 
4.4 Thesis work 
Done by myself 
 
 Conducting a thorough literature review on my research topic 
 Filling the ethics form, which was revised by my supervisor, until ethical approval 
was gained 
 Ordering the equipment that was required for the testing procedure [mouth pieces, 
filters, CO2 scrubbers, 3-litre airbags, nose clips, SF6 gas cylinders, disinfectant 
tablets (for washing the reusable equipment)] 
 Writing the invitation emails and communicating with the schools 
 Meeting with the head teachers and agreeing on the starting date and the 
requirements for the testing procedure 
 Preparing the required testing equipment for each participant 
 Calibrating the MBW machine prior to testing [recalibration was required after 4 
hours of testing] 
 Conducting the entire testing procedure and collecting the data for all 64 subjects 
 Extracting the data from the kit to the offline program 
 Entering the data into an excel sheet 
 Statistically analysing the data from the excel sheet using SPSS 
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 Writing up my thesis paper, under the guidance of my advisors 
 
Done with the help of others 
 
 Order the equipment travel case and a new RVU unit [with help of Dr Gilchrist] 
 Apply for the loan of the MBW equipment from the hospital by Dr Gilchrist 
 Training for using the MBW machine with help of research nurse in the UHNM 
hospital and Dr Alex Horsley 
 Preparation of the testing environment with the help of the teacher assistant   
 Organize the participants time schedule for testing 
 Training on extracting and analysing the data with Dr Horsley 
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5 Results 
5.1 Dataset 1 
5.1.1 The demographics of the Keele dataset population 
 
Sixty four (64) children were recruited in this study with no known respiratory disease or 
infection at the time of testing, The data from two subjects were not used due to 
equipment technical factors (n=1) or clinical reasons (n=1) and have not been analysed 
further. LCI was successfully measured in 62 participants (93%). The participants aged 
between 9-15 years-old, there were 27 males and 37 females. The mean age was 11.8 
(standard deviation (SD)=1.99) years. The weight ranged between 24.2-80.0 kg. The 
mean weight was 46.11 (SD=13.45) Kg. The height range was 123.5-182.8 cm, and the 
mean height was 153.78 (SD=14.16) cm. The body mass index (BMI) range was 13.69-
33.2 Kg.m2, the mean BMI was 19.14 (SD= 3.68) Kg.m2. (Table 8)  
Table 8 Summary of the demographics of the study population of dataset 1 
  
Age at testing: mean (SD) 11.7 (1.99) 
Age range (9-15) 
Gender (M/F) 35/27 
Height: mean (SD)  153.7(13.4) 
Weight: mean (SD)            46.1 (14.1) 
BMI: mean (SD)  19.14 (3.7) 
 
5.1.2 Preprocessing data 
5.1.2.1 Removing the outlier values 
 
All readings collected throughout the study were checked and the readings that did not 
correspond to the ERS/ATS consensus statement criteria (Robinson et al., 2013a) were 
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removed from the data. After removing the data that did not fit the criteria, we ended up 
having 23 out of 62 participants with two MBW test readings, instead of three. Of note, 
this had no effect on our results, as two valid test readings for each participant is 
considered reliable in assessment of MBW outcome measures in children (Robinson et 
al., 2013a; Yammine et al., 2012). It is important to clarify here that the preprocessing of 
the data and removing of outliers was applied by myself to Dataset 1 but not to Dataset 2, 
as the data added from Manchester was used after being processed and checked by the 
research team in Manchester. 
 
5.1.2.2 Checking serial dependency 
 
The data was checked to identify if the three repeated measures had any pattern of serial 
dependency. This was carried out graphically and is shown in Figure 17. There was no 
evidence of any serial dependency in the data indicating that the readings are likely to be 
independent of each other. This indicates that MBW testing provides an accurate 
measurement of the actual gas exchange occurring in the lungs of each participant across 
all three serial measurements. 
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Figure 17 Serial dependency of MBW outcome measures 
This illustrated the serial dependency for the MBW outcome measures graphically: the graphs in this figure 
illustrate the values of each outcome measure (Figure 1.a. LCI, 1.b.  FC, 1.c. Scond, and 1.d. Sacin) for the 
three measurement tests and if there was dependency between them. The x-axis identifies the first, second 
and third measurement tests, and the y-axis shows the values of the outcome measure represented by each 
graph. The figure shows that the three repeated measures were independent of each other, indicating that 
there was no pattern of serial dependency. 
 
 
5.1.2.3 Testing for normality of the variables 
 
All the variables in our study have been subjected to testing of normality to check if they 
were normally distributed. This was done using Shapiro Walk test. The evidence 
suggested that data for the variables LCI, Sacin, and Scond (p=0.468, p= 0.205, p=0.231) 
were normally distributed The results for FRC data, however, was not normally 
distributed (p=0.002). Further exploration of the non-normally distributed variable FRC 
suggested that the presence of an outlier was responsible for the skew and this was 
removed to increase homogeneity in the data. This made the FRC variable normally 
distributed (p=0.200). Normality of all the variables guided our choice of using 
parametric statistical tests in the SPSS analysis of our results, presenting them as mean 
and standard deviation. 
 
5.1.2.4 The reliability testing using Bland Altman plot for the difference in the MBW 
outcome measures 
 
The Bland and Altman plots in Figure 18 demonstrated the reliability of the extracted 
LCI, FRC, Scond, and Sacin values by measuring agreement between the values extracted by 
myself and another assessor. The LCI mean error (SD) between the two assessors was 
0.04 (0.24) and the mean absolute error (SD) was 8.77 (0.15); the variability for the LCI 
 119 
 
measurements (the limits of agreement) were between -0.52 and 0.44 (Figure 18a). The 
FRC mean error (SD) between the two assessors was 0.03 (0.14) and the mean absolute 
error (SD) was 1.52 (0.03); the limits of agreement were between -0.25 and 0.3 (Figure 
18b). The Scond mean error (SD) was 0.0005 (0.010) and the mean absolute error (SD) was 
0.01 (0.0001); the limits of agreement were between 0.02- (-0.02) (Figure 18 c). The Sacin 
mean error (SD) was 0.006 (0.05) and the mean absolute error (SD) was 0.36 (0.006); the 
limits of agreement were between -0.097 and 0.09 (Figure 18 d). 
This Bland Altman plots representing the agreement of the extracted data between the two assessors (Figure 
2.a. LCI, 2.b. FRC, 2.c. Scond, and 2.d. Sacin): the x-axis illustrated the average of the measurements extracted 
by the two assessors for each participant, and the y-axis illustrates the difference between the two 
measurements the two assessors. The mean difference of the differences between the two extracted 
measurements for each participant was denoted by the red line. The two green lines demonstrated the limits 
of agreement for the measurements extracted by the two assessors, and they were calculated as mean 
±1.96*SD. 2.a. demonstrated the LCI mean difference = (-0.04) and the limits of agreement = (-0.52- 0.44). 
2.b demonstrated the FRC mean difference = (0.03) and the limits of agreement = (0.30 - -0.25). 2.c. 
demonstrated the Scond mean difference = (0.001) and limits of agreement = (0.02- -0.02). 2.d. demonstrated 
the Sacin mean difference = (0.06) and the limits of agreement = (0.085 - -0.097). 
Figure 18 Bland and Altman plots 
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5.1.3 The descriptive analysis of the MBW outcome measures  
 
The mean (SD) value for the LCI for our study population was 6.18 (0.34), the minimum 
value was 5.27 and the maximum was 7.00. The mean (SD) for the FRC was 2.04 (0.72), 
while the minimum value was 0.95 and the maximum was 4.18. Scond mean (SD) was 0.10 
(0.03), the minimum was 0.03 and the maximum was 0.17. Sacin mean (SD) was 0.01 
(0.02), the minimum was -0.02 and the maximum was 0.09 (Table 9).  
 
Table 9 Summary of the normal values of the MBW outcome measures for dataset  
Dataset 1 Mean (SD) Minimum Maximum 
LCI 6.18 (0.34) 5.27 7.00 
FRC 2.04 (0.72) 0.95 4.18 
Scond 0.01 (0.02)  -0.02 0.09 
Sacin 0.10 (0.03) 0.03 0.17 
This demonstrated the normal values of the MBW outcome measures for dataset 1 by showing the mean 
(SD), minimum, and maximum values for LCI, FRC, Scond and Sacin respectively 
 
5.1.4 The influence of demographic variables and environmental factors on the 
MBW outcome measures (LCI, FRC, Scond, and Sacin) 
 
The environmental factors were identified as follows: exposure to tobacco smoke, early 
life respiratory infection, premature delivery, socioeconomic status, activity level and 
living distance from main road (Chapter 2; section 2.4). The  demographic variables were 
identified as age, gender and BMI.  Results will be presented as Dataset 1 (Keele dataset) 
and Dataset 2 (combined Keele and Manchester dataset), which were described in the 
methodology.  
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5.1.4.1 Factors excluded from the data analysis  
 
Some factors we assessed in the questionnaire were excluded from the data modelling due 
to a scarcity of the data relevant to these factors in our study population. None of our 
participants were exposed to first-hand smoking, only one participant was exposed to 
second-hand smoking, only one participant was prematurely born (<34 weeks term), and 
only two participants had positive history of hospitalization for early life respiratory 
infection. Therefore, statistical analysis could not be performed for assessment of the 
effect of these environmental factors (exposure to tobacco smoke, early life respiratory 
infection, and premature delivery) on our MBW outcome measures. Statistical analysis 
was performed on the remaining environmental and demographic factors: socioeconomic 
status (free school meals), activity level and pollution (living distance from main road), 
age, gender, and BMI. 
 
5.1.4.2 Difference between LCI means based on demographic and environmental 
factors 
 
5.1.4.2.1 Free school meals 
 
The demographical data for the participants who were taking free school meals were (n = 
6), three males and three females. Their mean age (SD) was 12 years-old (2.3). Their 
mean weight (SD) was 51.9 (23.1), mean height (SD) was 157.06 (15.6) and mean BMI 
(SD) was 21.2 (6.1). The participants who did not have free school meals were (56), 32 
males and 24 females. Their mean age (SD) was 10.5 years-old (2.5). Their mean weight 
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(SD) was 38.4 (10.9), mean height (SD) was 142.01 (12.2) and mean BMI (SD) was 18.7 
(3.4). 
 
An independent sample T-test was performed to find that there was no significant 
difference (p-value=0.14) between LCI means based on free school meals (Table 10). 
Table 10 Difference between LCI means based on free school meals 
Free school meals 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Yes (N=6) No (N=56) Lower Upper 
LCI 6.38(0.23) 6.16(0.34) 1.50 0.14 0.02(0.15) -0.07 0.51 
 
 
5.1.4.2.2 Gender 
The demographical data for the participants were 35 males and 27 females. The mean age 
for male participants (SD) was 13.3 (1.6) years and 10.59 (1.3) years for the females. The 
mean weight (SD) for males and females was 54.2 (12.2) kilograms and 39.9 (11.9) 
kilograms, respectively. The mean height (SD) was 164.7 (10.8) centimeters for males 
and 145.3 (10.8) centimeters for female subjects. The BMI mean (SD) was 19.8 (3.5) 
kg/m2 and 18.6 (4.1) kg/m2 for males and females, respectively.  
 
An independent sample T-test was performed and showed there was no significant 
difference (p-value=0.76) between LCI means based on gender (Table 11).  
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Table 11 Difference between LCI means based on gender. 
Gender 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Male (N=35) Female (N=27) Lower Upper 
LCI (6.17)(0.34) (6.20)(0.35) 0.30 0.76 0.08(0.07) 0.20 0.09 
 
5.1.4.2.3 Activity level 
 
Activity level was categorized into five levels (0-4) as seen in question seven of the 
questionnaire (Appendix 7):   
 0 for None (no physical activity or exercise) 
 1 for Little bit 
 2 for Medium  
 3 for Often   
 4 for Very often. 
 
The demographical data for the participants based on activity level groups are shown in 
the Table 12. Of note, there were no participants in the 0 level group. 
 
Table 12 Summary of demographic data based on activity level groups. 
Activity 
level 
Number of 
participants 
Mean age 
(SD) 
Male Female Mean weight 
(SD) 
Mean height 
(SD) 
Mean 
BMI (SD) 
1 4 12.25 (2.06) 4 0 58.2 (10.4) 158.5 (10.3) 23.2 (4.1) 
2 32 10.75 (1.25) 17 15 40.37 (12.6) 146.65 (10.23) 18.4 (3.7) 
3 14 10.0 (0.8) 9 5 38.1 (65) 141.6 (5.1) 19.03 (3.2) 
4 12 10.75 (2.9) 5 7 37.65(13.05) 142.25 (13.2) 18.1 (3.2) 
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The results of the ANOVA show that there was no significant difference in LCI values 
based on activity level groups. (F=2.70, p-value=0.054) (Table 13). 
 
 
Table 13 LCI difference based on activity level 
LCI Vs Activity 
Very often (SE) Often (SE) Medium (SE) 
Little bit 0.12 (0.19) 0.32 (0.19) 0.36 (0.18) 
Medium -0.25(0.11) -0.04 (0.10)  
Often -0.21(0.13)   
This represented the differences between the means of the LCI values based on activity level of the 
participant, e.g.  the difference between the mean of the LCI value for the participants who exercised very 
often and those who exercised little bit = 0.12 (0.19). A significant difference (p-value <0.05) in LCI values 
between any of the two activity level groups is indicated by a (*). N.B. We did not compare the group with 
itself as it is not feasible. 
 
5.1.4.3 Differences between FRC values based on demographic and environmental 
factors 
 
5.1.4.3.1 Free school meals 
 
An independent sample t-test was performed to find that there was no significant 
difference (p-value=0.84) between FRC means based on free school meals (Table 14). 
 
Table 14  Difference between FRC means based on free school meals. 
Free school meals 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Yes (N=6) No (N=56) Lower Upper 
FRC 2.09(0.63) 2.02(0.73) 0.20 0.84 0.07(0.31) -0.56 0.69 
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5.1.4.3.2 Gender 
 
An independent sample t-test was performed to find that there was a significant difference 
(p-value=0.01) between FRC means based on gender (Table 15). 
Table 15 Difference between FRC means based on gender 
*significant at p-value<0.05;  **significant at p-value<0.01 
Gender 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Male (N=35) Female (N=27) Lower Upper 
FRC 2.23(0.78) 1.78(0.55) 2.54 0.01* 0.17(0.14) 0.10 0.80 
 
 
5.1.4.3.3 Activity level 
 
One-way ANOVA was carried out to investigate the difference in FRC mean values 
based on the activity level of the child. The results of the ANOVA showed that there was 
no significant difference in FRC values based on levels of activity level groups. (F=1.26, 
p=0.30) (Table 16). 
 
Table 16 FRC difference based on activity level 
FRC Vs Activity  Very often(SE) Often(SE) Medium(SE) 
Little bit 0.43(0.41) 0.30(0.40) 0.02(0.38) 
Medium 0.42(0.24) 0.28(0.23)  
Often 0.13(0.28)   
This represented the differences between the means of the FRC values based on activity level of the 
participant, e.g.  the difference between the mean of the FRC value for the participants who exercised very 
often and those who exercised little bit = 0.43(0.41) L. A significant difference (p-value <0.05) in FRC 
values between any of the two activity level groups is indicated by a (*). N.B. We did not compare the 
group with itself as it is not feasible. 
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5.1.4.4 Differences between Scond values based on demographic and environmental 
factors 
 
5.1.4.4.1 Free school meals 
 
An independent sample t-test was performed to find that there was no significant 
difference (p-value=0.70) between Scond means based on free school meals (Table 17). 
       
Table 17 Difference between Scond mean values based on free school meals. 
Free school meals 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Yes (N=6) No (N=56) Lower Upper 
Scond 0.01(0.01) 0.01(0.02) -0.39 0.70 -0.002(0.01) -0.02 0.01 
 
 
 
5.1.4.4.2 Gender 
 
An independent sample t-test was performed to find that there was a significant difference 
(p-value=0.049) between Scond means based on gender (Table 18). 
 
Table 18 Difference between Scond mean values based on gender. 
*significant at p-value<0.05;  **significant at p-value<0.01 
Gender 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Male (N=35) Female (N=27) Lower Upper 
Scond 0.01(0.01) 0.02(0.02) -2.01 0.049* 0.15 (0.14) -0.02 -0.00004 
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5.1.4.4.3 Activity level 
 
One-way ANOVA was done to investigate the difference in Scond mean values based on 
the activity level of the child. The results of the ANOVA showed that there was no 
significant difference in Scond values based on levels of activity level groups (F=0.397, p-
value=0.76). (Table 19) 
Table 19 Scond difference based on activity level 
Scond Vs Activity Very often(SE) Often(SE) Medium(SE) 
Little bit -0.0001(0.01) -0.0004(0.01) 0.004(0.01) 
Medium -0.005(0.01) -0.005(0.01)  
Often 0.0002(0.01)   
 
 
5.1.4.5 Differences between Sacin values based on demographic and environmental 
factors 
5.1.4.5.1 Free school meals 
 
An independent sample t-test was performed to find that there was no significant 
difference (p-value=0.33) between Sacin means based on free school meals (Table 20). 
 
. 
Table 20 Difference between Sacin mean values based on free school meals. 
Free school meals 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Yes (N=6) No (N=56) Lower Upper 
Sacin 0.09(0.03) 0.11(0.04) -0.987 0.33 -0.02 (0.02) -0.05 0.02 
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5.1.4.5.2 Gender 
 
An independent sample t-test was performed to find that there was no significant 
difference (p-value=0.22) between Sacin means based on gender (Table 21). 
 
Table 21 Difference between Sacin mean values based on gender. 
Gender 
Variable 
Mean (SD) 
t-value p-value 
Mean difference 
(SE) 
Confidence interval 
Male (N=35) Female (N=27) Lower Upper 
Sacin 0.10(0.03) 0.11(0.05) -1.25 0.22 -0.03(0.03) -0.04 0.01 
 
 
 
5.1.4.5.3 Activity level 
 
One-way ANOVA was carried out to investigate the difference in Sacin mean values based 
on the activity level of the child. The results of the ANOVA showed that there was no 
significant difference in Sacin values based on levels of activity level groups (F=1.75, 
p=0.17) (Table 22). 
 
 
Table 22 Sacin difference based on activity level. 
Sacin Vs Activity Very often(SE) Often(SE) Medium(SE) 
Little bit -0.04(0.02) -0.01(0.02) -0.03(0.02) 
Medium -0.01(0.01) 0.02(0.01) 
Often -0.03(0.02) 
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5.1.4.6 Modelling the relationship between MBW outcome measures (LCI, FRC, 
Scond, Sacin) and the demographic and environmental variables using 
linear regression analysis 
 
5.1.4.6.1 The influence of the demographic and environmental factors on LCI 
 
To find which factor had an effect on LCI, a regression analysis was done for each factor 
individually except the height and BMI which were investigated together due to the 
interrelationship of the two variables. 
 
The following variables were found to have no significant effect on LCI: gender (F-test= 
0.93, p=0.762), BMI and height (1.928, p=0,155), distance from the main road (F=0.318, 
p=0.575), free school meals (2.259, p=0.138), and activity level (f= 0.958, p=0.332) 
(Table 23). 
 
Table 23 Regression result of demographic and environmental factors on LCI. 
Factor F-test p-value 
Gender 0.93 0.76 
BMI & Height 1.93 0.16 
Distance from main road 0.32 0.58 
Free school meals 2.26 0.14 
Activity level 0.96 0.33 
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5.1.4.6.2  The influence of the demographic and environmental factors on FRC 
 
A regression analysis was done to investigate the influence of the demographic and 
environmental factors on FRC. The results of the regression model of FRC vs the factors 
were shown in Table 23. Gender (F=6.46, p=0.01, FRC value= 2.679-0.448*Gender), 
BMI (F=19.48, p=0.00, FRC value = -2.461+(0.033*height) -(0.034*BMI) and living 
distance from the main road (F=31.64, p=0.00, FRC value=2.967-0.235* living distance 
from the main road) had a significant effect on FRC values (Table 24). Free school meals 
(F=0.04, p=0.84) and activity level (F=3.55, p=0.06) had no significant effect on FRC 
(Table 25). 
 
Table 24 Regression result of demographic and environmental factors on FRC 
*significant at p-value<0.05;  **significant at p-value<0.01 
Factor F-test p-value 
Gender 6.461 0.014 * 
BMI & Height 19.480 0.000 ** 
Distance from main road 31.640 0.000 ** 
Free school meals 0.044 0.835 
Activity level 3.554 0.064 
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Table 25 Results of significant factors affecting FRC  
*significant at p-value<0.05;  **significant at p-value<0.01 
Factor B T-test P-value 
95.0% Confidence Interval for B 
 
Lower Bound Upper Bound 
Constant 2.68 10.00 0.00** 2.14 3.21 
Gender -0.45 -2.54 0.01* -0.80 -0.10 
Constant -2.46 -3.05 0.003** -4.07 -0.85 
Height 0.03 6.24 0.00** 0.02 0.04 
BMI -0.03 -1.64 0.11 -0.08 0.01 
Constant 2.97 15.94 0.00** 2.59 3.34 
Distance from main road -0.24 -5.63 0.00** -0.32 -0.15 
 
 
5.1.4.6.3 The influence of the demographic and environmental factors on Scond: 
 
A regression analysis was carried out to investigate the influence of the demographic and 
environmental factors on Scond. The results of the regression model of Scond vs the factors 
are shown in Table 26. Gender (F=5.25, p=0.03, Scond value= -0.001+0.008*Gender) had 
a significant effect on Scond values. BMI and height (F=3.09, p=0.053), distance from 
main road (F=1.58, p=0.22), free school meals (F=0.15, p=0.70), and activity level 
(F=0.52, p=0.47) had no significant effect on Scond. (Table 27). 
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Table 26 Regression result of demographic and environmental factors on Scond 
*significant at p-value<0.05;  **significant at p-value<0.01 
Factor F-test p-value 
Gender 4.041 0.049 * 
BMI & Height 3.087 0.053 
Distance from main road 1.576 0.215 
Free school meals 0.153 0.697 
Activity level 0.521 0.473 
 
 
Table 27 Results of significant factors affecting Scond,  
*significant at p-value<0.05;  **significant at p-value<0.01. 
Factor B T-test P-value 
95.0% Confidence Interval for B 
 
Lower Bound Upper Bound 
Constant -0.001 -0.23 0.82 -0.01 0.01 
Gender 0.008 2.01 0.049* 0.00 0.02 
 
 
5.1.4.6.4 The influence of the demographic and environmental factors on Sacin 
 
A regression analysis was carried out to find investigate the influence of the demographic 
and environmental factors on Sacin. The results of the regression model of Sacin vs the 
factors were shown in (Table 28), and it indicated that the demographic and 
environmental factors had no significant effect on Sacin values: gender (F=1.55, p=0.22), 
BMI and height (F=1.00, p=0.38), distance from main road (F=1.06, p=0.31), free school 
meals (F=0.97, p=0.33), and activity level (F=0.36, p=0.55).  
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Table 28  Regression result of demographic and environmental factors on Sacin 
Factor F-test p-value 
Gender 1.56 0.22 
BMI & Height 0.998 0.38 
Distance from main road 1.06 0.31 
Free school meals 0.97 0.33 
Activity level 0.36 0.55 
 
5.2 Dataset 2 
5.2.1.1 The demographics of the combined dataset population 
 
The combined dataset (Keele + Manchester) was comprised of a total of 162 subjects with 
no known respiratory disease or infection at the time of testing, 100 from Manchester and 
62 from Keele, all of which had acceptable based on ERS/ATS Consensus Statement 
criteria LCI measurement. (Robinson et al., 2013a). The age range of the subjects in the 
combined database was five to 59 years of age. Seventy-five (75) were males and (87) 
were females. The mean age (SD) was 17.3(10.7) years. The weight ranged between 14 
to105 kg. Mean weight (SD) was 51.3 (19.2) kg. The height range was 100.0-190.7 cm, 
and the mean height (SD) was 154.88 (18.6) cm. The body mass index (BMI) range was 
10.2-45.6 kg/m2, and the mean BMI (SD) was 20.6 (4.8) kg/m2 (Table 29). 
 
Table 29 summary demographics of the study population of the dataset 2 
Age at testing: mean (SD) 17.3 (10.7) 
Age range (5-59) 
Gender (M/F) 75/87 
Height: mean (SD)  154.88(18.6) 
Weight: mean (SD)            51.3 (19.2) 
BMI: mean (SD)  20.6 (4.8) 
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5.2.2 The descriptive analysis of the MBW outcome measures for dataset 2  
 
The mean (SD) value for the LCI for our study population was 6.14 (0.47), the minimum 
value was 5.07 and the maximum was 7.83. The mean (SD) for the FRC was 2.11 (0.89), 
while the minimum value was 0.65 and the maximum was 4.76. Scond mean (SD) was 0.01 
(0.01), the minimum was 0.01 and the maximum was 0.31. Sacin mean (SD) was 0.11 
(0.05), the minimum was -0.02 and the maximum was 0.09 (Table 30). 
 
Table 30 Summary of the normal values of the MBW outcome measures for dataset 2 
Dataset 2 Mean (SD) Minimum Maximum 
LCI 6.14 (0.47) 5.1 7.8 
FRC 2.11 (0.89) 0.65 4.76 
Scond 0.01 (0.01) 0.01 0.31 
Sacin 0.11 (0.05) -0.02 0.09 
This summarized the normal values of the MBW outcome measures of dataset 2 represented in the mean 
(SD), minimum, and maximum values for LCI, FRC, Scond and Sacin respectively. 
 
To further analyse the relationship between age and MBW outcome measures, we 
calculated the means, standard deviations, as well as the minimum and maximum values 
for LCI, FRC, Scond, and Sacin for the paediatric age group in Dataset 2 separately and for 
the adult age group separately (Table 31). 
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 Table 31 The summary of the normal values of the MBW outcome measures for children versus 
adults in dataset 2. 
This summarised the normal values of the outcome measures for the children versus the adults represented 
as the mean (SD), minimum, and maximum values for LCI, FRC, Scond and Sacin respectively. 
 
Participants were categorized based on their age into 18 age groups. The youngest age 
group were 5-6 year-olds and the oldest age group were 49-59 year-olds. The pediatric 
age group ranges were categorized in increments of one year, while the adult age group 
ranges were categorized in increments of ten years. This difference in age range was set 
because the focus of our research was to set normative MBW values for the pediatric 
population rather than the adult population. Age group categories and the demographical 
data for the participants based on age groups are shown in  
Table 32.  
 
 
 
 
 
 
Dataset 2 Children Adults 
Number 111 51 
Age range 5-18 19-59 
MBW outcome LCI FRC Scond Sacin LCI FRC Scond Sacin 
Mean (SD)    6.2 (0.4) 1.8 (0.8) 0.01 (0.01) 0.11 (0.05) 6.1 (0.6) 2.8 (0.8) 0.01 (0.01) 0.11 (0.05) 
Minimum  5.07 0.7 -0.02 0.01 5.2 1.2 0.00 0.04 
Maximum  7.0 4.2 0.09 0.31 7.8 4.8 0.08 0.25 
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Table 32 Summary of demographic data based on age groups 
Age 
group 
Age 
range 
Male Female Mean 
weight(SD) 
Mean 
height(SD) 
Mean BMI(SD) 
1 5-6 2 3 19.60(2.61) 108.12(5.60) 16.73(2.70) 
2 6-7 3 4 21.29(3.86) 117.61(3.09) 15.42(2.61) 
3 7-8 1 2 25.00(1.41) 125.70(2.25) 15.99(0.07) 
4 8-9 4 1 26.40(2.07) 131.16(3.99) 15.49(1.46) 
5 09-10 4 7 34.91(7.76) 139.23(7.08) 17.81(2.95) 
6 10-11 6 10 40.73(12.18) 144.31(4.55) 19.42(5.36) 
7 11-12 8 12 40.00(10.31) 149.36(11.86) 17.60(2.58) 
8 12-13 8 4 52.73(11.93) 157.86(6.61) 20.98(4.30) 
9 13-14 8 1 51.00(9.64) 163.63(8.99) 18.91(2.33) 
10 14-15 3  58.67(10.07) 165.77(2.93) 21.38(3.95) 
11 15-16 12 2 59.64(9.38) 171.35(7.59) 20.29(2.58) 
12 16-17  4 67.25(11.53) 165.00(6.27) 24.76(4.47) 
13 17-18 - - - - - 
14 18-19 2  173.25(12.37) 64.00(11.31) 21.18(0.64) 
15 19-29 8 16 169.66(9.83) 67.00(9.11) 23.25(2.69) 
16 29-39 3 16 167.04(8.52) 71.05(15.31) 25.51(5.88) 
17 39-49 2 4 171.00(7.07) 76.17(8.89) 26.07(3.13) 
18 49-59 1 1 162.95(11.38) 71.00(5.66) 27.09(5.90) 
 
 
5.2.3 The influence of age on the MBW outcome measures (LCI, FRC, Scond, and 
Sacin) 
 
One-way ANOVA was performed to assess: 
 Difference between LCI means based on age groups: No significant difference in 
LCI values based on age group was found (F=1.32, p=0.20).  
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 Difference between FRC means based on age groups: A significant difference in 
FRC values based on age groups was found (F=10.83, p=0.000**).  
 Difference between Scond means based on age groups: There was a significant 
difference in Scond values based on levels of age groups (F=1.08, p=0.38). 
Difference between Sacin means based on age groups: A significant difference in 
Sacin values based on levels of age groups was found (F=1.06, p=0.40).  
Of note, the significant differences in the means of Scond and Sacin can be seen only when 
the (5-6) age group is assessed. 
 
Pearson correlation was carried out to assess the correlation between age and MBW 
outcome measures. No significant correlation was found except with LCI (r = 0.07, p = 
0.40) FRC (r =0.55, p = 0.00), Scond (r = 0.04, p = 0.63) and Sacin (r = 0.06, p = 0.43) 
(Table 33). 
Table 33 The correlation between the age and the outcome measures of dataset 2  
*significant at p-value<0.05;  **significant at p-value<0.01 
Dataset 2 outcome 
measures 
Pearson correlation p-value 
LCI 0.07 0.40 
FRC    0.55** 0.00 
Scond 0.04 0.63 
Sacin 0.06 0.43 
This Illustrated the correlation between the age and the outcome measures of dataset 2 the results of 
correlation showed that there was no significant correlation between age and LCI, Scond and Sacin but FRC 
was significantly correlated with age. 
 
 
5.2.3.1 Modelling the relationship between the MBW measures and the demographic 
variables 
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A regression analysis was carried out (Figure 19). Results of the regression model of LCI 
vs age showed that age has no significant effect on LCI values (F-test= 0.72, p=0.40). 
(Table 34) 
 
Table 34  Regression result of age on MBW outcome measures: LCI, Scond and Sacin 
Age effect on F-test p-value R2 
LCI  0.72 0.40 0.004 
Scond 0.24 0.63 0.001 
Sacin 0.62 0.43 0.004 
 
 
This represented the linear regression graphs for the MBW outcome measures vs age assessors from dataset 
2 (Figure 19.a. LCI, Figure 19.b. FRC, Figure 19.c. Scond, and Figure 19.d. Sacin): the x-axis represented the 
age in years, and the y-axis represented MBW outcome value. The linear regression line was denoted by the 
middle line with the regression equation was displayed on the line. The upper and lower black lines 
demonstrated the confidence interval. 
 
 
Figure 19 Linear regression for the MBW outcome measures versus age 
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5.2.4 Total time of testing session 
 
The total time of testing session was measured and converted into minutes. The mean 
time for the three reading was 17 minutes and 36 seconds (SD=2.5 minutes). The time 
was measured and provided by the Innocor device. The maximum time consumed in the 
three repetitions was 26 minutes and the minimum was 13 minutes and 20 seconds. The 
two repetitions mean time consumed was 12 minutes (SD=3.3 minutes). The maximum 
time was 19 minutes and 20 seconds and the minimum was nine minutes and 20 seconds. 
 140 
 
6 Discussion 
 
In this study, there were several research questions we aimed to answer. Our main 
objective was to determine normative values for LCI, the main MBW outcome measure, 
as well as Scond and Sacin. Furthermore, we wanted to identify the effect of a variety of 
demographic and environmental factors, such as age, gender, exposure to tobacco smoke, 
and prematurity on MBW outcome measures and model any relationships. We also aimed 
to assess the practicality and reliability of performing MBW testing using an SF6-based 
portable MBW machine in a community. 
 
6.1 Normative LCI, Scond, and Sacin values in children 
 
One of our main objectives in this study was to propose normative values for LCI, Scond, 
and Sacin in children when using the SF6-based portable MBW device (Innocor). I 
demonstrated that normative values were  6.18 (SD = 0.3, 95% CI = 6.10 to 6.25) The 
normative paediatric values we present in this research are comparable to values 
calculated for healthy individuals within a similar age range in previous studies conducted 
using different MBW devices and gases (Table 35) (Aurora et al., 2004; Fuchs et al., 
2009; Gustafsson et al., 2003; Horsley et al., 2008a; Jensen et al., 2013). As discussed in 
the literature review, the differences in normal values of LCI for the different gases and 
machines occurs due to the difference in behaviour of the tracer gases, difference in 
washout of the gases by the body, and differences in the equipment and systems used for 
each gas (Table 6) (Subbarao et al., 2015).  
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The normal range for LCI calculated in our study is very similar to that for previous 
studies involving SF6 as the tracer gas; however, the mean and upper limit of normal are 
both lower in our study compared to those described in research studies done on the 
paediatric population; this comparison is demonstrated in Table 35 (Gustafsson et al., 
2003; Horsley et al., 2008a; Jensen et al., 2013; Lum et al., 2013). 
 
Aurora et al (2004) presented a mean LCI value for the normal subjects in their study that 
was noticeably higher than the normal LCI value we calculated in our study as well as 
those suggested by the other studies in the literature that used SF6; this difference may be 
due to the smaller sample size (N=33) or due to selection bias as the normal subjects in 
this study were represented by a control group, rather than a random selection from the 
community (Aurora et al., 2004). It is known that a control group in a case-control study 
is subject to greater selection bias than other study designs, as it is usually not truly 
representative of the population being studied due to the nature of recruitment of control 
subjects in these studies. In fact, most of the studies in the literature (Gustafsson et al., 
2003; Horsley et al., 2008a; Jensen et al., 2013) suggesting normal LCI values are case-
control studies, subjecting them to more selection bias than our study. Fuchs et al (2009), 
however, utilized a cross-sectional study approach similar to ours, aiming to set 
normative values for LCI using the EasyOne Pro N2-based device; interestingly, the 
normal mean LCI values calculated was very similar to our results using the Innocor SF6-
based device, although other studies utilizing N2 as a tracer gas showed higher normal 
LCI values compared to SF6  (Fuchs et al., 2009). This may suggest that the EasyOne Pro 
N2-based system in particular may yield similar values as SF6-based MBW systems. 
Further research, however, is needed to establish such a conclusion. 
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Table 35 A comparison between the LCI value for healthy individuals in several studies using different 
MBW devices and different inert gases with our study result from dataset 1. 
 Gustafsson 
et.al (2003) 
Aurora 
et.al(2004) 
Jensen 
et.al(2013) 
Jensen 
et.al(2013) 
Horsley 
et.al 
(2008) 
Fuchs et.al 
(2009) 
Our 
result 
Equipment MS MS MS MS Innocor Easy One 
Pro 
Innocor 
Gas SF6 SF6 SF6 N2 SF6 N2 SF6 
Sample size 28 33 62 62 12 44 62 
Age range 4.5-18.7 5.9-16.8 3-18 3-18 6-16 5.3-20.3 9-15 
LCI (SD) 6.3 (0.4) 6.5 (0.5) 6.2 (-) 6.8 (-) 6.3 (0.5) 6.2 (0.4) 6.18 
(0.3) 
Upper limit of 
LCI 
7.1 7.5 - - 7.3 7 7 
 
 
6.2 Reliability 
 
To ensure the reliability of the measurements extracted by myself from the Innocor 
machine, we compared my measurements with those extracted by an expert assessor, 
which showed no significant difference. Most importantly, this indicates that the 
measurements that were taken by myself and used in the statistical analysis are reliable, 
and secondly, that an individual trained to use the Innocor device is capable of extracting 
measurements that are as reliable as those obtained by an expert, which adds value to the 
Innocor device especially in assessing its feasibility of use in the community, rather than 
clinical, setting as a screening tool. Moreover, the limits of agreement provided by the 
Bland and Altman test may help in providing an acceptable range of error for values 
extracted from the Innocor device by a trained assessor. Looking at the resulted limits of 
agreement for the LCI values between the two assessors, we found that the error range 
was 0.96. This range is representing a ratio of 15% out of the full scale of LCI mean value 
that was calculated out of our data (6.2) for healthy individuals. Therefore, ± 7.5 of the 
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mean LCI value is much smaller than the difference between the mean LCI value in 
healthy and that is seen in people with pathology (referred to Table 7,  CF = 8.7). 
 
6.3 The influence of demographic variable and environmental factors on the 
MBW outcome measures 
 
One of our aims in this study was to assess the relationship between demographic and 
environmental factors on the MBW outcome measures. the factors I chose were 
determined by previous research which identified the early life factors associated with 
future impairment of lung function. (Kouzouna et al., 2016). Most of these factors were 
assessed through the questionnaire that was given to each participant. However, some 
were measured by myself on the day of testing before the start of the MBW testing 
session for each participant; these were height, weight, and the calculation of the BMI. 
Unfortunately, three of the assessed environmental factors, (tobacco smoke, prematurity, 
and early life hospitalization for respiratory illness), could not be statistically analysed 
due to the poor rates of completion of the relevant question. A possible reason for this is 
the catchment of the school, in which the schools we studied may have been of a well-off 
socioeconomic status or a well-educated population; such areas are expected to have 
lower rates of smoking compared to poorer, less-educated communities (Gong et al., 
1995; Jenkins et al., 1997; Memon et al., 2000; Pierce, 1989). Moreover, in the UK, there 
is a noticeable drop in smoking rates likely due to national efforts that aim to decrease the 
prevalence of smoking by setting laws that restrict tobacco use and launching 
international awareness campaigns. Moreover, the age of our study population in Dataset 
1 did not exceed 16 years of age, making access to tobacco smoke more difficult. (Bauld 
et al., 2012; McNeill et al., 2015). This drawback in our study may have occurred due to 
our limited sample size of only 62 participants as well as the limited geographical area 
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(only two schools) from which our participants were recruited. In the future, this may be 
overcome by studying a larger sample population and conducting a study over a larger 
geographical area. Also, it is possible that limiting smoke exposure to tobacco smoke 
only, in an era where many methods of smoking have become popularized such as 
electronic cigarettes, illegal smoking, and hookah pipes, may have contributed to an 
underrepresentation of smoking exposure in our study population.  
 
LCI was not found to be significantly affected by any of the demographic and 
environmental factors investigated in our statistical analysis, which were age, gender, 
BMI and height, activity level, social deprivation (represented as free school meals), and 
pollution level (represented as distance from main road). This is consistent with most of 
what is found in the literature. We did find, however, some variation in the literature 
regarding the effect of age and body size (height and BMI) on this outcome measure. Our 
study was consistent with the findings that the LCI was independent of body size and age 
(Aurora et al., 2005a; Horsley et al., 2008a). However, this was inconsistent with the 
findings of Lum et al (2013) who concluded that LCI was body size and age dependent 
(predicted LCI equation = 5.99 + (73.85 x height-1) and CV=0.08, where height was 
represented in centimeters) (Lum et al., 2013). 
 
One study by Verbanck et al (Verbanck et al., 2012) found that LCI, Sacin and Scond 
consistently increased with age; however, the study population age range was 25-65 
years, which is different from the age range studied in our population, which was 5-59 
years. Seventy-four percent (74%) of our study population (120 out of 162 participants), 
were aged less than 25, and, therefore, the conclusion by Verbanck et al does not 
necessarily contradict our results, but may be more representative of an older age group 
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than that studied in our population. Of note, only 6/162 in our study were above 40, 
representing only 4% of Dataset 2. Three of these six participants were noticed to have 
LCI values above the upper limit of the confidence interval (Figure 19.a). This may 
suggest that after the age of 40, LCI results may be affected. Studies done using nitrogen-
based mass spectrometry have shown that in people who exceed the age of 40, an increase 
in LCI seems to occur due to the increased ventilation inhomogeneity that occurs as a 
feature of aging lungs (Htun et al., 2018; Verbanck et al., 2012; Verbanck et al., 2016). 
We further noticed that two of these three participants were found to have a higher than 
normal BMI, which may further suggest that body size may affect LCI values after the 
age of 40. Further research on adults above 40 years may thus be needed to further 
investigate the effect of age and body size on MBW outcome measure in this older age 
group. Overall, however, we found no significant change in LCI with age, BMI, or height.  
 
The fact that LCI was found to be unaffected by all our assessed demographic and 
environmental factors makes this outcome measure valuable in that a single normative 
value and range can be set for all genders, body sizes, and age groups, particularly less 
than 40 years. This makes comparisons across genders, ages, and body sizes easier, 
whether in clinical practice or for research purposes. Moreover, the stable range of 
normality across most of the age range studied makes LCI a distinctive lung function 
measure that can be used in future longitudinal studies in the paediatric population, since 
it is not affected by changes in lung volumes related to normal growth of lung tissue, as 
well as changes in activity level. These characteristics are unlike those of spirometry 
measures which vary normally according to age, gender, and body size (Wang et al., 
2009; Wang et al., 2017). 
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While LCI was found to be unaffected by all assessed factors, Scond and Sacin were found 
to be significantly affected by some factors and not significantly affected by others. BMI 
and height, activity level, social deprivation, and pollution were found to have no 
significant effect on both Scond and Sacin. Gender, however, was found to have a significant 
effect (p-value=0.049) on Scond, but no significant effect on Sacin. In contrast to our study 
results, Verbanck et al found a small but significant gender difference for Sacin (Verbanck 
et al., 2012); the tracer gas used by Verbanck et all, however, was nitrogen, which 
produces different results from SF6-based MBW testing. Nevertheless, these differences 
found may direct further research to investigate the relationship between gender and Sacin 
and Scond more thoroughly, although they may be considered secondary MBW outcome 
measures compared to LCI.  A significant difference in both Scond and Sacin based on age 
was found. When we referred to Table 33 and Table 34, we noticed that the significant 
difference based on age was limited to the Scond and Sacin values between the 5-6 year old 
age group vs all the other age groups. This was also appreciated on the regression graphs 
modelling the relationship between age and Scond and Sacin (Figure 19.c and Figure 19.d) 
respectively. We traced back these point values and found that they referred to a single 
participant in the 5-6 year age group provided by the Manchester data in the combined 
dataset (Dataset 2). We decided, however, to consider this participant’s measurements 
within our analysis since the LCI, our main outcome measure, and FRC were acceptable 
in accordance with the ERS/ATS consensus statement criteria.  
 
Consistent with our expectations, FRC was significantly affected by age, gender, BMI 
and height. FRC is known to be affected by these variables because it represents the 
volume of air present in the lungs at the end of passive expiration. This changes with 
varying lung size and factors that affect the elastic recoil of the lung. Lung size varies 
across genders and increases from childhood to adulthood. Elastic recoil decreases with 
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BMI due to the extra weight opposing the outward recoiling of the chest wall. Aging also 
affects the ability of the lung to recoil (Aurora et al., 2005b; Jensen et al., 2013). FRC was 
found to be significantly affected by pollution (represented by distance from main road). 
However, because FRC was the only outcome measure we found to be affected by this 
environmental factor, further research is required to investigate the effect of pollution on 
MBW lung function measures in healthy children. Finally, FRC was not found to be 
affected by social deprivation or activity level.  
 
6.4 Clinical applicability 
 
This is the first research study to use a genuinely portable MBW system operated by a 
single researcher (myself) in a community setting.This has demonstrated the possibility of 
performing MBW testing in a community setting and the feasibility of its large scale use 
as a screening tool for subclinical respiratory disease in children. It is considered a 
strength that the assessment of each participant was performed on the same school visit, 
by the same researcher, in one time-setting, thereby eliminating operator variability in the 
three sets of outcome measurements. 
 
Use of a compact and robust analyser, combined with an SF6-gas source that can be 
stored in small on-board cylinders, means that I was able to package an entire MBW 
system into a transport case and take it directly into schools. This ease of portability is 
important for community-based assessment of MBW. Nitrogen-based portable MBW 
machines, such as EasyOne Pro, on the other hand, require a source of 100% oxygen gas, 
which is stored in remarkably larger cylinders, making portability of this system in the 
community-setting more difficult compared to Innocor. 
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One SF6-gas cylinder was enough for 9-14 sets of washout; this variability is due to the 
varying participant sizes, as the amount of gas consumed increases with increasing size of 
the lungs. Therefore, the younger the child, the less the amount of gas was consumed and 
the less the number of SF6-gas cylinders were needed. 
 
The duration of the MBW test during our study was on average 12 min for two test runs 
and about 17.5 minutes for three runs. The time for gas exchange is less in children than 
adults due to their smaller lung size. Moreover, healthy lungs wash out the tracer gas 
faster than diseased lungs. This shortens the time of testing in the healthy paediatric 
population, especially when two measurements rather than three are applied, making it a 
feasible screening method in this age group.   
 
In terms of the effect of gas choice on test duration, SF6-based MBW testing was found to 
take less time compared with N2-based MBW systems (Bayfield et al., 2016). This can be 
explained by two phenomena: (1) the faster washout of SF6 due to its exogenous nature 
and gas behaviour compared to the endogenous N2, and (2) the longer time needed 
between test runs using N2-based MBW due to the need for N2 gas to return to its baseline 
concentration in the lungs prior to the start of the next washout.  
 
Although MBW testing is more time-consuming compared with spirometry, which takes 
on average 5-10 minutes, MBW has several advantages over spirometry in clinical 
application. First of all, it can detect very early changes in lung function, making MBW 
more sensitive to lung pathology and disease progression (Goksor et al., 2008; 
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Gustafsson, 2005; Owens et al., 2011); this may make this method appropriate for 
screening of chronic lung disease. Secondly, unlike spirometry, MBW requires minimal 
patient cooperation and is not effort dependent, as it assesses lung function while the 
patient is in passive breathing, which makes MBW attractive to specialists in the field of 
paediatric pulmonary medicine. In our study, the children that underwent the MBW test 
cooperated well and found no difficulty or challenge in following the instructions of the 
test throughout the testing period. 
 
Computed tomography (CT) and high resolution computed tomography (HRCT) are two 
other widely used methods of lung assessment in medical practice. Although CT images 
are able to provide information about early lung abnormalities, it is not justified to use CT 
scanning on young, healthy children as a screening tool as it exposes them to unnecessary 
radiation that increases their risk of developing future malignancies (Ward et al., 2017). 
This risk is higher in the growing child compared to the adult because growing cells are 
more sensitive to radiation-induced cell damage, which is why CT imaging in paediatric 
medicine is reserved for cases in which an accurate diagnosis is more important to the 
child’s health than the risk of future malignancy posed by the radiation. Moreover, CT 
and HRCT are more time-consuming than MBW testing; CT imaging may take a total of 
30-60 minutes, including the time spent getting the patient ready for the scan, which is 
much longer than the total of 3 runs of MBW testing conducted in our study. Further 
disadvantages of CT are that it can only be carried out in a hospital setting, requires the 
attention of more medical personnel, and requires more patient cooperation or sedation as 
movement throughout the scan duration must be minimized for acceptable image 
resolution (Sarma et al., 2012). 
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Many studies have been conducted over the past decade assessing the sensitivity and 
repeatability of LCI in disease conditions such as CF, bronchiectasis and COPD. They 
have all agreed that LCI is considered a repeatable and highly sensitive measure of lung 
function abnormality compared to spirometry outcome measures as well as computed 
tomography imaging of the lung parenchyma. (Green et al., 2011; Gustafsson et al., 2008; 
Rowan et al., 2014; Trinkmann et al., 2016)  
 
6.5 Limitations 
 
As with any research study, our results and findings have to be taken into consideration in 
light of some limitations. Firstly, our study was subjected to selection/sampling bias, as 
we only received permission to recruit participants from two out of an intended 14 
schools, which also resulted in a limited sample size for us to work with. This may have 
occurred as a result of our choice of email as a method used in contacting the schools. A 
direct meeting with the school principal or head teacher to explain the study and deliver 
the invitation personally may have been more effective in eliciting a response. However, 
we were restricted to the used of email as a means of sending the invitation in accordance 
with the recommendations of the ethics committee. Being able to reach a larger number 
of schools would have made our sample more representative and generalisable to the UK, 
as a larger geographical area and sample size would have been achieved. Moreover, the 
small sample size and limited geographical representation may have contributed to the 
fact that we were unable to test for the effect of tobacco smoke exposure, prematurity, 
and early life hospitalization on the MBW outcome measures due to the very few and 
insufficient reports of exposure to these factors. In addition, a larger sample size may 
have provided further strength to our statistical results, increasing confidence in our 
normative values for MBW outcome measures. In order to set normative data that can be 
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generalised to a variety of populations, we suggest that further research be done in 
different geographical locations, covering all age groups, ethnicities and social classes. 
Our study may be considered as an initiative in producing widely generalisable LCI, Scond, 
and Sacin normative values for future clinical use. 
 
Secondly, the use of a questionnaire to identify many of the factors we investigated in our 
study in itself is also considered a source of bias. Questionnaires are known to introduce 
recall bias to data. It is considered a systematic error caused by differences in the 
accuracy or completeness of the recollections retrieved by the study participants 
regarding past events. However, we found that using a questionnaire was the most 
practical and efficient way to assess the demographic and environmental factors we aimed 
to analyze in our research study. 
Smoking exposure could have been measured using a urinary or salivary sample from the 
children being studied. This method, however, is considered invasive when working with 
children in a public sector such as schools, and therefore, consent may not be available. 
Furthermore, the cotinine test was expensive and could not be justified for a preliminary 
study. As result, we relied on the questionnaire to assess exposure to tobacco smoke, 
although reliability of this method may be less favorable. 
 
Assessment of tobacco smoke exposure was limited to cigarette smoking with no 
assessment of exposure to other types of smoking (e.g. illegal smoking, electronic 
cigarette smoking, and hookah pipe smoking). The agreement of assessing only for 
tobacco smoking followed a discussion between the supervisor and myself, in which it 
was agreed that cigarette smoking was the most frequent legal method of smoking. This 
agreement was made to emphasize more truthful answers. 
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Parents/gaurdians may have difficulty recalling the occurrence of early-life respiratory 
infections in their children’s lives, and therefore, to ensure obtaining more accurate 
answers in assessing this risk factor, we asked about the frequency of hospital admissions 
during childhood for a respiratory infection, as hospitalization is more likely to be 
remembered. This also indicates the seriousness of the lung condition and the need for 
treatment. When people visit the general practitioner (GP) however, medication may not 
be prescribed, and because of not having the permission from NHS ethics, then exploring 
the participants’ medical history was only possible through the parents’/guardians’ 
knowledge.  
 
Finally, we faced a few technical limitations at the beginning of our testing period, as we 
were working with a machine that – like any machine – was subject to manufacturing 
flaws and technical problems. At the initial phase of our testing trials, we faced recurrent 
device failures that showed up as pauses during the test, which resulted in delay of the 
testing process. These technical issues required that I travel to meet with the machine 
expert in order to solve the technical problem I had faced. Unfortunately, this issue 
resulted in a delay our in testing and decreased the time available to collect more data. 
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7 Conclusion and future recommendations 
 
This research aimed to identify normative values for the main MBW outcome measures 
for the paediatric population, investigate and assess any relationships between 
demographic and environmental factors and MBW outcome measures, and demonstrate 
clinical applicability and usability of the portable MBW method outside the clinical 
setting. Based on quantitative and qualitative analyses of the data collected in our 
research study, it can be concluded that MBW outcome measures, namely LCI, Scond, and 
Sacin, in children are not affected by demographic factors, such as age, gender, height, and 
BMI, but further investigation is needed to assess the effect of environmental factors, 
such as exposure to smoke, prematurity, and early life respiratory infections, on these 
measures. This may be an aim for future research. 
 
The normative values for the paediatric age group that have been suggested in our study 
have been found to be very similar to normal values reported previously in the literature. 
Further research is needed, however, to identify normative values for the adult population 
as well as explore the effect of demographic factors, particularly age, on these measures, 
as age may possibly affect outcome measures after the age of 40. Further work also needs 
to be directed in setting normative values of MBW outcome measures for infants and 
preschoolers, as this age group was excluded from our study population.  
 
Supporting what has been suggested in the previous literature, LCI has been found to be a 
reliable and reproducible measure of lung function that has shown a consistently narrow 
range of normal values throughout childhood and early adulthood (from 5-40 years of 
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age). This makes LCI a possibly very valuable measure in serial assessments of lung 
function in this age range, particularly in monitoring of chronic lung disease.  
 
In our research, we also successfully demonstrated the usability and practicality of 
performing MBW testing on children in the community setting using the portable SF6-
based Innocor device and thus the possibility of taking MBW testing outside of the 
clinical setting. This may direct future efforts in exploring the feasibility of using the 
MBW method as a screening tool for detecting early chronic respiratory disease in 
children, as the medical literature has shown that most chronic respiratory diseases, such 
as asthma, COPD, and CF, can be detected prior to development of symptoms and the 
occurrence of irreversible lung damage. Establishing an early diagnosis for these 
potentially debilitating diseases may significantly improve prognosis by guiding earlier 
intervention when damage is still reversible. We further recommend that future work is 
directed in identifying the group of children in the population who will benefit from 
undergoing such a MBW screening test according to a risk score determined by research 
that aims to identify the risk factors that affect lung function in early life and progress to 
symptomatic lung disease. In assessing exposure to smoking, further research may 
reassure reliability of responses by using cotinine testing rather than questionnaires. As 
this study follows a cross-sectional approach, there is a need for longitudinal studies 
(cohorts) in the future to better assess the effect of known environmental risk factors for 
chronic lung disease on MBW outcome measures obtained throughout childhood. 
 
Further recommendations for future work include setting normative values for MBW 
outcome measures using the other available commercial devices and gases, such as the 
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EasyOne Pro and Exhalyzer D, as our normative values cannot be applied to machines 
other than the SF6-based Innocor device. 
 
Furthermore, in order to establish normative values that can be generalised for use in the 
clinical setting in the UK, further research should aim to recruit a larger study population 
from different cities and areas in order to make the sample more representative of the 
general UK population. Future similar international efforts are further needed to 
generalise values to a global level. 
 
Finally, to improve the clinical applicability and feasibility of MBW testing in the 
community setting, studies have demonstrated ways to decrease test duration, which 
include taking two rather than three measurements and decreasing the final washout 
concentration measured to 1/20th rather than the standard 1/40th of the initial tracer gas 
concentration inhaled. Further studies, however, need to be conducted to investigate the 
reliability of LCI(1/20th) in normal individuals compared to LCI(1/40th), as not enough 
studies have investigated the reliability of this method. 
 
In the end, MBW testing seems to be emerging in the field of pulmonary medicine as a 
promising method of lung function assessment, which may very well be a part of the 
standard clinical care of respiratory disease patients in the near future. Research 
investigating this method is therefore in high demand.   
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9.6 Appendix 6 
To the Head teacher                  dd/mm/yyyy 
Dear ………………,             
I am a student reading for a PhD in Keele University with Dr Fran Gilchrist (a local paediatric 
respiratory consultant in UHNM) and Professor Anand Pandyan (from Keele University). My 
study aims to measure lung function in children and explore what factors (e.g. living next to the 
main road, smoking/exposure to cigarette smoke, physical activity etc.) affect the measures of 
lung function. 
I am looking for potential participants for this study. Would it be possible for us to meet in person 
to discuss if it is possible to use your School as a site to recruit participants for my study? This 
letter outlines the measurements I propose to undertake in this research study. 
I will be using two methods to measure lung function: 
The spirometer (the current standard of measurement) and a newer technique called the Multiple 
Breath Washout test. The newer method is easier on the children, however, the child will need to 
breathe an inert gas which is proven to be safe. The time to take both measurements is 
approximately 30 minutes. I am in a position to take all the measurements in your school. 
In order to conduct this study, I would require the following support from your school:  
●    Provision of an area to collect my data 
●    The help of an assistant who is familiar with the children to help with measurements (a 
stipend will be available to this person or the school to cover the costs) 
●    As I do not have contact details for children and the parents/guardians, your support would be 
needed in sending out study-related information and paperwork via the students to the 
parents/guardians on my behalf. (N.B. I will bring copies of all relevant documents that I will be 
using to advertise this study to our meeting). 
Just to reassure you I will not start this study until I first have your permission and the permission 
from the University. The University approval processes will confirm that this study meets all the 
ethical requirements as currently required by law. Currently, this study is estimated to start in (to 
be confirmed). I will call you in the next week to arrange for a meeting to discuss the potential of 
you supporting this study. 
Yours sincerely, 
Amnah Alrumuh (a PhD student) 
a.k.a.alrumuh@keele.ac.uk 
Mackay Building 
School of Health & Rehabilitation 
Keele University, Staffordshire, ST5 5BG 
Tel: +44 (0) 1782 734191 
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9.7 Appendix 7 
 
The LCI-Norm Study 
This questionnaire has to be filled by the participant’s parents/care taker. 
Child’ name:     Study ID No:   Gender          Weight            
Height      DOB   Address               Post code 
-Does your child currently receive antibiotics for a lower respiratory infection? Yes
 No 
- Is your child diagnosed with asthma, viral induced wheeze, protracted bacterial 
bronchitis, CF, or any other chronic respiratory condition?                           
Yes No 
- Has your child used anti-asthma medication in the last 3 months prior to the study? Yes
 No 
*if you answer ‘yes’ to any of previous questions, unfortunately your child can not 
take part in this study 
Would you answer these questions? 
1- Was your child born full term (>36 weeks)?     Yes
 No 
If No, how many weeks? …………….……………….. 
2- Is your child exposed to cigarette smoke at home?     Yes
 No 
If yes, for how long has he/she been exposed to cigarette smoke? 
(Month/year)……….……… 
3- Does your child smoke?       Yes
 No 
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If yes, for how long has your child been smoking? (Month/ 
year)……….………….. 
4- Does your child have a free meal at school?     Yes
 No 
 
5- Do you live near a main road?      Yes
 No 
 
 
6- Has your child been hospitalised for respiratory/breathing problem/infections 
before age of 2?        
 Yes No 
If yes, for how many times?       …………………..……….. 
7- Which one of the following describes your child activity out of school hours (e.g. 
played sports, went running, swimming, bike riding, did aerobics) best for the last 
7 days?  
 
Read all five statements. Before deciding on the one answer that describes 
him/her. 
o None  0 hours 
o Little bit 1 hour/week 
o Medium   two and half hour/week 
o Often  5 hours/week 
o Very often > 5hours/week 
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9.8 Appendix 8 
Name of the School Address Head teacher E mail 
Woodhouse Academy 
Tel: 01782 973600 
81 Woodhouse Ln, 
Biddulph, Stoke-on-Trent 
ST8 7RL 
Ms Claire Butler 
principal@woodhouseacademy.
staffs.sch.uk> 
JCB Academy 
Tel: 01889 506100 
Mill St, Rocester, 
Uttoxeter ST14 5JX, 
United Kingdom 
Mr Jim Wade https://jcbacademy.com 
Forsbrook CE Primary 
School 
Tel: 01782 392577 
Cheadle Rd, 
Stoke-on-Trent, 
Staffordshire 
ST11 9PW 
Mrs Natasha 
Richards 
office@forsbrook.staffs.sch.uk 
Thistley Hough 
Academy 
01782 883 500 (Main 
Office) 
Thistley Hough, Penkhull 
Stoke-on-Trent, ST4 5JJ 
Holly Hartley 
Secondary 
office@thistleyhough.org.uk 
 
St Margaret Ward 
Catholic Academy 
01782 883000 
Little Chell Lane 
Tunstall 
Stoke-on-Trent 
ST6 6LZ 
C.Smith office@smwca.org.uk 
Harpfield Primary 
Academy 
01782 234984 
Palmers Green 
Hartshill 
Stoke on Trent 
Mr R T Woollacott 
Primary 
enquiries@harpfieldprimaryacad
emy.org.uk 
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ST4 6AP  
Sutherland Primary 
01782 594133 
Beaconsfield Dr, Stoke-
on-Trent ST3 3DY 
Garry Boote 
sutherland@sutherlandacademy.
co.uk 
 
Hillside Primary 
01782 235350 
Stoke-on-Trent ST2 7AS Mrs N Morris 
office@hillsideprimary.org.uk 
 
Forrest Park 
01782 234979 
Woodall Street 
Hanley 
Stoke on Trent 
Staffordshire 
ST1 5ED 
Miss S L Irving 
admin@forestpark.org.uk 
 
Sneyd Green Primary 
School 
Tel: 01782 234460 
 
Sneyd Street, 
Burslem, 
Stoke-on-Trent, 
ST6 2NS 
Mrs Rosina Lee 
sneydgreen@sgfl.org.uk 
 
St Mary’s Catholic 
Academy 
01782 234820 
Norton-Le-Moors, Ford 
Green Rd, Stoke-on-
Trent ST6 8EZ 
 
Mr I. Beardmore 
stmaryrc@sgfl.org.uk 
 
St John the Evangelist 
Catholic Academy 
The Avenue 
Kidsgrove 
Mrs H Butters 
 
headteacher@stjohnskidsgrove.
org.uk 
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01782 296736 Staffordshire 
ST7 1AE 
 
 
St Wilfrid's Catholic 
Academy, 
Tel: 01782 235676 
Queen's Avenue, 
Tunstall, 
Stoke-on-Trent 
ST6 6EE 
MRS MASON office@stwilfridsnewman.co.uk 
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